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Background: Therapeutic Risk Minimisation (RM) has become as an area of extensive research in 
recent years with the release of Good Pharmacovigilance Practice Module XVI in 2014 which provides 
a regulatory framework for selection, development and evaluation of the effectiveness of additional 
risk minimisation measures (aRMMs) in Europe. Over a quarter of new products currently approved 
centrally by the European Medicines Agency (EMA) have accompanying aRMMs to manage and 
mitigate risks that could have serious consequences for patients and are considered to be 
insufficiently managed by routine measures alone. Most of these aRMMs are educational and 
communication materials for healthcare professionals (HCPs) or patients such as brochures, leaflets, 
guides, checklists, Direct HCP Communications (DHPCs), patient cards, pregnancy prevention 
programmes (PPPs). Safety concerns addressed by aRMMs range from adverse reactions associated 
with the drug to medication and administration errors, or the increased risk in special populations such 
as pregnant women. 
Efforts are being made in Europe to evaluate the effectiveness and implementation of aRMMs, to 
establish whether an intervention has been effective, and, if not, why and which corrective actions 
are necessary. The effectiveness of aRMMs may be assessed through process indicators (e.g. receipt, 
use, knowledge, self-reported behaviour, mainly via survey studies), behavioural changes (e.g. drug 
utilization studies) and/or health/safety outcomes (e.g. rates of adverse events). The term risk 
minimisation evaluation (hereinafter ‘RMEv’) is used in this document to describe a study or group of 
studies that assess the effectiveness of aRMMs for one specific product. Studies linked to one product 
are considered part of the product RMEv. RMEv should ideally include measures of effectiveness at 
the three levels of evaluation: process indicators, behavioural outcomes, and health/safety 
outcomes. However, this may vary by product. 
This thesis evaluates subject participation, country selection, study results and regulatory 
consequences of survey studies evaluating the effectiveness of aRMMs via process indicators in 
Europe (hereinafter EU RM Surveys). Additionally, this thesis describes RMEv which include process 
indicators and outcomes and provides a potential methodological framework for RMEv at the three 
evaluation levels (process indicators, behavioural outcomes, and health/safety outcomes) via a non-
interventional post-authorisation safety study (PASS) with results endorsed by EMA regulators. The study 
was conducted to evaluate the effectiveness of the abatacept (ORENCIA®) patient alert cards 
(PACs) in rheumatoid arthritis (RA) patients and HCPs. Two PACs are available, one for each 
formulation (intravenous [IV] and subcutaneous [SC]), to help inform patients and HCPs of the 
potential risks and actions required during treatment with the product, specifically for infections and 
allergic reactions, with the ultimate goal of reducing the occurrence of undesirable outcomes (e.g., 
hospitalisations), or severity (e.g., reducing delays in seeking medical care). 








Methods: We conducted a systematic literature review in the EU PAS Register, PubMed and grey 
literature to search for study reports and manuscripts of completed EU RM Surveys between Jan 2011 
and Jan 2018. Regulatory consequences/actions were extracted from Assessment Reports of study 
results issued by competent authorities. Random effects models to combine proportions were used 
for: participation rates (i.e. proportion of subjects invited who completed the survey; proportion of 
subjects eligible who completed the survey), receipt (i.e. proportion of participants who reported 
having received the materials), reading (i.e. proportion of participants who reported having read the 
materials among those who received them), use (i.e. proportion of participants who reported having 
used the materials among those who received them), and knowledge (i.e. proportion of participants 
who correctly responded the knowledge questions).  
The search was updated in October 2019 using the EU PAS Register, PubMed, and grey literature to 
capture a greater number of EU RM Surveys. Studies identified were used to extract more detailed 
data on country selection and subject participation overall and by country. This allowed to calculate: 
number and percentage of studies in which each country participated, number and percentage of 
completers that each country provided, by study and overall: 1) as the percentage of completers 
each country provided to the overall number of completers in all studies; or 2) as the percentage of 
completers each country provided to the overall number of completers in studies with that country 
participation identified. Response rate was calculated as the percentage of participants who 
completed the survey among those invited to participate. The range of response rates was described. 
As part of the search conducted in October 2019 studies to assess the effectiveness of aRMMs 
(hereinafter EU RM studies) using behavioural and/or health/safety outcomes were also retrieved. 
Identified studies linked to one product were assigned to the product RMEv. Only RMEv that included 
both process indicators and outcomes (behavioural and/or health/safety outcomes) were reviewed. 
Data were extracted which included: at RMEv level (ATC group, type of aRMM, targeted safety 
concerns, number of studies conforming the RMEv i.e., 1 study, 2 studies or ≥3 studies) and at study 
level (study design, countries, outcome measures, data sources). Where available study results were 
obtained and summarised.  
A PASS study evaluating the effectiveness of abatacept PACs and consisting of three sub-studies was 
carried out in five European countries: 1) survey of HCPs (nurses and physicians), 2) survey of patients, 
and 3) retrospective chart review in the same patients who completed the survey. This permitted 
linking clinical and safety outcomes obtained via the chart review with survey responses in the same 
patients. Survey responses were analysed descriptively, and summary scores for endpoints (scores of 
utility, utilisation, knowledge, behaviour, and global score) were calculated. All analyses were 
performed overall and by receipt versus non-receipt of the PACs. 








The study assessed whether better responses provided by abatacept-treated patients in the patient 
survey were associated with improved outcomes (e.g. availability of results of screening tests for 
tuberculosis (TB) and viral hepatitis (VH) prior to abatacept use, occurrence of infections leading to 
hospitalisation and/or infections leading to emergency room visits and time from occurrence of 
infection to receiving medical attention). Univariate analyses correlated within-patient clinical and 
safety outcomes responses to process indicators in the patient survey. 
For all the analyses, differences between groups were assessed using parametric and non-parametric 
statistical methods as applicable. P-values < 0.05 were considered statistically significant. 
Results: In the initial search conducted in January 2018, 109 EU RM studies were identified, of which 
24 had a survey component and results available at the time of the analysis. Of these, 23 studies 
targeted HCPs. The pre-specified sample size was reached in 52% of studies. The pooled HCP 
participation was 5% defined as completers/invited and 89% for completers/eligible. Receipt of 
materials was recalled by 60% of HCPs and 77% of items scored knowledge >60%. Eight studies 
targeted patients/caregivers. The pre-specified sample size was reached in only two. The pooled 
participation was 93%, defined as completers/eligible. Materials were received by 50–80% of patients 
and read by over 90%. Patients only scored knowledge >60% in 38% of items. Further action was 
requested by regulators in 59% of studies. 
In the updated search conducted in October 2019, of 129 EU RM studies, the number of completed 
surveys raised up to 48. Twenty-eight different European countries participated in the 44 surveys that 
targeted HCPs (mean: 6 countries per study). UK, Spain, France and Germany were the most 
frequently selected countries, contributing 64% of all participants with country-specific data. 
Seventeen different European countries participated in the 14 surveys that targeted 
patients/caregivers (mean: 5 countries per study). UK, Germany, France and Spain were the most 
frequently selected countries, contributing 66% of all participants with country-specific data. 
In the search of October 2019, 102 product-specific RMEv were identified, of which 18 (18%) had both 
process indicators and outcomes. Of the 18 RMEv, ten consisted of one study only, five of two studies, 
and three of three or more studies. A total of 30 studies were included within the 18 RMEv. The designs 
of the studies were: 19 (63%) cross-sectional surveys (47% targeted patients and 89% healthcare 
professionals), 17 (57%) retrospective studies (47% using pre/post approach) and 3 (10%) prospective 
studies. Nineteen studies included process indicators that were receipt (n=14), use (n=12), knowledge 
(n=17) and self-reported behaviour (n=15). Regarding outcomes, 67% of the 18 RMEv evaluated 
behavioural outcomes and 50% health/safety outcomes. Three of the 18 RMEv evaluated both 
behavioural and health/safety outcomes. For five RMEv, correlations between process indicators and 
outcomes were performed, two at the patient level. Results were available for 14 of the 18 RMEv. In 
HCP surveys, the median percentage was 57% for receipt, 92% for reading, 80% for use, 77% for 








knowledge and 74% for behaviour. In patient surveys, the median percentage was 56% for receipt, 
87% for reading, 65% for use, 47% for knowledge and 69% for behaviour. Knowledge was better in 
healthcare professionals than patients (p < 0.05). Three of the 5 RMEv which included a correlation 
analysis had results available. Of these, only one (the abatacept study later described) found a 
positive trend for a lower occurrence of outcomes as process indicators improved, though this was 
not statistically significant. 
In the abatacept case study, data on 190 patients and 79 HCPs (50 physicians and 29 nurses) were 
analysed. Sixty percent of patients were aware of the PAC, of whom 95% had received it. Knowledge 
of risk of infection was higher among patients who had received the PAC vs those who had not (64% 
vs 46%; p = 0.013). Infections leading to hospitalisation increased with decreasing patient survey global 
scores: scores of >67%, 34%-67% and ≤ 33% were associated with hospitalisation rates of 2.5%, 5.2% and 
8.4%, respectively (p = 0.4). Among HCPs, 90% were aware and 68% had accessed the PAC. More 
nurses than physicians were aware (93% vs 88%), had accessed (78% vs 74%), read (90% vs 59%), 
distributed (81% vs 66%) and explained the content (94% vs 43%) of the PAC. Knowledge of risk of 
infection was higher among HCPs who had (91%) vs those who had not (73%) accessed/received the 
PAC (p = 0.053). 
Conclusions: The field of therapeutic RM has become an area of intensive research since the 
implementation of GVP XVI. As of October 2019, at least 129 EU RM studies had been designed and 
conducted to assess the effectiveness of RMMs for 102 different products in Europe. About forty 
percent of EU RM Surveys provided evidence that supports the effectiveness of RMMs based on 
regulatory Assessment Reports. The remaining sixty percent of studies required further action for 
distribution strategies, re-distribution, and follow-up assessment, changes to existing materials, further 
data awaited and, in a minority, removal of the materials. However, this review identified some 
challenges that remain in the design, conduct, and reporting of survey studies, which may benefit 
from more detailed guidance, use of common definitions, standardization of reporting. Some of the 
limitations of cross-sectional study designs (i.e., surveys) may be overcome by drug utilisation and 
outcomes evaluations which have been used conjunctively with EU RM Surveys in eighteen percent 
of RMEv to supplement the results of process indicators. There are currently few studies correlating 
within-patient survey results with heath/safety outcomes. This thesis provided a potential framework 
for the evaluation of effectiveness of aRMMs via a case study involving surveys and a retrospective 
chart review to correlate process indicators and safety outcomes in the same patients. This novel study 
design bridges the gap of linking process indicators with outcomes at the individual-patient level and 
strengthens the clinical relevance of results from surveys. The results support the effectiveness of the 
abatacept PACs. The practical impact of this study resulted in no modifications to the content of the 
PACs or further evaluations being requested by EMA regulators. The learnings of this thesis may be 








used by MAHs, academic groups and regulatory authorities to inform the design of future RMEv 
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Therapeutic risk minimisation (RM) has become an area of extensive research in recent years with the 
release of specific guidance from the main regulatory agencies worldwide [e.g. Food and Drug 
Administration (FDA) in 2005 [1], European Medicines Agency (EMA) in 2014 [2], Japanese 
Pharmaceuticals and Medical Devices Agency (PMDA) in 2012 [3]). Risk minimisation with additional 
risk minimisation measures (aRMMs) refers to the implementation of strengthened requirements for 
medicinal products where safety concerns are not sufficiently addressed by routine measures alone 
[e.g., Summary of Product Characteristics (SmPC), patient leaflet]. Within this context, the evaluation 
of whether aRMMs work as intended is a key aspect of the product RM strategy. Differences in post-
marketing safety regulatory policies are noted across regions [4]. This thesis concentrates on studies 
that evaluate the effectiveness of aRMMs (hereinafter EU RM studies) within the European setting.  
3.1.1. Regulatory Context 
Regulatory guidance on the development of the EU Risk Management Plan (EU-RMP) was first released 
in November 2005 [5], becoming a key component of the EU centralized authorisation procedures for 
medicinal products. In line with regulatory guidance [6], the EU-RMP summarizes the increasing 
knowledge on the safety profile of an authorised medicine throughout its lifecycle, including any study 
planned for this purpose (i.e. pharmacovigilance studies), and any measure introduced to minimise 
the therapeutic risk associated with its use. With these regulatory changes, the EU-RMP became legally 
enforceable [7]. In the European Union (EU), marketing authorisation holders (MAHs) must submit a 
RMP to the EMA at the time of application for a marketing authorisation. RMPs are continually modified 
and updated throughout the lifetime of the medicine. 
In December 2010, the European Parliament and European Council adopted the amendments to the 
EU Pharmacovigilance (PhV) legislation, which came into force in July 2012 with the application of 
Regulation N⁰ 1235/2010, Directive 2010/84/EU, and subsequent Commission Implementing Regulation 
N⁰ 520/2012 [8–10]. The new PhV legislation introduced significant changes around PhV processes in 
Europe including the release of 16 guideline modules outlining good PhV practices (GVP) [11,12] and 
strengthened risk management requirements for medicinal products centrally authorised in EU.  
In July 2012, the Pharmacovigilance Risk Assessment Committee (PRAC) was created [13] to help 
strengthen the safety monitoring of medicines across Europe. The PRAC is responsible for assessing all 
aspects of risk management of human medicines, including the detection, assessment, minimisation 
and communication of the safety concerns, design, and evaluation of post-authorisation safety 
studies (PASS) and PhV audit. The PRAC also provides recommendations on PhV and risk management 
systems, including the monitoring of their effectiveness [14]. 








3.1.1.1. Therapeutic Risk Minimisation: Specific Regulatory Guidance in Europe 
Risk minimisation measures (RMMs) are “interventions intended to prevent or reduce the occurrence 
of adverse drug reactions associated with the exposure to a medicine or to reduce their severity or 
impact on the patient, should adverse reactions occur” [9]. RMMs include routine measures (rRMMs) 
applied to all authorized medicines (i.e., SmPC, labelling, package leaflet, pack size(s), and legal 
status of the product) and aRMMs. Most safety concerns are addressed by rRMMs. Additional risk 
minimisation measures are only introduced when routine measures are deemed to be insufficient for 
the safe and effective use of a medicine.  
In 2009, Aronson et al. proposed a strategy to inform decision-making for regulatory action when new 
adverse events arise during the lifecycle of a medicinal product, including protective strategies to 
minimise risks [15]. A regulatory framework for selection, development and evaluation of the 
effectiveness of aRMMs is available in the Guideline on GVP Module XVI first adopted in 2014 [2] and 
its addendum [16]. In the same year, the Council for International Organizations of Medical Sciences 
(CIOMS) Working Group IX published Practical Approaches to Risk Minimisation, which provides a 
framework for the evaluation of effectiveness of RMMs [17].  
Additional risk minimisation measures may differ widely in purpose, design, target audience and 
complexity. These measures might be used to guide appropriate patient selection with the exclusion 
of patients where use is contraindicated, to support on-treatment monitoring relevant to important 
risks and/or management of an adverse reaction. Additionally, specific measures may be developed 
to minimise the risk of medication errors [18,19] and/or to ensure appropriate administration of the 
product where it is not feasible to achieve this through the product information and labelling alone. 
Table 1 describes the types of aRMMs that may be considered in addition to the routine measures. 
Table 1. Types of aRMMs [2] 
Type of aRMM Description 
Educational Programmes 
Educational materials 
for HCPs e.g., brochures 
or checklists 
Contents should provide recommendations on the use, contraindications or 
warnings related to specific safety concerns described in the RMP referring to the 
SmPC and the package leaflet for additional information. The material would 
include guidance on prescribing, including patient selection, testing and 
monitoring; administration or dispensing procedures; management of risks; how 
and where to report adverse reaction of special interest. 
Educational materials 
for patients/caregivers 
e.g., brochures  
Contents should aim to enhance patient/caregiver awareness of the early signs 
and symptoms of specific adverse reactions and actions to take. The material 
would include guidance on correct administration of the product or remind the 
patient on any action that needs to be taken e.g., inform HCP.   
Patient card 
Tool that can be carried with ease to ensure that information regarding the 
patient’s current therapy and its important risks is held by the patient at all times 
and reaches the relevant HCP when needed. The information should be kept to 
the minimum necessary. 








Type of aRMM Description 
Controlled Access Programmes 
Controlled Access 
Programme 
Programme that established the requirements that need to be fulfilled before the 
product is prescribed, dispensed or used. These programmes should only be 
considered in special circumstances where the restriction is required to ensure its 
safe use. Controlled access programmes may involve testing, examination of the 
patient, documentation of receipt, procedures for patient follow-up, dispending 




A PPP aims to minimise pregnancy exposure (i.e., female patients not pregnant 
when starting therapy or to prevent pregnancy during the course of treatment 
during treatment) with a medicinal product with known or potential teratogenic 
effects. A PPP may include educational tools targeting HCPs or patients, 
controlled access at prescribing or dispensing, counselling, etc. A pregnancy 




A DHPC is a communication tool targeted at HCPs to inform them of the need to 
take certain actions or adapt their practices in relation to a medicinal product. 
  
 
Marketing authorization holders are required to monitor the outcome of aRMMs. Evaluation of 
effectiveness of RMMs is important to manage the benefit‐risk balance of a medicinal product. Further 
details on RM evaluation are provided in Section 3.1.3.2.  
Relevant regulatory guidance documents are summarised in Figure 1 and Table 2. 
 












Table 2. Regulatory guidance on RM in Europe (currently effective) 
Regulatory Document / Effective Date Description 
Guidance on the format of the RMP in 
the EU – in integrated format [20] 
Effective Date: Oct 2018 
Provides a template for EU-RMPs 
GVP Module XV – Safety 
communication [21] 
First released in Jan 2013 
Effective Date of 1st Revision: Oct 2017 
Guidance on how to communicate and coordinate safety 
information concerning medicinal products authorised in the EU, 
with particular consideration to DHPCs. 
GVP Annex II – Templates: 
Communication Plan for Direct 
Healthcare Professional 
Communication [22] 
First released in Jan 2013 
Effective Date of 1st Revision: Oct 2017 
Provides a template for DHPCs 
GVP Annex II – Templates: 
Communication Plan for Direct 
Healthcare Professional 
Communication (CP DHPC) [23] 
Effective Date: Oct 2017 
Provides a template for communication plan of DHPCs 
GVP Module VIII – Post-authorisation 
safety studies [24] 
First released in Jul 2012 
Effective Date of 3rd Revision: Oct 2017 
Provides general guidance for the transparency, scientific 
standards and quality standards of non-interventional PASS 
conducted voluntarily or pursuant to an obligation imposed by an 
EU competent authority; describes procedures whereby an EU 
competent authority may impose on a marketing authorisation 
holder an obligation to conduct a PASS; describes procedures that 
apply to non-interventional PASS pursuant to an obligation 
imposed by an EU competent authority for the protocol oversight 
and reporting of results, for subsequent changes to the marketing 
authorisation 
GVP Module XVI – Risk minimisation 
measures: selection of tools and 
effectiveness indicators [2] 
First released in Mar 2014 
Effective Date of 2nd Revision: Mar 2017 
Guidance on the principles for the development and 
implementation of aRMMs, including examples of RM tools. The 
evaluation of the effectiveness of RMMs. 
GVP Module V – Risk management 
systems [25] 
First released in Jul 2012 
Effective Date of 1st Revision: Oct 2017 
Guidance on the principles of risk management planning. This 
Module includes the principles of RM and should be read in 
conjunction with GVP Module XVI and GVP Module XVI 
Addendum I on educational materials 
GVP Module XVI Addendum I – 
Educational materials [16] 
Effective Date: Dec 2015 
Guidance on the submission of draft education materials to the 
competent authorities of Member States as well as guidance for 
these competent authorities on the assessment of such materials, 
in particular as regards the format and content. Individual Member 
States may have additional requirements, and as such this 
guidance should be followed together with other national 
guidelines 
Good practice guide on risk 
minimisation and prevention of 
medication errors [19] 
Effective Date: Nov 2015 
This good practice guide is one of the key deliverables of the 
Agency’s medication error initiative and offers guidance on RM 
and prevention of medication errors. The guidance includes 
population-specific aspects in paediatric and elderly patients, as 
well as guidance on the systematic assessment and prevention of 
the risk of medication errors throughout the product life cycle. 








Regulatory Document / Effective Date Description 
Risk minimisation strategy for high-
strength and fixed-combination insulin 
products Addendum to the good 
practice guide on risk minimisation and 
prevention of medication errors [26] 
Effective Date: Nov 2015 
Guidance as a checklist to ensure that the risk of medication errors 
is addressed consistently for all high strength insulins/fixed 
combination insulins and in line with the regulatory requirements 
specified in GVP Module V on risk management planning and GVP 
Module XVI on RMMs: selection of tools and effectiveness 
indicators. 
 
3.1.1.2. European Risk Management Plan (EU-RMP) 
The EU-RMP is a key requirement for medicinal products centrally approved in Europe. Planning, 
implementing, or evaluating the effectiveness of aRMMs are key elements of the EU-RMP [20]. 
The EU-RMP includes:   
1) Safety Specification: identification or characterisation of the safety concerns for the medicinal 
product including the risks that need to be further characterised or managed proactively. 
Adverse reactions are referred to as safety concerns in the EU-RMP. In the EU-RMP, a list of all 
safety concerns for the medicinal product is included. A safety concern is any of the important 
identified risks, important potential risks, or missing information included in the EU-RMP.  
2) Pharmacovigilance Plan: routine or additional pharmacovigilance activities (i.e. studies) in 
place to characterise and quantify serious or clinically relevant risks of adverse reactions, and 
to identify new adverse reactions. Studies in the pharmacovigilance plan should relate to the 
safety concerns identified in the safety specification irrespective of whether the studies are to 
identify and characterise important risks/missing information, or to assess the effectiveness of 
aRMMs [20]. Studies conducted after authorisation of the medicinal product to further 
investigate or characterise the safety profile of the drug are known PASS. 
3) RM Plan: rRMMs or aRMMs planned or in place including the evaluation of the effectiveness of 
these activities. In the EU-RMP, a list of all RMMs, additional or routine, is included.  
3.1.1.3. Post-Authorisation Safety Studies  
A PASS is any study relating to an authorised medicinal product conducted with the aim of identifying, 
characterising or quantifying a safety concern, confirming the safety profile of the medicinal product, 
or of measuring the effectiveness of RMMs [24]. A PASS may be pursuant to an obligation imposed by 
a competent authority (categories 1 and 2) or initiated, managed, or financed voluntarily by a MAH 
(categories 3 and other). A description of the PASS categories is provided in Table 3.    
Table 3. Categories of PASS in the EU-RMP [27] 
Category Description Status 
1 Imposed as an obligation 
Mandatory and subject to 
penalties 








Category Description Status 
2 
Imposed as a specific obligation in the framework of a 
marketing authorisation granted under exceptional 
circumstances 
Mandatory and subject to 
penalties 
3 
Required in the RMP to investigate a safety concern or to 
evaluate the effectiveness of RMMs 
Legally enforceable 
Other 
Not obligations or required studies in the RMP but which 
could provide relevant information on the safety profile of 
the product 
Non-imposed PASS, not required 
in the RMP 
 
For non-interventional PASS imposed as an obligation, the draft study protocol shall be submitted by 
the MAH to the PRAC or to the national competent authority of the Member State that requested the 
study. The final study report (FSR) shall also be submitted to the competent authority within 12 months 
of the end of data collection. Requirements and recommendations for submission of the protocol and 
FSR are specified in Module VIII Addendum I [28]. Regulatory Assessment Reports (AR) are generated 
by the competent authorities in response to the FSR submission, either requiring changes to the report, 
requesting supplementary information or approving the report with no further changes or discussion. 
ARs are therefore a source for identifying regulatory consequences, and can be requested to the 
EMA via the Access to Documents request [29].  
3.1.1.4. EU PAS Register 
The EU electronic Register of Post‐Authorisation Studies (EU PAS Register) is a publicly available source 
of non-interventional post-authorisation studies (PAS), launched in 2010 and hosted by the European 
Network for Centres of Excellence in Pharmacoepidemiology and Pharmacovigilance (ENCePP) 
under the auspices of the EMA [30]. According to the GVP Module VIII, MAHs are legally required to 
register non-interventional PASS imposed as an obligation (i.e., categories 1 and 2). It is also 
recommended to register all category 3 (required in the RMP) non-interventional PASS and any other 
PASS to support transparency and facilitate the exchange of information between different 
stakeholders. The EU PAS Register includes study documents such as study protocol and report of the 
registered studies (based on status—planned, ongoing, or completed), which provides a unique 
opportunity to examine study details. Therefore, the EU PAS Register is a valuable resource for PASS, 
including those evaluating the effectiveness of RMMs and those mandated by EMA. 
3.1.2. Products with aRMMs in Europe 
Products with aRMMs account for almost a third of centrally authorised products in Europe [31,32]. 
Zomerdijk et al. reported that 5% of the active substances authorized before the new legislation (up 
to 2005) had aRMMs, while aRMMs were identified for 29% of the active substances approved after 
the new legislation (2006-2009). Additional RMMs were most frequently agreed for active substances 
concerning ‘alimentary tract and metabolism’, ‘anti-infectives for systemic use’ and ‘antineoplastic 
and immunomodulating agents’ [32]. Similarly, a posterior review found that 26% of centrally 








authorised products were approved with aRMMs in Europe between 2006 and 2015 (yearly frequency 
ranging from a minimum of 12% in 2008 to a maximum of 41% in 2010; Figure 2) and the 
antineoplastic/immunomodulating group being the most prevalent (26%) [31]. All aRMMs consisted of 
educational interventions, mostly targeting physicians/nurses (96%). Patients were targeted in 50% of 
instances. A high presence of educational materials (86%, educational material (86%); 4%, black-box 
warnings; 4%, withdrawals) was also reported in the review by Nkeng et al., which had a wider 
geographical scope (US, Japan, Canada, Australia, Europe) [33]. 
 
 
Figure 2. Frequency of aRMMs imposed for centrally approved medicinal products in Europe 
(Adapted from [31]) 
 
A review of RMPs for products assessed by the Medicines and Healthcare products Regulatory Agency 
(MHRA) in the UK showed that 42% of approved RMPs included aRMMs between 2005 and 2011 [34]. 
The most frequent types of risks requiring aRMMs were adverse drug reactions (39%) and medication 
errors (23%). 
Zomerdijk et al. defined key elements (also referred to as key messages in this report) as components 
of aRMMs agreed by regulatory authorities at European level [35]. Each aRMM may have multiple 
elements. The median number of key elements was 9.5 per active substance. As shown in Figure 3, 
while 36% of the 801 identified key elements aimed to accomplish knowledge changes, 57% referred 
to behavioural changes. Key elements for HCPs, which mainly addressed behavioural changes (64%), 
were most frequently classified as “recommended actions regarding drug prescription” and 
“recommended actions regarding the drug administration process”. Of the key elements targeted at 
patients, 56% addressed behavioural changes, mainly consisting of “recommended actions to be 
followed during treatment use”. 









Figure 3. Key elements in identified aRMMs (Adapted from [35]) 
3.1.3. Risk Minimisation Planning 
The introduction of aRMMs should be considered as a “programme” where specific interventions, an 
implementation plan and evaluation approach are planned and developed. This would start with the 
selection, development and implementation of the most appropriate measure, and finish with the 
evaluation of its effectiveness, which may have consequences on the aRMMs.  
3.1.3.1. Selection, development, and implementation of aRMMs 
aRMMs may be requested by a regulator or proposed by the MAH to minimise a safety concern. When 
designing the RM Plan, careful consideration should be given to the following aspects:  
• Safety concern(s): nature and frequency of the safety concern(s). 
• Type(s) of interventions: a RM plan may consist of one or multiple interventions/aRMMs. The 
types of aRMMs that may be implemented are summarised in Table 1. The specific aRMMs in 
place for centrally approved products are available via de EMA website (i.e., in the SmPCs 
and European Public Assessment Reports). The local adaptations may be accessible through 
the websites of the competent authorities in each country (e.g. RMM Directory of the 
electronic Medicines Compendium in the UK [36], Centre for the Information of Medicines in 
Spain [37]). 
• Contents and implementation of the materials: The core materials and their key messages are 
generally agreed centrally with EMA. However, the local adaptation and implementation 
plan, including the procedures to reach the target population, should be devised and agreed 
locally with the competent authorities in the countries where the product is or will be launched. 
What works in a country may not work in the other. The aRMMs implemented with the agreed 
key messages are available in the SmPC and summary RMP from the EMA website. Local 
agencies may as well make the final materials in local language available via their websites.  
• Timing of implementation: in some instances, safety concerns are identified at time of central 
authorisation and thus aRMMs should be implemented and made available at that time. In 








other circumstances, safety concerns arise with the product already on the market, requiring 
an action plan after product launch. 
• Target audience: this may include HCPs (physicians, nurses, pharmacists) or patients/ 
caregivers.  
Best practices and research methods should be applied in designing and implementing aRMMs to 
ensure successful RM [38,39]. 
3.1.3.2. Evaluation of effectiveness of aRMMs 
Evaluating the effectiveness of aRMMs is key to establish whether an intervention has been effective 
or not in reducing product safety concerns, and if not why and which corrective actions are 
necessary. Prior research in this area reported that the evaluation of effectiveness of RMMs was limited 
to 31% of medicines which included aRMMs up to 2015, with an accelerated increase detected over 
time [4].  
The effectiveness of aRMMs can be evaluated by process and/or outcome indicators.  
• Process indicators measure the extent to which aRMMs were implemented (e.g., receipt of the 
materials by the target audience), whether they are used as expected (e.g., if the target 
audience reads the materials or whether they distribute them to patients), and the impact of 
the educational materials on the level of knowledge and/or self-reported behaviour of the 
recipient around key safety messages.  
• Outcome indicators provide an overall measure of the level of risk control achieved by the 
aRMM. Impact on safety outcomes can be assessed, for example, measuring changes in rates 
of an adverse drug reaction or other safety‐related outcomes [2] over time (e.g. before and 
after the implementation of aRMMs). In some instances, indirect or surrogate measures of the 
safety outcome may as well be used e.g. reduction in hospitalisations, changes in laboratory 
values [40]. Therefore, these are conjunctively referred to as health/safety outcomes in this 
document.  
• Other indicators are designed to assess the impact on behaviour via drug utilisation studies. 
The term behavioural outcome is used in this document to describe indicators which evaluate 
outcomes of clinical actions (e.g., prescribing behaviour or monitoring of clinical or laboratory 
parameters). These have been considered in this document as a separate entity in the 
evaluation of effectiveness as they constitute intermediate endpoints between processes and 
final safety outcomes.  
Prieto et al. was the first to describe the dual-evidence framework with process indicators and 
outcomes for RM evaluation, that later constituted the basis of GVP Module XVI [41]. This was further 
expanded by Banerjee et al. 2013 which placed particular emphasis on the challenges (e.g. 
appropriate data collection, perceived and real burdens of performing evaluation on clinical 








practice, lack of comparators and benchmarking, and uncertainty about the best outcome 
measures) and interpretation of study results [42].  
The term RM Plan is used in the EU-RMP of centrally approved products to describe the selection of 
RMMs and the studies/measures designed to assess their effectiveness which are required by EMA. 
However, if a study to assess the effectiveness of aRMMs falls under category 4, it may not be 
documented in the EU-RMP. Additionally, some products may be nationally approved with studies 
requested by the national competent authority, in which case national oversight procedures would 
apply. There may be as well studies independently initiated or conducted by academic groups. 
Therefore, no existing term has been used prior to this work to designate the combination of studies to 
assess the effectiveness of aRMMs. The term risk minimisation evaluation (hereinafter ‘RMEv’) is newly 
introduced in this document to describe not only a study, but a group of studies that assess the 
effectiveness of aRMMs for one specific product. Studies linked to one product are considered part 
of the product RMEv (Figure 4).  
RMEv should ideally include measures of effectiveness at the three levels of evaluation: process 
indicators, behavioural outcomes and health/safety outcomes. However, this may vary by product.   
 
Figure 4. Flow chart of RMEv through process and outcome indicators, during the product lifecycle 
When planning a RMEv the following aspects should be considered: 
• Timing of the evaluation: time points which may be relevant for evaluation include after initial 
implementation of a RM programme (e.g., within 12-18 months), on one occasion or on 








multiple occasions, in time for the evaluation of the renewal of a marketing authorisation, 
before and after the implementation of aRMMs, etc. 
• Measures of effectiveness: process indicators and/or outcomes may be measured. MAHs are 
encouraged to measure both process indicators and outcomes [2], however, this is performed 
only for certain products. In these cases, in which outcomes are not measured, the 
effectiveness of the implemented aRMMs may solely be based on the interpretation of results 
of process indicators.   
• Number of studies and design approach: while some RMEv consist of one only study, others 
may be formed by multiple studies which supplement each other. The evaluation approach 
should consider whether one or multiple evaluations are needed.  
• Geographical scope: countries where aRMMs have been implemented and where the 
evaluation of effectiveness proves feasible, representative, and reliable.  
• Study population: the selection of the study population should be consistent with the study 
objectives and audience of the aRMMs.  
• Threshold of effectiveness: certain study designs (e.g., surveys) may benefit from a predefined 
threshold to guide effectiveness interpretation. However, there is no clear guidance on 
whether this should or should not be part of evaluation plans.  
• Key contents targeted in the assessment: evaluations must be proportional and aligned with 
the intended objective of the key messages in the aRMMs e.g., behavioural changes versus 
knowledge changes. Refer to section 3.1.2 for further details on the key elements of materials.  
3.1.3.2.1. Methodological approaches to inform effectiveness evaluation 
Studies with a RM objective use standard epidemiological methods which may involve primary data 
collection (e.g., surveys or prospective designs) and secondary data use via medical chart 
abstraction or analysis of existing databases. The ENCePP Guide on Methodological Standards 
provides general guidance on study approaches and methods, while Annex 2 provides specific 
guidance and recommendations on methods for measuring the impact of PhV activities [43]. 
However, creativity is needed to find the most appropriate approach to address the specific needs 
of the study, which in some instances may require a combination of designs and measures.   
Survey studies (hereinafter EU RM Surveys) are primarily conducted to assess process indicators. 
Methods for survey methodology and main requirements for RM evaluation are outlined in GVP 
Module XVI [2]. The ENCePP Guide on Methodological Standards was recently updated to include, 
among other changes, a chapter about survey methodology [44]. 
3.1.3.2.2. Quantification and characterisation of the evaluations 








Leading research groups in the field, from regulatory, academic and industry settings, conducted 
reviews to characterise the type of evaluations available in the literature to assess the effectiveness 
of aRMMs in Europe (Table 4) [31,35,45–50]. 
About one third of the products with aRMMs had studies to assess their effectiveness [31,48], and are 
generally initiated upon request by a regulatory authority [45,51]. Of the 188 aRMMs identified by 
Gridchyna et al. worldwide between 2000 and 2010, effectiveness was evaluated in 35% [48]. Rubino 
and Artime reported that effectiveness evaluation was limited to 31% of medicines centrally 
authorised between 2006 and 2015 in Europe [31].  
Process indicators and changes in behaviour were frequently measured in effectiveness studies, while 
safety outcomes were limited to a minority of cases. The review by Mazzaglia et al. identified 59 studies 
for cardiovascular, endocrinology, and metabolic indications, most assessing process indicators 
(n=44), and only 15 assessing safety outcomes [47]. Gridchyna et al. reported that most of the studies 
(75%) evaluated changes in behaviour through prescribing or laboratory test practices, one quarter 
evaluated the effect on the occurrence of adverse events [48]. Farcas et al. used the EU PAS register 
as the main source of EU RM studies, registered up to June 2018 [45]. Of 29 studies with RM objectives 
identified, all assessed process indicators (mainly knowledge and behaviour), five also assessed 
outcomes (dual-evidence evaluation approach). By contrast, the review by Goedecke et al., which 
had a broader scope (studies assessing the impact of regulatory action), found that more than half 
of the studies measured changes in drug utilization patterns, 27% evaluated health outcomes, and 
18% targeted knowledge, behaviour, or changes in clinical practice [50].  
Most studies used a survey design, followed by retrospective designs based on medical records or 
existing databases. In Vora el al., 11/19 included studies were cross‐sectional surveys mostly involving 
HCPs, and 8/19 used secondary data sources (2/8 involved chart review using electronic medical 
records while 6/8 studies used multiple health care database) [51]. Of 29 studies identified in Farcas 
et al., 24 used surveys and one direct observation of patients/caregivers by HCPs. Nine studies used a 
retrospective design (retrospective chart reviews (n=4), prescription databases (n=3), disease registry 
(n=1) and PET scans interpretations (n=1)) [45]. Of 59 studies included in Mazzaglia et al., 25 used 
electronic healthcare databases and 18 used questionnaires [47]. 
The interpretation of results and whether pre-specified outcomes were successfully achieved is a key 
aspect of effectiveness studies. Effectiveness outcomes were considered successful in half of the 
studies, while the remaining were inconclusive or not possible to assess [52]. Mazzaglia et al. showed 
that 24/59 studies were completed; 17 being successful, six inconclusive requiring new evaluations, 
and one terminated early due to new safety restrictions and evaluation requirements [47]. UK 
regulatory risk communications were assessed in Weatherburn et al. where significant changes in 
targeted prescribing and clinical outcomes were observed [53]. 















Review sources Review scope Extracted Key Results 




aRMMs aRMMs were identified for 58/391 active substances. The proportion 
of active substances with aRMMs was 5% among those authorized 
before, and 29% among those approved after the new risk 
management legislation. All active substances with aRMMs required 
the provision of educational material, most frequently involving 
HCPs (n=57) and the patient (n=31). Thirty-three active substances 
required aRMMs on top of the provision of educational material, 
most frequently including patient monitoring and screening (n=19). 





(EMA, FDA, Australian 
Register of 
Therapeutic Goods) 
aRMMs A total of 119 aRMMs were identified. Interventions included 
educational material (31%), black-box warnings (19%) and 
therapeutic drug monitoring (9%). The website review produced a 
total of 1112 interventions: 326 posted between the years 2000 and 
2004, and 786 between the years 2005 and 2009. The main 
interventions observed were educational material (86%), black-box 
warnings (4%) and withdrawals (4%).  





aRMMs and the 
effectiveness of these 
aRMMs in existing 
electronic healthcare 
databases  
68 drugs with aRMMs contained 801 key elements of which 57% 
aimed at behavioural changes. 22% of all key elements, all aimed 
behavioural changes, were assessed eligible for analysis in existing 
databases. These mainly concerned recommendations targeted at 
HCPs regarding drug prescription, e.g., dose recommendations, 
contraindications or the need to perform laboratory tests for patient 
monitoring. 




aRMMs and the 
effectiveness of 
aRMMs 
The database encompassed 717 medicines, including 550 non-
generic products authorised in 2006–2015. Those authorised with 
aRMMs accounted for 26%. Yearly frequency ranged from 12% in 
2008 to 41% in 2010, though no time-trend was detected. 
Antineoplastic/immunomodulating products were the most 
prevalent (26%). All aRMM consisted of educational interventions, 
mostly targeting physicians/nurses (96%). Patients were targeted in 
50% of instances. Effectiveness evaluation was limited to 31% of 
medicines, though an accelerated increase by year was detected 





New drugs approved 
with aRMMs 
Implementation of aRMMs was 26% (42/159 drugs) in Europe, 8% 
(15/197 drugs) in the US, and 65% (92/142 drugs) in Japan 














Review sources Review scope Extracted Key Results 
[49] 1993 - 2017 Worldwide PubMed, Scopus 
(including Embase) 
and Web of Science 
databases were 
Studies of DHPC A total of 16 studies were included; 12 based on surveys, 2 on 
document analysis, and 2 primarily on interviews. The prevalent 
themes included “HCPs have less trust in communication from 
industry than authorities and medical associations”, “HCPs have 
diverse preferences for how to receive drug risk information” and 
“Clinical usability of the presented information is less than optimal.” 
[45] Up to 2018 Europe EU Post-Authorization 
Studies Register 
Studies that assessed 
effectiveness of 
RMMs 
A total of 29 studies were included. Twenty-six studies evaluated 
aRMMs, employed in case routine interventions are considered 
insufficient. All studies assessed process indicators, five also assessing 
outcome indicators, thus using a dual-evidence approach as 
recommended by the guidelines. However, none of the latter used 
a pre-post design, comparing the frequency of the adverse 
outcome before and after the implementation of RMMs. Behaviour 
and knowledge were the most often assessed process indicators. 
Outcome indicators included occurrence of adverse reactions, 
pregnancy, off-label use and medication errors. Only four studies 
had an established threshold, all for process indicators.  













and newsletters of all 
EU Member States 









due to safety reasons 
Eighteen single or combined active substances withdrawn, revoked 
or suspended within the EU for safety reasons between 2012 and 
2016 met the inclusion criteria. Case reports were most commonly 
cited, supporting 94% of regulatory actions, followed by randomised 
controlled trial, meta- analyses, animal and in vitro, ex vivo or in 
silico study designs, each cited in 72% of regulatory actions. 
Epidemiological study designs were least commonly cited (44%). 
Multiple sources of evidence contributed to 94.4% of regulatory 
decisions. Death was the most common adverse drug reaction 
leading to regulatory action (28%), with four of these related to 
medication error or overdose. Median (IQR) time taken to reach a 
decision from the start of regulatory review was found to be 204.5 
days (143, 535 days) and decreased across the study period. 
Duration of marketing prior to regulatory action, from the medicinal 
product’s authorisation date, increased 
[50] Up to 2017 Worldwide MEDLINE and 
EMBASE 
Analytical methods 
that assess the 
impact of European 
Union or non- 
A total of 153 articles were included. Over a third of articles studied 
analgesics and antidepressants. Interventions most frequently 
evaluated are regulatory safety communications (28.8%), black box 
warnings (24%) and direct healthcare professional communications 
(11%); 55% of studies measured changes in drug utilization patterns, 














Review sources Review scope Extracted Key Results 
European Union 
regulatory actions 
27% evaluated health outcomes, and 18% targeted knowledge, 
behaviour or changes in clinical practice. Unintended 
consequences like switching therapies or spill-over effects were 
rarely evaluated. Two-thirds used before–after time series and 16% 
before–after cross-sectional study designs. Various analytical 
approaches were applied including interrupted time series 
regression (31%), simple descriptive analysis (29%) and descriptive 
analysis with significance tests (24%). 





aRMMs and to 
identify 
methodological gaps 
A total of 188 aRMMs were identified in the literature, of which 
effectiveness was evaluated in only 65 (35%) at the time of 
publication. The largest proportion of studies reviewed (75%) 
attempted to evaluate changes in behaviour through prescribing or 
laboratory test practices. One quarter of studies evaluated the 
effect of aRMMs on the occurrence of adverse events. Only a 
minority of studies used robust designs, such as randomized 
controlled trials (9%) or a quasi-experimental design with a parallel 
comparison group (12%). 
[51] 2010 - 2016 European 
Union 
EU PAS Register Evaluation of 
effectiveness of 
RMMs 
A total of 19 studies were included. Eleven were cross‐sectional 
surveys and 8 used secondary data sources. Eighty‐nine percent 
evaluated aRMMs (used when routine RMMs are considered 
insufficient), and 36% evaluated changes in routine RMMs 
(applicable to all medicinal products). A total of 42 effectiveness 
indicators were identified: 18 process and 24 outcomes. Half of the 
indicators were successful; 2% indicators were partially successful; 
17% indicators were inconclusive. Effectiveness of the remaining 
31% indicators could not be determined owing to limited 
information. The UK was the most frequent country for the conduct 
of RM effectiveness studies. 
[47] 1995 - 2015 European 
Union 









and the associated 
regulatory outcomes  
A total of 44 studies assessed implementation measures, whereas 
only 15 assessed safety outcomes. Fifty-one studies used non-
experimental designs and 25 studies employed electronic 
healthcare databases. Of the 24 completed studies, 17 were 
considered satisfactory and supported immediate regulatory 
decision making, 6 were considered inconclusive and required new 
evaluations, and 1 was terminated early because new safety 
restrictions were required, thereby necessitating a new evaluation.  














Review sources Review scope Extracted Key Results 
[53] Up to 2017 United 
Kingdom 
MEDLINE, EMBASE, 





relevant to UK 
regulatory risk 
communication 
A total of 40 studies examining 25 UK regulatory risk communications 
were included. Product withdrawals, restriction in indications and 
be aware communications were associated with relative mean 
changes of −78%, −34% and −11% in targeted drug prescribing 
respectively. DHPCs were associated with relative mean changes of 
−47% compared to −13% for drug bulletins. Of 7 studies examining 
unique health outcomes related to the safety concern, risk 
communications were associated with a mean −10% decrease in 
intended and a 7% increase in unintended health outcomes. UK 
regulatory risk communications were associated with significant 
changes in targeted prescribing and potential changes in clinical 
outcomes. 
[56] Available 




SmPCs Regulatory rationale 
and criteria to 
require a PPP in the 
EU and to describe 
the different 
elements 
included in the 
existing PPPs 
Five of the seven drugs obtained a PPP based on an established or 
expected high teratogenic risk in humans. Similarities in the PPPs 
were: pregnancy tests both before and monthly during drug use; 
contraceptive use and pregnancy prevention counselling. 
Differences regarded educational materials, restricted drug supply, 
continuation of contraceptive use and pregnancy 
tests after treatment. The last two differences could be explained by 








Worldwide MEDLINE and 
EMBASE 
Federal Institute for 
Drugs and Medical 
Devices (BfArM), the 
EMA, and the FDA 
websites 
Impact of safety 
warnings on drug 
therapy 
72 studies were identified. A total of 39% studies described the 
impact of safety warnings on drug therapy as being effective, 
whereas 17% studies did not. Further, 36% studies 
described a partial implementation of the warnings (one part of the 
warning had an impact on drug therapy and another did not). 
Unintended effects were investigated in 8% studies. 
While 47% studies examined safety warnings on psychotropic drugs 
using an interrupted time series design (53%), a before/after (26%), 
and a time series design (21%), 38 (53%) studied other substances 
using an ITS design (34%), a before/ after (40%), and a time series 
design (26%). The proportion of an effective impact on 
drug therapy was lower in the “psychotropic drugs” group (23%) 
than in the “others” group (53%). 








3.1.3.2.3. Regulatory Evaluation and Consequences  
The outcome of the evaluation may be that aRMMs should remain unchanged or modifications are 
to be made to existing activities (Figure 5). Alternatively, the assessment could as well indicate that 
the existing aRMMs are insufficient and should be strengthened (e.g., through amendment of warnings 
or recommendations in the SmPC or package leaflet, improving the clarity of the RM advice and/or 
by adding additional tools or improving existing tools). Another decision may be that the RMM is 
disproportionate or lacking a clear focus and could be reduced or simplified (e.g., by decreasing the 
number of tools or frequency of intervention, or by eliminating interventions proved to be non-
contributory to RM) or that the implementation approach is inappropriate and does not reach the 
target audience. A recent review found a probability of discontinuation of aRMMs of 0.9% within 5 
years and 8.3% within 10 years after authorisation, arguing that a lack of robust data on effectiveness 
of aRMMs may be a potential reason for the low probability of discontinuation [58].  
In all circumstances, the burden on the patient and the healthcare system should be given careful 
consideration [2], minimising the potential for unintended consequences. In fact, Weatherburn et al. 
provides evidence that unintended consequences may occur when well-intended RM interventions 
are launched, which supports the need for continuous and systemic evaluation of effectiveness [53].  
 
Figure 5. Theoretical framework: consequences of RMEv 
3.2. Rationale for this Thesis 
Substantial research has been conducted in this field in recent years, since the implementation of the 
new PhV legislation and the launch of GVP Module XVI. However, certain evidence gaps/needs still 
remain, which deserve special attention:  








• Need for a quantitative assessment and interpretation of process indicator results across EU RM 
Surveys  
The registration of PASS in the EU PAS Register has increased steadily over time since its conception. 
Between 2012 and 2015, half of the protocols submitted to the PRAC for assessment had been entered 
in the EU PAS Register, 25.4% of which assessed the effectiveness of RMMs [59]. Up to the moment, as 
shown in our prior review the availability of information on studies of this kind in the public domain (e.g.  
European Public Assessment Reports) was limited and inconsistent, spread across various product 
information sources, hindering quantification and characterisation [31]. The publication of protocols 
and FSRs through the register has provided research groups in the field and MAHs the opportunity to 
learn from prior experience, and for an in-depth evaluation and interpretation of studies.  
While being involved in several studies evaluating the effectiveness of aRMMs and, in particular in 
those with a survey design assessing process indictors, it became apparent that there was a need for 
more exhaustive guidance and recommendations to facilitate the practical implementation of these 
studies, and ultimately allow for standardisation and improved reporting. The International Society for 
Pharmacoepidemiology (ISPE) Whitepaper on practical challenges and recommendations in RM 
Survey Studies in Europe developed by members of the Benefit Risk Assessment, Communication, and 
Evaluation (BRACE) Special Interest Group (SIG) also highlights the need for reflecting on the 
experience and learn from previous studies [60].  
Another prior review we conducted described study characteristics and results qualitatively, 
underscoring some of the challenges encountered in the interpretation of survey studies e.g. 
participation, selection and recall bias, study participation [52]. However, there was still a need for a 
more in-depth evaluation of survey studies by pooling results and providing a quantitative assessment. 
No previous published review had meta-analysed the results of EU RM Surveys. Objective 1 of this thesis 
addresses this research question using the EU PAS Register as the main source of information.  
Additionally, regulatory consequences of EU RM Surveys are scarcely described in the literature. A 
recent review found a low probability of discontinuation of aRMMs after their implementation, 
however, the reasons for a measure to remain or be removed are not yet fully understood [58].  
Therefore, Objective 1 also aims to further investigate regulatory action as a result of the conduct of 
the studies.  
• Need to characterise and quantify participation and country selection in EU RM Surveys and 
the potential for selection bias 
EU RM Surveys rely on the willingness of patients and/or HCPs to participate. As highlighted by our prior 
work, one main challenge of RM Surveys is participant recruitment which, if not well planned, may limit 
generalisability and result in selection bias [52]. For example, if those who participate differ from those 








who do not, this may result in a non‐representative sample. Also, if the pre-specified sample size is not 
achieved this may affect the robustness of study results. These are also challenges we have 
encountered when conducting studies of this kind, where the implementation of mitigation 
approaches such as extension of recruitment periods, reduction of pre-specified sample sizes or the 
use of research panels was warranted to increase participant recruitment. Some other studies also 
described operational challenges such as access, approval, feasibility, and resources, which hindered 
participation. In particular, for patient surveys identifying and contacting patients to participate is 
particularly difficult due to the inability to directly recruit patients, which usually depends on 
prescribing physicians, with the potential for resulting in a more biased sample [60].  
GVP XVI raises the importance of applying a scientifically sound methodology in EU RM Surveys to 
promote unbiased and statistically stable results however it also acknowledges a potential selection 
bias if the selected population is not representative of the target users (i.e. more motivated or 
educated HCPs and/or patients are more likely to be engaged) [2]. GVP XVI and the ISPE Whitepaper 
offer some approaches that may help minimize this bias [2,60]: 1) selection of an optimal sample frame 
considering the characteristics of the population that was targeted for the aRMM such as age, 
gender, geography, 2) ensuring diversity of the sample frame to allow for sub-group analyses by main 
characteristics, 3) devise a recruitment strategy with special consideration to the selected survey 
participant source (e.g. sponsor lists, research panels, societies) and 4) collect the proportion of non-
responders and their characteristics to assess the representativeness of the participants. However, the 
feasibility of deploying these strategies in practice may be limited.  
Country selection is another well-known challenge of EU RM Surveys. An ideal sampling frame would 
include all countries where the aRMMs were implemented, with invitations sent proportionally to the 
type and number of HCPs per country that were exposed to the aRMMs, and actual survey 
completion similarly representative. However, feasibility constraints usually limit the sampling frame to 
a number of countries [60]. Our prior work provides a qualitative overview of participation in EU RM 
Surveys, with the following key findings for the 11 surveys reviewed [52]: 
• All surveys were voluntary, and mainly conducted online. 
• The sources of participants varied across surveys: three surveys used a network or an 
established panel of HCPs, four targeted prescribers/potential prescribers who were sent the 
RMMs, one selected patients and caregivers who received the aRMMs and the remaining 
three randomly selected prescribers or potential prescribers of which one also randomly-
selected patients.  
• The number of included countries ranged from 5 to 10 per survey. The countries most frequently 
selected were the United Kingdom, Spain, Denmark, Germany, France, Netherlands, and 
Sweden.  








• The total number of participants in the nine surveys was based on pre-specified sample size 
estimations and ranged from 250 to 802, and the range of participants per country was 2 to 
212. 
Our previous work additionally suggests that some survey studies had disproportionate participation 
across countries, which may be a reflection of the usage of the product or difficulties identifying 
prescribers in these countries. However, the number of surveys in this review was limited. Therefore, 
there was a need to further characterise country selection and subject participation in EU RM Surveys, 
investigating the extent to which participating countries contribute participants to the overall sample 
size. Objective 2 of this thesis addresses this research question. 
• Need to standardise reporting and enhance quality of EU RM Surveys 
The Risk Minimization Evaluation Studies “RIMES” checklist was recently developed by BRACE SIG 
members as a first effort to improve the quality of studies evaluating the effectiveness of risk 
minimization measures [61]. This checklist was applied to a selection of studies identified in a recent 
review where key opportunities for improvement in reporting were highlighted, including the selection, 
design, testing and implementation of RMMs, process and outcome metrics, including the extent to 
which programs reached the intended audience, were integrated into the target healthcare settings, 
or were sustained over time, and the burden of the program on the healthcare system and 
implications for patient access [62]. 
GVP XVI Appendix 1 for the evaluation of the effectiveness of RMMs in survey studies includes testing 
of data collection instruments, and participation and recruitment strategies [2]. However, this 
guidance is general and can be widely interpreted. In our prior research we have investigated 
reporting practices in FSRs of: 1) sampling strategies, 2) recruitment rates, 3) participation data, and 
4) qualitative approaches to testing data collection instruments.  
1) The sampling frames were mainly lists of HCPs targeted to receive the educational materials 
(7/13) and panels (4/13). Others used a master list in each country and a list provided by the 
sponsor. Of the 13 studies, eight used random sampling which was also stratified in two of the 
studies. However, there was insufficient detail in reports to assess how well the planned 
sampling method performed and hence assess representativeness of the final results [63]. 
2) Recruitment rates were reported in less than half of the included studies and the definitions of 
the numerator and denominator used varied: 3 reported eligible / screened, 3 used reached 
/ invited or contacted / approached, and 2 used completers / eligible. Other rates included: 
contact rate (contacted / targeted), and cooperation rate (completers / agreed). Response 
rate was defined as agreed/contacted in one report and screened / (invited-undelivered) in 
another report. This great variability in reporting participation rates raises the need for 
standardised reporting and criteria for inclusion in reports [64]. 








3) Over half of the studies described how participation data had been derived using flowcharts 
or tables. Participation sets were named and reported differently across studies: 10/13 reported 
The number of participants invited, 7/13 contacted, 6/13 screened, 7/13 eligible, 5/13 agree, 
and all reported completers. This shows great variability in reporting participation information 
[64]. 
4) A minority of survey studies reported using qualitative methods (no testing was reported for the 
two patient surveys) with wide variability in terminology [65].  
All these highlight the need for additional guidance and standardization of terminology. This is 
addressed in the discussion of this thesis with the provision of recommendations.  
• Need for RMEv approaches that evaluate process indicators as well as outcomes to allow for 
a comprehensive interpretation of the impact of aRMMs 
RMEv may include studies that evaluate process indicators or outcomes separately, while other RMEv 
may use hybrid approaches to assess process indicators and outcomes within the same study. 
Marketing authorisation holders are encouraged to measure both process indicators and outcomes 
[3]; however, this is performed only for certain products. Prior reviews looked at studies individually, 
while RMEv as a whole are not well described in the literature. Objective 3 of this thesis addresses this 
research question. 
• Linking process indicators and outcomes within the same patients 
More studies with evaluation approaches that assess process indicators and outcomes are warranted, 
using novel methodological designs. One such example is presented here to address Objective 4 of 
this thesis. 
Abatacept (ORENCIA®) is a selective immunosuppressant indicated for the treatment of rheumatoid 
arthritis (RA), polyarticular juvenile idiopathic arthritis and psoriatic arthritis. As part of a regulatory 
commitment to the EMA, patient alert cards (PACs) were developed for each formulation 
(intravenous [IV] and subcutaneous [SC]), to help inform patients and HCPs of the potential risks and 
actions required during treatment with the product, specifically for infections and allergic reactions. 
The only difference between the two PACs, both provided in each medicine pack, is that the IV PAC 
includes a field to indicate the date of the most recent injection, while the SC PAC does not. The 
principal aim of the PACs is to ensure appropriate action by patients and HCPs when an infection 
occurs, with the ultimate goal of reducing the occurrence of undesirable outcomes (e.g., 
hospitalisations), or severity (e.g., reducing delays in seeking medical care). HCPs are expected to be 
active key players to provide and explain the contents of the PAC to RA patients. 








A study to evaluate the effectiveness of the abatacept PACs in RA patients and HCPs using process 
indicators was conducted. The study design also linked these process indicators with clinical and 
safety endpoints in the same patients via a chart review sub-study. 
  










The objectives of this thesis are to:  
• Objective 1: Conduct a systematic review and meta-analysis of completed survey studies 
evaluating the effectiveness of aRMMs via process indicators in Europe (hereinafter EU RM 
Surveys):  
a. To describe and summarize EU RM Surveys 
b. To pool data on country selection and participation rates 
c. To pool data on process indicators: receipt, use, knowledge, and self-reported 
behaviour 
d. To qualitatively assess reporting practices around EU RM Surveys (lessons learned) and 
provide recommendations  
e. To describe and summarise the submission process and decisions taken by regulators 
according to regulatory assessment reports1. 
• Objective 2: Evaluate participation in EU RM Surveys to assess the effectiveness of aRMMs in 
Europe: 
a. To describe country selection and participation in EU RM Surveys in Europe 
b. To describe subject participation in EU RM Surveys in Europe 
• Objective 3: Conduct a systematic review of RMEv that include process indicators and 
outcomes: 
a. To describe RMEv including process indicators and outcomes to assess the 
effectiveness of aRMMs with the aim to characterise:  
i. Process indicators 
ii. Outcome measures (behavioural outcomes via drug utilisation studies or 
health/safety outcomes) 
iii. Evaluation approach (process indicators and outcomes in the same study or in 
more than one study) and study design (cross-sectional; prospective cohort; 
retrospective cohort)  
iv. Data sources (surveys, medical chart reviews, prospective data collection, 
etc.) 
b. To describe general study results and, specifically, the impact of RMEv on process 
indicators and safety outcomes 
• Objective 4: Conduct a study to evaluate the effectiveness of aRMMs linking process indicators 
and outcomes. 
 
1 Assessment Reports (ARs) are regulatory documents issued by competent authorities which describe the actions/decisions 
taken by regulators based on the results of the studies 








a. To evaluate the effectiveness of abatacept PACs for RA patients and HCPs using 
process indicators: receipt and use of the PACs, knowledge and implementation of 
behaviours around key messages in the PACs.  
b. To link and correlate process indicators with clinical and safety endpoints in the same 
patients as a measure of the impact of the PACs. 
All these objectives will help draw lessons and recommend guidance on improvements in the 



































5.1. Objective 1: Systematic review and meta-analysis of completed EU RM Surveys 
 
5.1.1. Search strategy 
A literature search was conducted using the EU PAS Register, PubMed and grey literature (i.e., Google) 
to identify completed EU RM Survey Studies from 1 January 2011 (when the first records appeared in 
the EU PAS Register) to 31 January 2018. The following terms were used: drug safety, patient survey, 
health-care professional survey, educational materials, patient alert card, pregnancy prevention, 
restricted access, dear or direct healthcare professional communication, dear doctor letter, DHPC, 
risk minimization, additional risk minimisation measures, and aRMMs. 
5.1.2. Inclusion criteria 
Studies with a cross-sectional survey component assessing the effectiveness of routine or additional 
RMMs including at least one European country were eligible. Only completed studies with results in the 
form of FSRs or manuscripts between 1 January 2011 and 31 January 2018 were included. 
5.1.3. Data sources 
The EU PAS Register, Medline, and Google were used to obtain FSRs and manuscripts of eligible studies. 
Assessment Reports of the FSRs were sought from the EMA and other national regulatory authorities as 
they describe the actions/decisions taken by regulators based on the results of the studies. MAHs, the 
EMA and other national regulatory authorities were contacted to obtain FSRs for completed studies 
with partial or no results available on the searched data sources. Regulatory documents were 
requested from EMS via the Access to Documents request form [29]. To compare included versus 
excluded studies for potential bias, characteristics of the studies were obtained from the protocol in 
the EU PAS Register where detailed results were not available in the FSRs. 
5.1.4. Data extraction  
Data were extracted by one reviewer (Esther Artime) and checked by the second reviewer (Pareen 
Vora), with disagreements resolved by consensus and involvement of a third reviewer (Nawab 
Qizilbash), if necessary. Data for study characteristics were extracted which include study design (one-
wave survey, multi-wave survey, pre- and post-cross-sectional survey, other), target population 
(general practitioners, specialists, nurses, pharmacists, patients/caregivers), target number of 
countries included, whether imposed by the regulator or voluntary, Anatomical and Therapeutic Class 
(ATC) group of the drug, characteristics of the RMMs (routine only, HCP brochures/leaflets/guides, 
DHPC, patient brochures/leaflets/guides, patient card), number of targeted safety concerns in the 
RMMs and dates of implementation of the RMMs. 








5.1.4.1. Participation data           
Independently of the reported proportions, data were also extracted to calculate participation rates 
based on the number of subjects invited to participate (responders and non-responders), eligible, 
targeted and completers of the survey, where available. Participation data were abstracted or 
calculated in two ways: the number of completers divided by number invited [13] and the number of 
completers divided by number eligible [14].  
5.1.4.2. Results of process indicators 
Process indicators evaluated in the selected studies (i.e., receipt, reading and use of the materials, 
knowledge, and implementation of behaviour around key messages) were described. Data on 
receipt of the materials were extracted for those who participated in the study (i.e., completers) while 
reading and use of the materials were extracted for those who reported receipt. Use was defined as 
the proportion of participants who reported having used, carried the materials with them (among 
patients), handed out and/or explained the materials to patients (among HCPs). The knowledge and 
implementation of the safety and clinical management messages in the materials were extracted for 
completers and for those who received, read and/or used the materials.  
5.1.4.3.  Consequences and decisions taken by regulators based on study results 
For studies with ARs available at the time of the analysis, the main regulatory concerns mentioned by 
regulators (low response rates, selection bias or limited receipt of materials) as well as the decisions 
taken were extracted. The latter included: no further action or further action (improve distribution of 
aRMMs or re-distribute, changes to the contents/format of existing aRMMs, pending further 
discussion/data, follow-up assessment requested, removal of aRMMs, changes to the SmPC, aRMMs 
implemented or re-analysis by reading/non-reading).    
5.1.4.4. Qualitative assessment of reporting practices and provision of recommendations 
Based on the revision of final study reports and manuscripts of studies identified in this review, a 
qualitative assessment of reporting practices will be conducted with additional recommendations for 
improvements provided.  
5.1.5. Statistical analysis 
All data extracted (participation, process indicators, and consequences) were described using 
numbers and percentages.   
Data for participation and each process indicator (receipt, use, knowledge, behaviour) were meta-
analysed and reported using random effects models. Forest plots with and without pooling are 
presented. Heterogeneity between studies was assessed with the I2 statistic [15]. To explore sources of 
heterogeneity and possible differences in summary estimates, we performed pre-defined subgroup 
analyses according to the type of aRMMs: HCP brochure, leaflet or guide, HCP checklist, DHPC, 








patient brochure, leaflet or guide, and patient card. Study characteristics for included and excluded 
EU RM Survey Studies (study reports not available) were compared using chi-square to assess study 
selection bias. 
Analyses were performed using excel and MedCalc statistical software.  
  








5.2. Objective 2: Evaluate participation in EU RM Surveys to assess the effectiveness of 
aRMMs in Europe 
 
5.2.1. Search strategy 
A literature search was conducted using the EU PAS Register, Medline and grey literature [Google, 
International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) 
abstracts] to identify completed EU RM Survey Studies from 1 January 2011 (when the first records 
appeared in the EU PAS Register) to 12 October 2019.  
The following terms were used: drug safety, patient survey, healthcare professional survey, 
educational materials, patient alert card, pregnancy prevention, restricted access, dear or direct 
healthcare professional communication, dear doctor letter, DHPC, risk minimisation, risk minimization, 
additional risk minimisation measures, and aRMMs. In the EU PAS Register, all study titles were screened, 
with search terms used to guide the selection. Where there was uncertainty, study details and 
documents in the EU PAS Register were reviewed. 
Literature reviews identified in the searches were also screened for potential citations. 
5.2.2. Inclusion criteria 
Studies with a cross-sectional survey component assessing the effectiveness of routine or additional 
RMMs via process indicators including at least one European country were eligible. Only completed 
studies with results available in the form of FSR, manuscript or abstract between 1 January 2011 and 
12 October 2019 were included. 
5.2.3. Data sources 
The EU PAS Register, Medline, and grey literature [Google, ICPE abstracts] were used to obtain FSRs, 
abstracts and manuscripts of eligible studies.  
5.2.4. Extraction of participation data 
Data were extracted by one reviewer (Macarena Garrido-Estepa) and checked by the second 
reviewer (Esther Artime), with disagreements resolved by consensus and involvement of a third 
reviewer (Nawab Qizilbash), if necessary. Data for study characteristics were extracted: 1) target 
number of countries; 2) number of countries with participants; 3) target population (HCPs, 
patients/caregivers); 4) target number of participants; 5) invited participants; 6) contacted 
participants; 7) screened participants; and 8) completers (participant HCPs/patients that completed 
the survey).  
Independently of the reported proportions, participation data were abstracted or calculated as the 
number of completers divided by number invited. Eligible, targeted and completers of the survey 
were identified, where available. 








5.2.5. Statistical analysis 
All participation data were described using number and percentages.   
The following were calculated: number and percentage of studies in which each country 
participated was calculated, number and percentage of completers that each country provided, by 
study and overall: 1) as the percentage by country of completers provided to the overall number of 
completers in all studies identified; or 2) as the percentage by country of completers provided to the 
overall number of completers in studies with that country participation identified. 
Response rate was calculated as the percentage of participants who completed the survey among 
those invited to participate. The range of response rates was described for the total of studies 
developed in each country. 



















5.3. Objective 3: Systematic review of RMEv that include process indicators and 
outcomes 
 
5.3.1. Search strategy 
A literature search was conducted using the EU PAS Register, PubMed, and grey literature [Google, 
ICPE abstracts] to identify studies of products approved in Europe that evaluated the effectiveness of 
aRMMs, from 1 January 2011 (when the first records appeared in the EU PAS Register) to 12 October 
2019. Systematic literature reviews identified in the searches were also screened for potential citations. 
The following search terms were used: drug safety, patient survey, health care professional survey, 
prescriber education, patient alert card, pregnancy prevention, medication guide, restricted access, 
dear or direct health care professional letter, dear doctor letter, risk minimisation, risk minimization, 
drug utilisation, educational materials, DHPC, additional risk minimisation measures and aRMMs. In the 
EU PAS Register, all study titles were screened, with search terms used to guide the selection. Where 
there was uncertainty, study details and documents in the EU PAS Register were reviewed. 
5.3.2. Inclusion criteria 
Identified studies conducted in at least one European country were grouped by product and type of 
measure (process indicator, behavioural or health/safety outcome). Process indicators were required 
to have at least one measure of awareness, receipt, use, knowledge, or self-reported behaviour, 
collected via surveys. Outcome measures included behavioural outcomes obtained via drug 
utilisation studies or studies measuring monitoring parameters, and health/safety outcomes. Studies 
linked to one product were considered part of the product RMEv. Only RMEv with both process 
indicators and outcomes (within one or multiple studies) were included. Additionally, RMEv with study 
results available in the form of study report, manuscript or abstract were also identified. 
5.3.3. Data sources 
The EU PAS Register, Medline, and grey literature [Google, ICPE abstracts] were used to obtain FSRs, 
abstracts and manuscripts of eligible studies. If results were not available at the extraction date (i.e., 
12 October 2019), protocols and summaries from the EU PAS Register were used to extract 
characteristics.  
5.3.4. Data extraction  
Data were extracted by one reviewer (Esther Artime) and checked by the second reviewer 
(Macarena Garrido-Estepa), with disagreements resolved by consensus and involvement of a third 
reviewer (Nawab Qizilbash), if necessary.  
Data were extracted at two levels: by product/RMEv, and by study within the RMEv. Product 
characteristics were extracted which included ATC group, aRMMs (HCP brochures/ leaflets/ guides, 
DHPC, patient brochures/ leaflets/ guides, patient card), and safety concerns targeted in the aRMMs. 








The number of studies linked to each product were computed and RMEv grouped by the number of 
studies conforming the evaluation (1 study, 2 studies or ≥3 studies).  
For studies within each RMEv, the following characteristics were extracted:  
1) study design components: survey (patient or HCP survey), retrospective (post-implementation or 
pre-/post-implementation of aRMMs), prospective, or other study designs;  
2) participating countries;  
3) type and size of study population (e.g., HCPs, patients, others);  
4) measures: a) Process indicators: receipt, use, knowledge, self-reported behaviour; b) Behavioural 
outcomes: off-label / on-label / inappropriate prescribing, monitoring, reading errors; c) Health/safety 
outcomes: adverse events and reactions (including those leading to resource use such as 
hospitalisation, emergency room visits, etc.) and, medication errors, and  
5) data sources: healthcare databases, company safety database, medical records data extraction, 
primary data collection or others.  
For RMEv with study results available, the number of participants and/or drug prescriptions, as 
applicable, were extracted for tabulation. Study results were extracted and presented separately (by 
RMEv) for process indicators and outcomes. For example, for process indicators, the percentages of 
participants reporting having received, read or used aRMMs, as well as those reporting correct 
knowledge and behaviours around key messages were obtained. For outcomes, the reported result 
of each behavioural (e.g., proportion of off-label use) or health/safety outcome (e.g., number of 
events) was also extracted and described.     
5.3.5. Statistical analysis 
Categorical variables are summarised by frequencies and percentages and continuous variables with 
medians and ranges. Non-parametric statistical methods were used, when appropriate, to assess if 
the groups had similar statistical distribution (e.g., Mann-Withney U or Kolmogorov-Smirnov test).  
Product and study characteristics are presented in tables overall and for RMEv with results available. 
All analyses were performed with Stata v.12 and Excel.  
  








5.4. Objective 4: Case Study to Evaluate the effectiveness of aRMMs linking process 
indicators and outcomes  
 
5.4.1. Study Design 
The study consisted of three sub-studies:  
• Two cross-sectional surveys for 1) HCPs and 2) patients to assess process indicators (awareness, 
receipt, utility, utilisation, knowledge, and behaviour related to the PACs) and 
• 3) a retrospective chart review of patient data to assess clinical and safety outcomes. 
The study was conducted in France, Germany, Spain, Sweden and the United Kingdom.  
The details of the study design are illustrated in Figure 6.  
 
Panel A: Patient scenarios valid for inclusion in the study. Horizontal arrows represent abatacept 
treatment periods for specific patients. Patients who received abatacept within the 3 months prior to 
the date of questionnaire completion were eligible for participation in the study. 
 
Panel B: Retrospective data collection. Follow-up data were collected for the 2 years prior to the date 
of informed consent, or less if abatacept was commenced less than 2 years from the date of informed 
consent. 









Figure 6. Design features of the three related sub-studies  
 
Panel A shows the scenarios considered valid for inclusion in the patients’ sub-studies. In the 
retrospective chart review sub-study, follow-up data were collected for 2 years before the date of 
informed consent, or less if abatacept was commenced less than 2 years from the date of informed 
consent (Figure 6, Panel B).  
Key messages contained in the PACs are listed in Table 5.  
Table 5. Key Messages in the abatacept Patient Alert Cards 
Safety Concerns Key Messages 
Infections 
 
• Patients receiving abatacept are at increased risk of infections 
• Avoid abatacept in patients with severe infection 
• Need for screening for infections prior to abatacept: TB and VH 
• Seek medical attention if symptoms suggestive of infection occur e.g., 
fever, persistent cough, weight loss, listlessness 
Allergic Reactions 
Seek medical attention if symptoms of allergic reactions occur including 
chest tightness, wheezing, severe dizziness and light headedness 
Others 
 
• Show the PAC to any doctor who may treat them 
• Take a full list of medicines on visiting a HCP 
• Keep the PAC for 3 months after the last dose of abatacept 
• Document the abatacept start date (IV and SC) 
• Document the date of the most recent abatacept treatment (IV only) 
• Complete patient’s name and the doctor’s name and phone number 
 
The study, classified as a PASS, was conducted according to GVP Modules XVI [2] and VIII [24] and 
best practices based on guidelines [66–69] and publications [35,41,42,48,50,59–61,70]. The protocol 
was approved by Ethics Committees in all five participating countries.  
5.4.2. Study Population and Sampling 








Only patients treated with abatacept for RA in the 3 months preceding the date of completing the 
questionnaire were included. After informed consent patients received the survey questionnaire. Data 
were extracted from the clinical medical records of patients who had completed the survey 
questionnaire.    
The following population sets were defined in the patient survey: 
• Study Population: All patients in the participating countries identified as potentially eligible to 
participate in the patient survey. 
• Eligible Set: All patients in the who fulfilled the inclusion and exclusion criteria. 
• Enrolled Set: All patients in the who participated in the survey. 
• Completers: All patients in the who completed the survey and were used in the analysis. 
Physicians were selected using random sampling applied to lists of rheumatologists provided by the 
MAH and panels (Figure 7). Nurses were identified through physicians. Physicians and nurses who 
recruited patients were not eligible for the HCP survey. ´Fair market´ fees were paid for completed 
questionnaires.  
 
Figure 7. Sampling and recruitment strategy 
 
The following population sets were defined in the HCP survey: 
• Invited: All HCPs in the participating countries invited to participate in the HCP survey. 
• Evaluable Set: All HCPs in the participating countries who were successfully contacted and 
agreed to complete the feasibility questionnaire. 
• Eligible Set: All HCPs who completed the feasibility questionnaire and fulfilled the inclusion and 
exclusion criteria. 
• Enrolled Set: All HCPs who accessed electronic Case Report Form (eCRF). 








• Completers: All HCPs who at least completed the eligibility criteria and socio-demographic 
questions in the HCP Survey. 
Patients and HCPs were identified by a unique code in the Electronic Data Capture (EDC) platform, 
allowing linkage of patients between the survey and the retrospective chart review.  
5.4.3. Data Collection Tools  
HCP and patient questionnaires were translated into local languages, and cognitively pretested by 
HCPs and patients. The questionnaires consisted of multiple-choice questions including conditional 
branching based on responses to previous questions to improve user friendliness and reduce missing 
data. Patient questionnaires were completed online or on paper. HCP questionnaires were only 
available online.  
For the retrospective chart review, HCPs or data managers were trained to extract information from 
patient´s clinical medical records and enter it into the EDC platform. The EDC platform guided data 
extraction and contained edit checks and management of queries to improve data quality.   
5.4.4. Sample Size Calculation 
The study aimed to recruit 400 patients to allow precision of less than ±5% around plausible estimates 
(ranging from 50% to 90%) of correct responses for process indicators related to the PACs. This number 
would also permit the detection of a moderate decrease in the risk of infection-related hospitalisations 
(odds ratio <0.23) between patients with ≥80% correct responses versus <80% correct response. A 
target of 80 HCPs would allow precision ±6.6 to 11.0% around plausible estimates (70% to 90%) of 
correct responses for HCP process indicators. 
5.4.5. Study Endpoints & Data Analysis 
 
5.4.5.1. Healthcare Professional and Patient Surveys 
HCPs and patients with questionnaires received before database closure were considered as 
‘completers’. Participation rates were defined as the number of participants with completed 
questionnaires among the  number invited in each category or among the number eligible [66,67].  
The definition of study endpoints and scores is provided in Table 6.  
Table 6. Study Endpoints 
Study Endpoint Definition 
Awareness Proportion of HCPs/patients who were aware of the PAC 
Receipt • Proportion of HCPs who had access or received the PAC  
• Proportion of patients who recalled receiving the PAC 
Utilisation • Proportion of HCPs/patients who recalled having read the PACs  
• Proportion of HCPs who explained contents to their patients 
• Overall utilisation score 








Study Endpoint Definition 
Utility • Patient’s assessments of understandability and readability of the PACs 
(clarity, conciseness, completeness, brevity) 
• Overall utility score 
 
In the Patient Survey, the utility score was computed as 100 times the sum score 
of items assessing clarity, conciseness, completeness and briefness (recoded as 
0 = worst value to 4 = best value), and understandability (ranging from 0 to 4), 
divided by the maximum possible score of 20.  
In the HCP survey, the utility score was computed as 100 times the sum score of 
items assessing helpfulness, clarity, conciseness, completeness and briefness 
(recoded as 0 = worst value to 4 = best value), divided by the maximum possible 
score of 20. For all other endpoints, the score was calculated as the percentage 
of correct responses to variables that assessed the endpoint, that is, 100 times 
the sum of all variables, divided by the number of variables. 
Knowledge • Proportion of HCPs/patients with correct responses to questions related to the 
important identified risks of infections and allergic reactions associated with 
abatacept treatment 
• Overall knowledge score 
Self-reported 
Behaviour 
• Proportion of HCPs/patients with correct responses to behavioural questions 
• Overall behavioural score 
Global Score An average score that summarises the overall correct utilisation of the PAC, 
correct knowledge, correct behaviour and utility.  
This score is presented in three categories by tertiles: high level (scores >67%), 
medium level (scores 34-67%) and low level (scores 0-33%). 
Correlation of 
global score of 
the patient 
survey with: 
Percentage of patients with: 
• Results of any test to screen for TB prior to administration of abatacept 
therapy 
• Results of any test to screen for VH before administration of abatacept 
therapy 
• Infections leading to hospitalization  
• Infections leading to emergency room visits 
Average number of days per patient from first symptom onset of infection until 
receiving medical attention. 
 
Percentages were computed using the number of participants who answered specific questions as 
the denominator, excluding missing responses. All analyses were performed overall and by receipt 
versus no receipt of the PAC.  
5.4.5.2. Retrospective Chart Review 
The extracted outcomes included (Table 6): availability of results of screening tests for tuberculosis (TB) 
and viral hepatitis (VH) prior to abatacept use (Yes/No), occurrence of infections leading to 
hospitalisation and/or infections leading to emergency room visits (Yes/No), and time from 
occurrence of infection to receiving medical attention. Numbers and percentages were calculated 
for each outcome. The mean number of days between the dates of first symptom onset of the 
infection and receiving medical attention was calculated.   








Univariate analyses correlated within-patient clinical and safety outcomes responses to process 
indicators in the patient survey. The primary analysis assessed the frequency of infections leading to 
hospitalisation in patients by tertiles of the patient survey global score of the PAC using a two-sided 
chi-square test.  














6.1. Objective 1: Systematic review and meta-analysis of completed EU RM Surveys 
 
6.1.1. Study Selection 
Figure 8 describes the study selection flowchart according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) Statement. From all studies identified, 127 assessed 
the effectiveness of RMMs, and a survey component as a method of data collection was identified in 
54 studies. A total of 24/54 EU RM Surveys met the inclusion criteria and were analysed using FSRs: 16 
from the EU PAS Register, four were obtained from MAHs and four from the EMA. There were 30 studies 
excluded due to the absence of results, but their study characteristics were available from study 
protocols or EU PAS Register summaries. 
 
 
*Internet, selected conferences 
Abbreviations: EMA, European Medicines Agency; FSR, final study report; MAH, Marketing Authorisation Holder; NA, 
National Agency; RM, risk minimisation 
 
 
Figure 8. Flowchart of the selection process based on PRISMA guidelines – Objective 1 








6.1.2. Study Characteristics 
The characteristics of the studies included in the analysis are presented in Table 7. Of the 24 studies, 
18 (75.0%) were requested by a regulator. Eleven (78.6%) were classified as PASS Category 3. 
Seventeen (70.8%) were for centrally approved drugs by EMA. Survey designs were one-wave for 21 
(87.5%) and multi-wave in 12.5% of studies; no studies had a pre-post survey design. HCPs were 
included in 23 (96.0%) studies, composed of 91.7% specialists, 58.3% general practitioners (GPs), 20.8% 
nurses, and 25.0% pharmacists. Patients and/or caregivers were included in 8 (33.3%) studies. There 
was a mean (SD) of 7 (3) countries targeted per study. Only, two studies evaluated the effectiveness 
of routine RMMs. 
A total of 34 aRMMs were reported in 24 studies: 15 (68.2%) HCP brochures; leaflets or guides; 8 (36.4%) 
DHPCs; 7 (29.2%) patient cards; and 4 (16.7%) patient brochures, leaflets or guides. Almost half (45.5%) 
of the studies evaluated materials implemented at the time of drug launch: 7 (31.8%) after a label 
change, concern for a new safety signal or a restriction of indication; and 4 (18.2%) for an extension 
of an indication or new formulation. The median (IQR) number of key safety concerns in the materials 
per study was 3 (1 to 5). The use of pre-defined thresholds to define success was only reported in 7 
(29.2%) studies, mostly using 80% or the ‘majority of respondents’ for the knowledge and/or behaviour 
endpoints.  
Differences between included and excluded EU RM Survey studies without FSRs (Table 7) were 
identified for types of aRMMs (less patient brochures and more DHPCs were evaluated in the included 
studies), ATC categories (41.4% of drugs were in the antineoplastic and immunomodulating group in 
the excluded set versus 16.7% among included studies; 10.3% of drugs belonged to the nervous system 
category in the excluded set versus 29.9% of included studies), and type of target population (91.7% 
of included studies involved specialists and 58.3% GPs versus 56.7% of excluded studies involving 
specialists and 6.7% GPs; p < 0.01). 
Table 7. Characteristics of Included and Excluded EU RM Surveys 
 Characteristics 
Included EU RM 
Surveys 
[N=24] 




 n (%) n (%)  
Type of RMM          
Routine 2 (8.3) 1 (3.3) 
0.84 
Additional (i.e., aRMM) 22 (91.7) 29 (96.7) 
Patient cards 7 (29.2) 13 (44.8)  
DHPC 8 (36.4) 5 (17.2)  
HCP Brochure/Leaflet/Guide 15 (68.2) 20 (69.0)  
Patient Brochure/Leaflet/Guide 4 (16.7) 20 (69.0)  
Timing of aRMM  N = 22 N = 29  
At launch 10 (45.5) 17 (58.6) 0.35 









Included EU RM 
Surveys 
[N=24] 




 n (%) n (%)  
After launch 1 (4.5) 2 (6.9) 
At extension of indication / new formulation 4 (18.2) 1 (3.4) 
After label changes / signal / restriction of indication 7 (31.8) 9 (31.0) 
Drug Approval Procedure    
Central Approval 17 (70.8) 27 (90.0) 
0.15 
National Approval 7 (29.2) 3 (10.0) 
Study Requested by Regulator      
Yes  18 (75.0) 24 (80.0) 
0.91 
No / Unspecified  6 (25.0) 6 (20.0) 
Study Category          
Category 1 or 2 (imposed by regulator)  3 (21.4) 3 (10.7) 
0.99 Category 3 (required in EU-RMP)  11 (78.6) 25 (89.3) 
Missing  10  2  
Study Design          
One-wave survey  21 (87.5) 25 (83.3) 
0.64 
Multi-wave survey  3 (12.5) 3 (10.0) 
Pre/Post survey  0 - 1 (3.3) 
Other  0 - 1 (3.3) 
Study Population           
Clinical Specialists  22 (91.7) 17 (56.7) 
<0.01 
General Practitioners (GPs)  14 (58.3) 2 (6.7) 
Nurses  5 (20.8) 4 (13.3) 
Pharmacists  6 (25.0) 3 (10.0) 
Patients/Caregivers  8 (33.3) 9 (30.0) 
Physicians unspecified  0 - 7 (23.3) 
No. Target Participating Countries           
1 – 5   9 (37.5) 19 (63.3) 
0.17 6 – 10   12 (50.0) 9 (30.0) 
>10   3 (12.5) 2 (6.7) 
Mean (SD)  7.1 (3.2) 5.5 (2.7)  
Number of Safety Concerns         
1 – 5   19 (79.2) 19 (67.9) 
0.31 
6 – 10   3 (12.5) 8 (28.6) 
>10   2 (8.3) 1 (3.6) 
Missing  0 - 2  
Median (Q1-Q3)  2.5 (1.0 – 5.0) 3.0 (1.0 – 7.5)  
Pre-specified criteria for success      
Yes  7 (29.2)   
Knowledge and/or behaviour - Majority  3 (42.9)   









Included EU RM 
Surveys 
[N=24] 




 n (%) n (%)  
Knowledge and/or behaviour - ≥80%  3 (42.9)   
Knowledge - 70%   1 (14.3)   
Receipt - 50%  1 (14.3)   
Use - 35%  1 (14.3)   
Unspecified  17 (70.8)   
Abbreviations: aRMM, additional risk minimisation measure; GP, General Practitioner; RM, risk minimisation 
 
6.1.3. Healthcare Professional Surveys 
HCPs were targeted in 23 of the 24 included studies. The pre-specified target sample size in the study 
protocol was reached in 52.2% of the 23 studies. Seven of the 11 studied that did not reach the target 
deviated by more than 10% from the pre-specified size. Fewer studies reached the target sample 
when only specialists were involved: 37.5% versus 57.1% in studies that also involved GPs (p = 0.66). 
Participation rates were reported and calculated as a proportion of invited and proportion of eligible 
(Figure 9 (a,b)). The pooled ‘Completers/Eligible’ rate was 88.5% (I2 = 99.5%), while the pooled 
‘Completers/Invited’ rate was 4.7% (I2 = 99.7%). Despite the great heterogeneity, all studies with data 
available to calculate ‘Completers/Invited’ (N = 17) had ≤10% participation, with the exception of 
one study (Study 4: 26.0%) which was restricted to one country only with a small but targeted number 
of HCPs invited. Exclusion of this study resulted in a pooled estimate ‘Completers/Invited’ rate of 4.0%. 
Studies varied in the outcomes reported: 69.6% of studies reported receipt, 34.8% reading, 47.8% use 
of materials, 95.3% knowledge/understanding of key safety concerns and 43.5% self-reported 
behaviour to implement the information. 




















                                
Figure 9. Participation Data in HCP and Patient surveys – Forest Plots 
 
Receipt was reported for 24 materials in 16 HCP Surveys. The proportion who received materials varied 
widely with no clear trend by type of material. Materials that were distributed together had similar 
results (e.g., 22.6% reported having received the checklist and 19.6% the brochure in Study 1). Figure 
10 (a–d) shows the pooled estimates by type of material based on a few data points that exhibit great 
heterogeneity: 54.1% (I2 = 98.2%) for HCP brochures, leaflets and guides; 33.9% (I2 = 99.0%) for HCP 
checklists; 41.4% (I2 = 64.4%) for DHPCs; and 55.3% (I2 = 99.0%) for patient cards. In eight studies, 89.8% 
(I2 = 90.0%) of HCPs reported reading all or some of the contents of the aRMMs among those who 
reported to have received them (Figure 10 (e)). Figure 10 (f–i) show the pooled estimates of use of 
materials (used, handed out and/or explained to patients) by type of aRMM: HCP brochures, leaflets 
and guides (71.7%; I2 = 58.9%), HCP Checklists (72.1%; I2 = 81.2%), patient brochures, leaflets and guides 
(87.9%; I2 = 65.0%), and patient cards (80.4%; I2 = 85.4%). Knowledge and understanding were reported 
for 69 safety concerns in 22 studies. The percentage of correct responses was >60% in 76.8% of safety 
concerns and >80% in 40.6% of safety concerns (Figure 11 (a)). Statistically significant differences in 
knowledge rates between HCPs who received, used or read the materials and those who did not 
were found for 7 safety concerns (Figure 11 (c)): squamous cell carcinoma (SCC) (p < 0.05; Study 1), 
urinary retention (p < 0.001; Study 5), confusion (p < 0.001; Study 5), hallucinations (p < 0.05; Study 5), 
psychosis (p < 0.05; Study 5), hypersensitivity to lactose monohydrate (p < 0.05; Study 24), and 
haemolysis and haemolytic anaemia (p < 0.001; Study 24). Although non-statistically significant, two 








safety concerns (‘food intake’ and ‘anaphylactic/ anaphylactoid reactions’) reported lower average 
knowledge scores in HCPs who did receive, use, or read materials compared with those who did not. 
Data on the implementation of behaviour resulting from aRMMs could not be abstracted and 















*For Study 20, response to the question ‘Are you familiar with the DHPC provided to you?’ was used as a proxy for receipt and therefore was 
included in this forest plot 































Figure 10. Receipt, Reading, and Use of aRMMs in HCP Surveys. Forest Plots A, B, C and D, 
respectively, represent receipt (percentage of HCPs who reported receipt) of aRMMs in HCP Surveys 
by aRMM type: HCP brochures, leaflets and guides; HCP checklists, Dear Healthcare Professional 
Communications (DHPCs); patient cards. Forest Plot E represents reading (percentage of HCPs who 
reported reading the materials) of HCP Brochures in HCP Surveys. Forest Plots F, G, H and I, 
respectively, represent use of aRMMs in HCP Surveys by aRMM type: HCP brochures, leaflets and 
guides; HCP checklists, patient brochures, leaflets and guides; patient cards. 
 
  











Figure 11. Knowledge of key Safety Concerns in HCP and Patient Surveys. Graphs A and B represent the distribution of knowledge results for the 
different key safety concerns in HCP and Patient Surveys, respectively. Forest plot C represents the level of knowledge of safety concerns in 
HCPs who received, read, or used the aRMMs versus those who did not. 








6.1.4. Patient Surveys 
Patients and/or caregivers were included in eight of the 24 included studies. Five of the eight patient 
surveys did not reach the pre-specified target sample size in the study protocol. Of these five studies, 
one was terminated due to low recruitment and the results of one study were not reported having 
recruited only seven patients. The pooled ‘Completers/Eligible’ rate, based on 4 studies with the 
number of patients eligible reported, was 92.8% (I2 = 96.5%; Figure 9 (c)). The number of patients invited 
was reported in only one study (Study 22), corresponding to a ‘Completers/Invited’ rate of 59.7%. All 
studies reported receipt of materials but varied in other outcomes reported: reading (5), utilization/use 
(4), knowledge of key safety information (6) and self-reported behaviour to implement the information 
(4). Receipt of materials (7 different materials) in patients ranged from 50% to 80% in six studies (Figure 
12 (a,b)): 75.2% (I2 = 12.7%) for patient brochures, leaflets or guides and 55.4% (I2 = 0.0%) for patient 
cards. Figure 12 (c,d) show that all or some of the contents of the materials, among those who had 
received them, were read by about 90% of the patients: 91.5% (I2 = 0.0%) for patient brochures, leaflets 
and guides, and 88.4% (I2 = 36.5%) for patient cards. 
Regarding use of aRMMs (Figure 12 (e,f)) results were higher for patient brochures, leaflets, and guides, 
88.4% (I2 = 12.9%) than for patient cards, 62.6% (I2 = 93.2%). Finally, knowledge and understanding were 
reported for 21 key safety concerns in six studies, 38.1% of items scoring knowledge levels >60% and 
9.5% of items scoring >80% (Figure 11 (b)). Data on the implementation of behaviour resulting from 
aRMMs could not be abstracted and analysed due to varying ways of reporting. 
 


































Figure 12. Receipt, Reading and Use of aRMMs in Patient Surveys. Forest Plots A and B, respectively, 
represent receipt (percentage of patients who reported receipt) of aRMMs in Patient Surveys by 
aRMM type: patient brochures, leaflets, and guides; patient cards. Forest Plots C and D represent 
reading (percentage of patients who reported reading the materials) of aRMMs in Patient Surveys 
by aRMM type: patient brochures, leaflets, and guides; patient cards. Forest Plots E and F, 
respectively, represent use of aRMMs in Patient Surveys by aRMM type: patient brochures, leaflets, 
and guides; patient cards. 
 
6.1.5. Regulatory Submission Process & Actions taken by Regulators  
Regulatory ARs were available for 22 of the 24 studies (one was not provided, and the other one was 
still ongoing at the time of the analysis). Table S1 describes the regulatory process for submission of 
study results to relevant competent authorities. Most FSRs were submitted to EMA/PRAC through a 
Type II variation (n=14) requiring RMP update, few were submitted at time of RMP or Periodic Safety 
Update Reports (PSUR) update (n=4).  
Table 8 and Figure 13 show that further action was required in 59.1% (13/22) studies based on obtained 
ARs: improvement of distribution methods or re-distribution (31.8%), changes to the contents/format 
of the existing materials (18.2%), in 18.2% further data involving other studies or other data were 
required to determine regulatory action and follow-up assessment required in 3 studies (13.6%). 
Concerns about the risk of selection bias, low response rates and limited generalizability of results were 
raised by regulators for at least 11 of the 22 studies during the assessment process. Receipt of materials 
was considered to be low in at least 31.8% studies resulting in re-distribution or improved distribution 








being requested. None of the studies resulted in changes to the benefit–risk balance of the medicinal 
products under evaluation. 
Table 8. Regulatory Actions according to Assessment Reports 
 






Studies with Assessment Reports 22 (91.7) 
Studies without Assessment Reports 2 (8.3) 
Ongoing Procedure 1  
Reason unspecified by national regulator 1  
Main regulatory concerns   
Low response rates 7 (31.8) 
Selection bias and generalizability of results 6 (27.3) 
Limited receipt of materials 7 (31.8) 
Regulatory Consequences   
No further action 9 (40.9) 
Further action required 13 (59.1) 
Improve distribution of aRMM or re-distribute 7 (31.8) 
Changes to contents/format of existing aRMMs 4 (18.2) 
Pending further discussion/data 4 (18.2)  
Follow-up assessment requested 3 (13.6)  
Removal of aRMMs 2 (9.1)  
Changes to SmPC 1 (4.5)  
aRMMs implemented 1 (4.5) 
Re-analysis by reading/non-reading 1 (4.5)  








6.1.6. Summary of Study Results 
The key findings show that among HCPs, the pre-specified sample size was reached in 52% of studies. 
Study participation was 89% defined as ‘Completers/Eligible’ and 5% defined as ‘Completers/Invited’. 
Receipt of materials was recalled by up to 60% of HCPs on average. Knowledge of safety concerns 
was assessed, with 77% of items scoring knowledge levels >60%. Among patients and/or caregivers, 
the pre-specified sample size was reached in 25% of studies. Participation by patients was 93% when 
defined as ‘Completers/Eligible’ (the number of patients invited reported in only one study). Receipt 
of patient materials ranged between 50%-80%. Materials were read by over 90% of respondents. 
Overall, 38% of items scored knowledge levels >60%. Behaviour was not analyzable due to the varying 
formulation and reporting of survey questions. A summary of results of EU RM Survey studies is provided 
in Figure 14. Further action based on study results was requested by regulators in 59% (13/22) of studies, 
which most frequently involved re-distribution of materials or re-formulation of the existing distribution 
strategy. 
 
Figure 14. Key results in EU RM Surveys  
 
  








6.2. Objective 2: Evaluate participation in EU RM Surveys to assess the effectiveness of 
aRMMs in Europe 
 
6.2.1 Study Selection 
Between 1st Jan 2012 and 12th October 2019, 129 EU RM Studies were identified, of which 92 had results 
available (Figure 15, according to the PRISMA Statement). Forty-eight studies had a survey 
component and were eligible for analysis: 44 were surveys of HCPs and 14 were surveys of patients 
and/or caregivers. Two additional patient surveys were identified but excluded; one was cancelled 
due to lack of recruitment and the other was attempted but results were not reported as only seven 
patients were recruited.  
 
 
Figure 15. Flowchart of the selection process based on PRISMA guidelines – Objective 2 
6.2.2 Healthcare Professional Surveys 
Twenty-eight different European countries were aimed for the HCP surveys with an average of 5 
(Range: 1 to 18) countries targeted per survey and 6 (Range: 1 to 18) finally participating.  








The total number of HCP participants was 18207. For 17502 of them country-specific information was 
available.  
Figure 16 shows the participation percentages in HCP Surveys by country. The most frequent countries 
participating in HCP surveys were the UK (33/44), Spain (28/44), France (29/44) and Germany (29/44), 
contributing 64.2% (by country range: 17.8% to 12.7%) of all participants with country-specific data. 
Italy, Sweden, Denmark, Netherlands, Belgium, and Austria participated in 18, 17, 15, 11, 10 and 10 
HCP surveys, respectively, recruiting 21.5% (Range: 2.0% to 6.3%) of all participants. The other 18 
countries participated in 1 to 9 studies and provided 14.3% (Ranging from 0% to 2.5%) of the HCP 
participants. The median HCP response rate by country ranged from 0.3% to 22.0%, being highest in 
Greece (22.0%), Italy (18.7%) and Czech Republic (18.4%).  
 
Figure 16. Map of Europe representing the percentages of participation by country in HCP Surveys 

























Range of % of participation 
Range of % of response 
(from invited) 
Max Min Med N Max Min Med N 
UK 33 75.0 3112 22.3 17.8 100.0 6.3 18.0 33 26.3 0.4 10.4 16 
Germany 29 65.9 2216 17.8 12.7 33.7 4.8 14.3 29 121.7 0.3 3.2 20 
France 29 65.9 2874 20.5 16.4 67.7 7.1 17.8 29 75.7 0.3 4.5 19 
Spain 28 63.6 3032 20.7 17.3 57.5 9.9 19.7 28 83.3 0.8 13.7 16 
Italy 18 40.9 1105 16.3 6.3 46.6 4.2 14.7 18 58.8 0.3 18.7 12 
Sweden 17 38.6 767 10.5 4.4 49.3 3.1 8.3 16 30.8 2.0 3.6 8 
Denmark 15 34.1 352 7.0 2.0 100.0 0.0 5.1 15 26.0 0.2 2.4 10 
Netherlands 11 25.0 554 12.4 3.2 32.3 3.2 7.1 11 13.2 4.1 7.2 7 
Austria 10 22.7 386 9.0 2.2 15.5 0.6 7.4 10 121.7 0.1 7.0 9 
Belgium 10 22.7 601 10.4 3.4 16.1 2.0 8.4 10 16.8 6.3 8.0 5 
Norway 9 20.5 112 3.2 0.6 12.2 0.0 4.1 9 2.7 0.0 0.3 5 
Ireland 6 13.6 72 3.6 0.4 20.2 2.1 2.9 6 16.7 1.1 11.8 6 
Greece 6 13.6 246 9.6 1.4 23.7 2.9 11.2 6 44.8 0.4 22.0 4 
Poland 6 13.6 204 7.0 1.2 12.2 4.4 8.7 5 19.0 2.0 2.2 3 
Slovakia 6 13.6 250.0 6.9 1.4 15.9 2.9 7.9 6 39.2 2.8 6.3 4 
Bulgari 5 11.4 188 5.9 1.1 14.1 2.9 6.2 5 55.1 4.4 12.7 5 
Hungary 4 9.1 205 8.0 1.2 12.5 3.9 6.5 4 64.0 3.2 15.8 4 
Portugal 4 9.1 437 13.8 2.5 19.0 6.8 12.8 4 78.5 0.6 5.5 3 
Czech Republic 4 9.1 266 10.5 1.5 15.8 13.9 13.9 4 24.0 12.8 18.4 2 
Finland 3 6.8 79 4.4 0.5 4.5 4.4 4.4 3 6.7 6.0 6.7 3 
Switzerland 2 4.5 52 7.3 0.3 7.8 6.8 7.3 2 - - - - 
Romania 2 4.5 185 9.6 1.1 - - - - - - - - 
Luxembourg 2 4.5 11 0.8 0.1 0.9 0.8 0.8 2 6.1 4.3 5.2 2 
Slovenia 1 2.3 0 0.0 0.0 - - - - - - - - 
Estonia 1 2.3 61 5.4 0.3 - - - - - - - - 
Latvia 1 2.3 62 5.5 0.4 - - - - - - - - 
Lithuania 1 2.3 73 6.5 0.4 - - - - - - - - 
Others non-EU 1 2.3 2 0.5 0.0 - - - - - - - - 








6.2.3 Patient/Caregiver Surveys 
For patient surveys, 17 different countries were involved with an average of 5.0 (Range: 3 to 10) 
countries targeted and participating per survey. One survey also included caregivers. The total 
number of patient/caregiver participants was 4129; 2996 with country-specific participation data. The 
UK (11/14), Germany (10/14), France (9/14) and Spain (7/14) were also the top recruiters in the patient 
surveys, recruiting 65.7% of all participants with country-specific data. The median patient response 
rate by country ranged from 90.3% to 10.0%, being highest in Spain (90.3%) and Germany (78.9%). 
 
Figure 17. Map of Europe representing the percentages of participation by country in Patient Surveys








Table 10. Patient/Caregiver Participation Data 
Country 















Range of % of participation 
Range of % of response 
(from invited) 
Max Min Med N Max Min Med N 
UK 11 78.6 452 14.7 15.1 31.1 0 10.3 11 57.8 57.1 57.5 2 
Germany 7 71.4 426 20.4 14.2 68.8 14.3 19.7 7 100 80.6 90.3 2 
France 10 64.3 750 26.6 25.0 26.4 2.3 10.7 9 100 20 78.9 3 
Spain 9 50.0 339 14.2 11.3 44.2 2.6 11.5 9 64 1 42.9 3 
Italy 6 42.9 285 24.46 9.5 48.8 1.6 42.2 6 34 23.6 28.8 2 
Sweden 4 28.6 42 11.0 1.4 22.4 0 7.8 4 26.7 16.7 21.7 2 
Austria 3 21.4 56 5.8 1.9 10.4 0 5.4 3 - - - 0 
Denmark 2 21.4 2 3.0 0.1 3.6 2.6 3.1 2 33.3 5 19.2 2 
Belgium 3 21.4 18 9.4 0.6 12.8 0 5.1 3 10 10 10 1 
Ireland 3 14.3 6 3.1 0.2 12.8 0 0.8 3 11.4 11.4 11.4 1 
Netherlands 2 14.3 11 7.8 0.4 8 6.3 7.1 2 - - - - 
Greece 2 14.3 0 0 0.0 - - - - - - - - 
Norway 2 14.3 269 30.1 9.0 35.5 14.9 25.2 2 - - - - 
Portugal 1 7.1 70 10.6 2.3 10.6 10.6 10.6 1 - - - - 
Bulgaria 1 7.1 59 7.4 2.0 7.4 7.4 7.4 1 - - - - 
Czech 
Republic 
1 7.1 103 12.80 3.4 12.8 12.8 12.8 1 - - - - 
Slovakia 1 7.1 108 13.5 3.6 13.5 13.5 13.5 1 - - - - 








6.3. Objective 3: Systematic review of RMEv that include process indicators and 
outcomes 
 
6.3.1. Study Selection Process 
As of 12 October 2019, 129 studies linked to 102 products were identified (Figure 18, according to the 
PRISMA Statement). Eighteen products (of 102; 17.6%) had RMEv involving both process indicators and 
outcomes with 30 associated studies (Table S2). Of these 14 RMEv had results available, with 24 
associated studies.  
 
*Grey Literature: Google, ICPE Abstracts 
ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management; MAH: Marketing Authorisation Holder; RM: risk 
minimisation; RMEv: risk minimisation evaluation 
Figure 18. Flowchart of the selection process based on PRISMA guidelines – Objective 3 
6.3.2. Characteristics of Products and RMEv with Process Indicators and Outcomes 








The 18 products with RMEv including process indicators and outcomes were distributed among the 
following ATC groups: six (33.3%) antineoplastic and immunomodulating agents; five (27.8%) nervous 
system; two (11.1%) blood and blood forming organs; and five products (27.8%) were each from 
different ATC groups (Table 11). Twelve of the 18 products (66.7%) were centrally approved.  
Materials targeted at HCPs were object of study in 15/18 RMEv: 12/18 (66.7%) were HCP guides, 
leaflets, or brochures, and 7/18 (38.9%) were DHPCs. Materials targeted at patients were evaluated in 
12/18 RMEv, 10/18 (55.6%) consisting of patient cards and 5/18 (27.8%) of patient guides, leaflets or 
brochures. Further details about the specific aRMMs are shown in Table S2.  
Table 11. Characteristics of products with RMEv involving process indicators and outcomes 
 
All RMEv 
N = 18 
RMEv with Results 
N = 14 
  n % n % 
ATC Level 5  
L-Antineoplastic and immunomodulating agents 6 33.33 5 35.71 
N-Nervous system 5 27.78 4 28.57 
B-Blood and blood forming organs 2 11.11 2 14.29 
G-Genito-urinary system and sex hormones 1 5.56 1 7.14 
C-Cardiovascular system 1 5.56 1 7.14 
A-Alimentary tract and metabolism  1 5.56 1 7.14 
M-Musculo-skeletal system 1 5.56 0 0.00 
V-Various 1 5.56 0 0.00 
Type of aRMMs in RMEv  
DHPC 7 38.89 6 42.86 
Patient card 10 55.56 8 57.14 
HCP guide, leaflet or brochure 12 66.67 9 64.29 
Patient guide, leaflet or brochure 5 27.78 4 28.57 
Number of studies per RMEv 
1 study  10 55.56 8 57.14 
2 studies 5 27.78 3 21.43 
≥ 3 studies  3 16.67 3 21.43 
Type of Outcomes 
Behavioural outcomes 12 66.67 10 71.43 
Health/Safety Outcomes 9 50.00 7 50.00 
Abbreviations: aRMM, additional risk minimisation measure; ATC, Anatomic and Therapeutic Class; DHPC, dear healthcare 
professional communication; HCP, Healthcare professional; RMEv, risk minimisation evaluation 
 
Ten of the 18 (55.6%) RMEv included both process indicators and outcomes within the same study 
protocol. The involved surveys combined with a retrospective analysis of the company safety 
database in four RMEv, surveys combined with patient´s medical records extraction in four RMEv, one 
prospective study allowing for the collection of process measures (use, helpfulness) and outcomes 
(proportion of inappropriate prescribing), and one HCP survey assessing knowledge and self-reported 








behaviour as well as reading errors. Five RMEv involved two separate studies, consisting of surveys and 
a drug utilisation study. Two RMEv consisted of three studies (two drug utilisation studies and a survey) 
and the remaining one consisted of four separate studies (three drug utilisation studies and a survey).  
The proportion of RMEv that evaluated health/safety outcomes was 50.0% while 66.7% evaluated 
behavioural outcomes. Three RMEv evaluated process indicators, behavioural and health/safety 
outcomes.  
Table 12 provides a listing of the RMEv included in the analysis. Table S2 provides the characteristics of 
each RMEv including the safety concerns addressed by the aRMMs.  
Table 12. RMEv included in the analysis and main RMEv characteristics 
RMEv 
Type of aRMM evaluated 
Study  
Ref. 
Measures of effectiveness  
Study Design Data Source 
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Abatacept  
(L04AA24) 
    x 
[84] 
 






























Type of aRMM evaluated 
Study  
Ref. 
Measures of effectiveness  
Study Design Data Source 




















































































































x     
Ongoing 
[86] 
  x x x  Survey HCP Survey 
Agomelatine  
(N06AX22) 






Survey Patient Survey 
Rituximab  
(L01XC02) 
x   x x [70,88] x x x x x  










x x    
[89] x  x x   Survey HCP survey 




















 x x  x x [70]  x x x  x 
























x    x 
[93] x x x    Survey 
HCP and 
Patient Surveys 









    x 
Ongoing 
[95] 











x  x  x 
Ongoing 
[96] 















x x  x  
[98] x x x x   Survey HCP Survey 
Ongoing 
[99] 






6.3.3. Characteristics of Studies in RMEv with Process Indicators and Outcomes 
Table 13 shows the characteristics of studies included in RMEv involving process indicators and 
outcomes. Of the 30 studies, 63.3% (19/30) included cross-sectional surveys (47.4% targeted patients 








and 89.5% HCPs), 56.7% (17/30) had retrospective components (47.1% used a pre/post assessment 
approach) and 10.0% (3/30) prospective designs. 
Process indicators were measured in 63.3% (19/30) of studies. Receipt of aRMMs was measured in 14 
of them, use of aRMMs in 12, level of knowledge in 17, and self-reported behaviour in 15. 
Behavioural outcomes from existing databases were assessed via drug utilisation studies in 50.0% 
(15/30) of cases. The proportion of patients receiving the target drug under on-label/off-label 
conditions or inappropriate prescribing (over time, before and after the aRMMs or at a specific time 
point) was evaluated by 11 studies. Two studies evaluated medication errors, while monitoring of 
metabolic parameters and reading errors were assessed each by one study.  
Health/safety outcomes were measured in 30.0% (9/30) of the studies and consisted of infusion-related 
adverse events (n=1), infections leading to hospitalisation, emergency room visits, etc. (n=2), bleeding 
(n=2), pregnancy exposures (n=2), hepatotoxicity and nephrotoxicity (n=1), and medication errors 
(n=2).  
Drug utilisation and health/safety outcomes data were obtained from: existing healthcare databases 
(n=10), company global drug safety databases (n=4), data abstraction from medical records (n=4) or 
via primary data collection (n=4). 
In five RMEv the correlation between process indicators and outcomes was assessed. Two studies 
attempted to correlate aggregate survey results with spontaneous reporting rates [78,85], two with 
outcomes recorded in the clinical records at an individual patient level [84,95,100], and one with 
prospectively collected events [96,97]. 
Table 13. Characteristics of Studies included in RMEv 
 
All Studies 
N = 30 
Studies with Results 
N = 24 
 n % n % 
Study Design Components N=30 N=24 
Retrospective 17 56.67 15 62.50 
          Time of evaluation (among retrospective) n=17   n=15   
  Post-implementation 9 52.94 8 53.33 
  Pre- and post-implementation 8 47.06 7 46.67 
Cross-sectional Survey 19 63.33 15 62.50 
          Type of survey (among cross-sectional surveys) n=19   n=15   
                Patient Survey 9 47.37 7 46.67 
  HCP Survey 17 89.47 13 86.67 
Prospective 3 10.00 1 4.17 
Type of Indicator/Outcome N = 30   N=24  
Process Indicators 19 63.33 15 62.50 
          Type of Process Indicators      










N = 30 
Studies with Results 
N = 24 
 n % n % 
                Receipt 14 46.67 11 45.83 
Use / usage / usefulness (reading/distribution) 12 40.00 8 33.33 
Knowledge 17 56.67 13 54.17 
Self-reported Behaviour 15 50.00 10 41.67 
Behavioural Outcomes e.g. Drug utilisation 15 50.00 13 54.17 
Type of Drug Utilisation Measures      
Off-label / on-label use / inappropriate 
prescribing 
11 40.00 10 41.67 
Monitoring metabolic parameters 1 6.67 2 8.33 
Reading errors 1 3.33 0 0.00 
Medication errors  2 6.67 1 4.17 
Health/Safety Outcomes 9 30.00 7 29.17 
Type of Health/Safety Outcomes      
Infusion related adverse events 1 3.33 1 4.17 
Infections (leading to hospitalisation, emergency 
room visits, etc.) 
2 6.67 1 4.17 
Bleeding 2 6.67 2 8.33 
Pregnancy exposures 2 6.67 2 8.33 
Medication errors 2 6.67 1 4.17 
Hepatotoxicity, nephrotoxicity 1 3.33 0 0.00 
Behavioural and/or Health/Safety Outcomes 21  17  
Data Source      
Company Global Drug Safety databases 4 19.05 4 23.53 
Healthcare Databases 10 47.62 8 47.06 
Medical records data extraction 4 19.05 3 17.65 
Primary data collection 4 19.05 2 11.76 
Abbreviations: HCP, Healthcare professional; RMEv, risk minimisation evaluation 
6.3.4. Results of Studies in RMEv involving Process Indicators and Outcomes 
Results were available for 14/18 products with RMEv (characteristics presented in Table 11), involving 
24 separate studies (characteristics presented Table 13). 
6.3.4.1. Results of Process Indicators  
Table 14 shows the summary results of process indicators. 
Of the 17 HCP survey studies in this review, 13 had results available. Data on receipt were available in 
nine studies, with a median of 57% (Range: 16% to 96%) respondents reporting having received the 
materials. Among recipients, the median proportion of respondents reading the materials, based on 
five studies, was 92% (Range: 72% to 98%) and for respondents using the materials, based on six studies, 
the median was 80% (Range: 68% to 97%). The median percentage of HCPs responding correctly to 
knowledge questions about key safety concerns was 77% (Range: 26% to 100%), while behaviour 
implementation was correctly indicated by 74% (Range: 0% to 96%) of respondents.  








Of the nine patient survey studies in this review, seven had results available. Data on receipt were 
available in six studies, with a median of 56% (Range: 30% to 67%) respondents reporting having 
received the materials. Among recipients, the median of respondents reading the materials, based 
on four studies, was 87% (Range: 80% to 91%) and the median of respondents using the materials, 
based on four studies, was 65% (Range: 38% to 94%). The median percentage of patients responding 
correctly to knowledge questions about key safety concerns was 47% (Range: 22% to 73%), while 
behaviour implementation was correctly indicated by a median of 69% (Range: 42% to 96%) of 
respondents.  
No statistically significant differences were found for receipt, reading or behaviour between HCP and 
patient survey studies. Significantly better results (p < 0.05) were observed for use and knowledge 
acquired in HCPs compared to patients with the Kolmogorov-Smirnov test, while only knowledge was 
found statistically significant (p < 0.05) with Mann-Whitney U test. 






















Studies with results (n) 9 5 6 9 7 
Indicators (n) 15 6 9 29 23 
Median (%) 56.9 91.8 80.3 77.1 74.0 
Max. (%) 96.2 97.8 97.2 100.0 96.0 
Min. (%) 16.2 71.7 68.0 25.8 0.0 
Patients 
Studies with results (n) 6 4 4 6 4 
Indicators (n) 7 4 5 13 11 
Median (%) 56.0 86.9 64.5 47.4 69.0 
Max. (%) 66.7 90.9 93.9 72.6 96.0 
Min. (%) 30.0 79.6 37.9 22.2 42.0 
p-value* 0.253 0.176 0.032 0.005 0.390 
p-value** 0.458 0.454 0.161 0.002 0.768 
a. Among those who received the materials 
* Non-parametric test-Kolmogorov-Smirnov 
**Non-parametric test-Mann-Withney U test 
Abbreviations: aRMM, additional risk minimisation measure; HCP, healthcare professional 
 
Results of process indicators within each RMEv are displayed in Table S3.  
6.3.4.2. Results of Behavioural and/or Health Outcomes 








Ten RMEv (involving 13 studies) reported results of behavioural outcomes and seven (involving 7 
studies) reported results of health/safety outcomes. Main results are summarised in Table 15 and Table 
S4, respectively.  
Among the 13 studies with results reporting behavioural outcomes, two assessed compliance with 
recommendations on performance of monitoring tests [72,87]. One reported an increase in 
performance of liver tests from the pre-implementation period with a median of 27.6% (Range: 15.1% 
to 56.3%) patients compliant with recommendations to a median of 42.3% (Range: 16.3% to 67.2%) 
post-implementation of the measures [87]. The other study evaluated performance of a range of 
monitoring tests with results that differed substantially between the two participating countries [72]; 
median of 33.2% (Range: 27.7% to 55.6%) of patients being monitored in the UK and 0.6% (Range: 0.0% 
to 6.9%) in Germany.  
Ten studies evaluated the proportion of off-label use and/or inappropriate prescribing, four of which 
reported this proportion after the implementation of measures. In one study, 34.5% of patients were 
prescribed cyproterone acetate/ethinylestradiol in accordance with the updated label [77]. The 
prescription of inappropriate doses of dabigatran to patients >75 years decreased from 34.5% to 15% 
a year after the safety update [94]. Valproate prescribing in women 14-45 years decreased 17% from 
2015 to 2010 after strengthening recommendations in the UK [91]. In another study [88] the median 
proportion of patients prescribed rituximab for off-label indications across the five participating 
countries was 29.9% (Range: 16.5% to 43.4%).  
Five studies evaluated changes in off-label/inappropriate use before–after the implementation of 
aRMMs, with declines in median proportions across countries noted in two studies (from 33.6% to 27.6% 
[77] and from 28% to 18% [92]) and moderate improvements in compliance with all label requirements 
reported by another study [82]. In the two studies with trimetazidine, changes in proportion of 
prescriptions diverged across countries [79,81]). One additional study [74] only had interim pre-
implementation results available at the time of this review.  
Among seven studies reporting health/safety outcomes, two provided the number of spontaneously 
reported cases within a reporting period [70], with no cases of the event of interest being reported. 
Two studies evaluated changes in number of cases over time; while one observed a decrease in 
pregnancies exposed to valproate after the implementation of measures [90], the other did not find 
a clear trend over time [94]. The remaining three evaluated the correlation of survey responses with 
the occurrence of the health/safety outcome of interest at different levels (i.e., correlation of 
aggregate results versus within patient correlation). From the two studies that correlated aggregate 
survey responses with reporting rates from safety databases [78,85], one reported no correlation 
between survey aggregated results (patients/HCPs) and adverse drug reactions in any combination 
(overall sample and per indication) which only turned positive among patients when outlier data 








points were removed from the analysis [85]. The study that correlated survey results with the event of 
interest in the same patients who completed the survey [84] reported a numerical trend in the 
reduction of events as the level of understanding and implementation of measures from the survey 
increased. However, due to the small number of events the correlation was not statistically significant. 
The three studies mention caution in the interpretation of the findings due to methodological 
limitations (e.g., small number of patients, spontaneous reporting rates, and ecological correlations). 







Correlation between ability to 
respond to (any) risk scenarios in the 
survey and the total or organ-
specific injection related adverse 
reactions reporting rates per country 
No correlation between ability to respond to (any) risk 
scenarios and total or organ-specific injection related 
adverse reactions reporting rates per country; or 
between the use of RM tools and total injection related 
adverse reactions reporting rates per country. 
Abatacept [84] 
Correlation between the global 
score of understanding and 
implementation of the patient alert 
card from patient survey and the 
number of infections leading to 
hospitalisation, retrospectively 
collected from patient medical 
records 
The percentage of patients with infections leading to 
hospitalisation increased as the global score of 
understanding and implementation of the patient alert 
cards (from the patient survey) decreased: 3% for 
scores ≥ 67%, 5% for scores 34-67% and 8% for scores 0-
33%. However, with few patients experiencing infection, 
the correlation was not statistically significant. 
Apixaban [85] 
Correlation between survey 
aggregated results of knowledge 
and behaviour and spontaneously 
reported preventable bleedings per 
country  
The analysis of scatter plots and correlation coefficients 
suggested no correlation between survey aggregated 
results (patients/HCPs) and ADR cases in any 
combination (overall sample and per indication). After 
removing influential data points from the analysis, there 
was evidence to support a correlation between overall 
patient/caregiver knowledge and the proportion of 
potentially preventable bleeding ADRs per country. This 
finding should be interpreted with caution since the 






Changes in pregnancy exposure 
before-after the implementation of 
the measures 
Overall, 923 pregnancies including 451 exposed to 
valproate (48.9%) from the entire pre-implementation 
period and 350 including 182 exposed to valproate 
(52.0%) from the entire post-implementation period 
were identified in the target countries. In Sweden and 
UK, providing the most interpretable pregnancy data in 
this report, the incidence rate of pregnancies exposed 
to valproate decreased from 0.0095 to 0.0080 per 12 
person-months and from 0.0169 to 0.0109 per 12 person-
months, respectively.  
Vismodegib [70] 
Number of spontaneously reported 
pregnancy cases exposed to the 
drug in a reporting period 
No pregnancy cases had been reported, either from 




Number of spontaneously reported 
medication error reports of product 
confusion in a reporting period 
There were 24 medication error reports in this period for 
which 8 were from the EU, but none from UK (from a 
global cumulative market exposure of 6519 patients). 
Product confusion with Herceptin was not reported for 
any. 
Dabigatran [94] 
Trend in quarterly proportion of the 
total number of patients treated 
with dabigatran and experiencing 
major bleedings over time 
Ranged from 0 to 0.5% of incident users with no clear 
trend over time.  








6.4. Objective 4: Case Study to evaluate the effectiveness of aRMMs linking process 
indicators and outcomes  
 
6.4.1. Patient Population   
The disposition of patients is presented in Figure 19.  
 
Figure 19. Study population in patient survey and retrospective chart review – Objective 4 
Participation rates calculated were: 59.7% (190/318) by completers/invited and 67.9% (190/280) by 
completers/eligible. 
6.4.2. Patient Survey   
 
6.4.2.1. Patient Characteristics 
The characteristics of patients in the survey are summarised in Table 16. The distribution of participants 
among the participating countries was: 39.5% (75/190) in Spain, 31.1% (59/190) in the UK, 15.8% 
(30/190) in Germany, 8.4% (16/190) in France and 5.3% (10/190) in Sweden. Patients were mainly aged 
> 55 years (70.5%, 134/190) and female (76.8%, 146/190). The majority of patients had been on 
Abatacept for > 1 year (66.5%, 125/188) at the time of completing the survey, followed by 7-12 months 
in 29/188 (15.4%) of cases. Abatacept was administered largely subcutaneously (66.1%, 125/189), with 
the patient being the primary administrator (53.4%, 101/189). Patients were poly-medicated; 72/188 
receiving 5-8 medicines (38.3%), 67/188 receiving 2-4 (35.6%) and 38/188 receiving more than 8 
(20.2%). A minority were on monotherapy with Abatacept (5.3%, 10/188). 




Country n (%) 
France 16 (8.42) 
Germany 30 (15.79) 
Spain 75 (39.47) 











UK 59 (31.05) 
Sweden 10 (5.26) 
Type of Questionnaire  
Paper  169 (88.95) 
Electronic  21 (11.05) 
Age group  
18-25 years 0 (0.00) 
26-35 years 6 (3.16) 
36-45 years 21 (11.05) 
46-55 years 29 (15.26) 
56-65 years 55 (28.95) 
> 65 years 79 (41.58) 
Gender  
Male 44 (23.16) 
Female 146 (76.84) 
Educational level  
No schooling completed 12 (6.38) 
Primary school 42 (22.34) 
No schooling completed/ Primary school 0 (0.00) 
Secondary school 81 (43.09) 
Some college further education (e.g., at a college) 24 (12.77) 
Bachelor’s degree 8 (4.26) 
Master’s degree or doctorate 15 (7.98) 
Other professional qualification 6 (3.19) 
Missing 2 
 
6.4.2.2. Patient Survey Results 
From those with information, 59.7% (111/186) of patients were aware of the PAC, of whom 94.6% 
(105/111) recalled having received or accessed it, mainly through the specialist nurse (44.8%, 47/105) 
and in the medication box (30.5%; 32/105); and 83.8% (88/105) had read the material. By route of 
administration, 65.6% (40/61) of patients were aware of the PAC for the IV formulation and 56.9% 
(70/123) for the SC formulation.  
More than half the patients who received the PAC or selected ‘I do not remember’ (56.6%; 60/106) 
indicated that the information contained in the material had been explained to them. Among 76 
patients who received explanation of the contents of PAC or who selected ‘I do not remember’, the 
source of the explanation was primarily a specialist nurse for 53.9% and a doctor in 35.5%.  
The PAC was carried at all times by 64.5% (69/107) of patients and 59.6% (62/104) were aware that 
they should present it to every physician involved in their healthcare. The mean scores were (SD): 
65.2% (29.5) for utilization, 87.2% (22.7) for understandability, 65.5% (42.3) for clarity, 64.2% (41.8), for 
conciseness, 61.1% (40.2) for completeness, 56.3% (42.3) for brevity, resulting in an overall mean utility 
score of 60.5% (32.8). A graphical representation of the scores is provided in Figure 20.  









Figure 20. Clarity, conciseness, completeness, brevity, and understandability of the PAC in the 
patient survey 
 
Levels of correct knowledge in patients is shown in Figure 21. The mean knowledge score (across all 
knowledge questions) was higher among those who recalled receiving the PAC compared to those 
who did not (64.5% vs 36.9%; p<0.001). As shown in Figure 22, knowledge about the risk of infections 
was higher among those who recalled having received the PAC compared to those who did not 
(63.8% vs 45.9%; p=0.013). Knowledge about pre-screening for TB and VH were correctly indicated by 
77.9% and 47.4% of patients, respectively. In both cases, this knowledge was among those who 
recalled having received the PAC compared to those who did not: 87.6% vs 65.9% for TB (p<0.01) and 
55.2% vs 49.2% for VH (p=0.016). While only 28.4% of patients identified the PAC as a source where to 
find information about the benefits and risks of abatacept, it was higher among those who recalled 
receiving the PAC than those who did not (35.2% vs 26.2%; p=0.021).  









Figure 21. Percentage of correct knowledge in patient surveys. Positive correct responses (=Yes) are displayed in dark blue and negative correct 
responses (=No) in light blue









Figure 22. Proportion differences in level of correct knowledge in patient survey according to receipt/non-receipt of the PAC 








The percentage of patients who were aware that a list of all other medicines being taken with 
abatacept should be carried at any visit to a HCP was higher among those who recalled having 
received the PAC than in those who did not (85.7% vs 72.9%; p=0.029). By contrast, the 
recommendation to keep the PAC for 3 months after the last dose of abatacept was only known by 
26.2% of patients who received the PAC vs 0.0% of those who did not. 
The majority of patients reported that HCPs informed them about the side effects of abatacept (66.1%; 
125/189). Implementation of behaviour was also assessed through hypothetical scenarios of when to 
seek immediate medical attention: correct responses were 68.9% (131/190) for fever, 80.5% (153/190) 
for chest tightness, 66.3% (126/190) for wheezing and 64.2% (122/190) for severe dizziness or feeling 
light-headed. 
The mean behaviour score was significantly higher among patients who recalled having received the 
PAC compared to those who did not (70.3% vs 64.2%; p=0.027). 
 
Figure 23. Scores in the patient survey: Utilisation, Knowledge, Utility, Behaviour and Global Score in 
the patient survey 
The mean (SD) global score was 46.1% (23.1) overall and higher among patients who indicated having 
received the PAC than in those who did not (65.6% vs 26.9%; p<0.001).  
 









Figure 24. Summary of patient survey results 
6.4.3. Retrospective Chart Review: Correlation of Patient Survey Process Indicators with 
Clinical/Safety Outcomes 
Of the 190 patients who completed the patient questionnaire, 181 had outcomes data extracted. The 
nine patients without outcomes data were due mainly to closure of the study before the data could 
be collected. Pre-treatment screening tests for TB and for VH were available in 83.4% (151/181) and 
69.1% (125/181) of patients, respectively; 76.8% (116/151) had the results available for TB and 88.8% 
(111/125) for VH before abatacept. 
During the follow-up period, seven of 181 patients (3.9%) had infections leading to emergency room 
attendance and 11 (6.1%) had infections leading to hospitalisation. The mean (SD) time from symptom 
onset of the infection to receiving medical attention (per patient), in 16 patients with data available, 
was 6.8 (± 6.9) days. 
Table 17. History of infections during the follow-up 
Follow-up Overall N=181 
Time from first symptom onset of infection until receiving medical attention 
(days) (per patient average) 
 
n (n missing) 16 (165) 
 Mean (Standard Deviation) 6.8 (6.9) 
 Median (Q1-Q3) 4.0 (1.0 - 13.5) 
 Min - Max 0.0 - 21.0 
Patients with infections leading to emergency room during the follow-up  
n (n missing) 181 (0) 
n (%) 7 (3.87) 








Follow-up Overall N=181 
Patients with infections leading to hospitalisation during the follow-up  
n (n missing) 181 (0) 
n (%) 11 (6.08) 
 
In the correlation analysis (Table 18), the percentage of patients with infections leading to 
hospitalisation increased as patient survey global scores decreased: scores of ≥67%, 34-67% and ≤33% 
were associated with hospitalisation rates of 2.5% (1/40), 5.2% (3/58) and 8.4% (7/83), respectively 
(p=0.44). A statistically significant association was observed for the correlation of the global composite 
score and screening for TB: global scores of ≥67%, 34-67% and ≤33% were associated with screening 
for TB scores of 60.0%, 81.0% and 54.2%, respectively (p=0.004). No significant correlation was found for 
screening for VH: global composite scores of ≥67%, 34-67% and ≤33% were associated with screening 
for VH scores of 57.5%, 70.7% and 56.6%, respectively. There was no correlation for emergency room 
visits and by days from first onset of symptoms of infection to receiving medical attention with global 
scores.   








Table 18. Correlation Analysis 
 Global Score (from patient survey) 
  High (>67%) Medium (34%-67%) Low (≤ 33%)     
Categorical variables Valid n n % col  n % col  n % col  Test   p-valueb 
Patients with results of any pre-screening test for TB before Abatacept 
Yes 116 24 60.00  47 81.03  45 54.22  
Chi-square 
test 
  0.004 b 
No 65 16 40.00  11 18.97  38 45.78      
Patients with results of any pre-screening test for viral hepatitis before Abatacept 
Yes 111 23 57.50  41 70.69  47 56.63  
Chi-square 
test 
  0.206 
No 70 17 42.50  17 29.31  36 43.37      
Patients with infections leading to unplanned hospitalisation during the follow-up 
Yes 11 1 2.50  3 5.17  7 8.43  
Fisher exact 
test 
  0.440 
No 170 39 97.50  55 94.83  76 91.57      
Patients with infections leading to emergency room visit during the follow-up 
Yes 7 1 2.50  2 3.45  4 4.82  
Fisher exact 
test 
  1.000 
No 174 39 97.50  56 96.55  79 95.18      









Test Statistic Value p-value 
Number of days from first symptom 
onset of infection until receiving 
medical attention (average per 
patient) a 
16 3 7.0 3.464 5 3.6 2.619 8 8.8 2.725 
Mann-
Whitney 
U 8.50 0.103 
a. The univariate analysis was performed among groups with at least 5 cases. 
b. Bold values correspond to statistical significance of the differences between groups (p<0.05) 
c. Yes is associated with "Medium Level" and No with "Low Level"  








6.4.4. Healthcare Professional Survey 
The disposition of HCPs in the study is presented in Figure 25. Only 320 HCPs were evaluable among 
2385 HCPs invited to participate. From these 320 HCPs, only 107 were eligible and 79 (50 physicians 
and 29 nurses) completed the questionnaire. The percentage of completers/invited was 3.3% 
(79/2385) and that of completers/eligible was 73.8% (79/107).  
 
Figure 25. Study Population in HCP Survey – Objective 4 
6.4.4.1. Healthcare Professional Characteristics  
The distribution of participants among the participating countries was: 29.1% (23/79) in France, 26.6% 
(21/79) in the UK, 21.5% (17/79) in Spain, 17.7% (14/79) in Germany and 5.1% (4/79) in Sweden. 
The characteristics of patients in the survey are summarised in Table 19. HCPs were mainly aged 
between 36 and 55 years (38.0% 36-45 years; 35.4% 46-55 years). Most respondents were female (63.3%, 
50/79) and physicians (63.3%, 50/79). Almost half (45.57%, 39/79) had 11-20 years of experience. The 
mean (SD) number of RA patients managed personally with Abatacept in the previous 12 months was 
29.3 (62.6). The main roles of HCPs in the treatment of patients with Abatacept were: follow-up (89.9%, 
71/79), discussion of the use of Abatacept (76.0%, 60/79) and discussion of the benefits of Abatacept 
(73.4%, 58/79). Eight (10.1%) HCPs had participated in clinical trials with Abatacept in the previous 12 
months. The majority belonged to academic centres (60.3%, 47/78) with a median of 21.0 (95% CI: 
13.0-42.0) patients treated with Abatacept in the previous year. Most centres had specialist nurses in 
their departments (86.8%, 66/79). 





France n (%) 23 (29.11) 
Germany n (%) 14 (17.72) 
Spain n (%) 17 (21.52) 











UK n (%) 21 (26.58) 
Sweden n (%) 4 (5.06) 
Age group  
 
18-25 years n (%) 0 (0.00) 
26-35 years n (%) 10 (12.66) 
36-45 years n (%) 30 (37.97) 
46-55 years n (%) 28 (35.44) 
56-65 years n (%) 11 (13.92) 
> 65 years n (%) 0 (0.00) 
Gender  
 
Male n (%) 29 (36.71) 
Female n (%) 50 (63.29) 
Type of HCP   
Rheumatologist n (%) 49 (62.03) 
Rheumatologist in training n (%) 1 (1.27) 
Specialist nurse n (%) 29 (36.71) 
Internist n (%) 0 (0.00) 
Years managing RA patients 
< 5 years n (%) 3 (3.80) 
5 - 10 years n (%) 19 (24.05) 
11 - 20 years n (%) 36 (45.57) 
 > 20 years n (%) 21 (26.58) 
Number of RA patients managed personally with Abatacept in previous 12 months 
n (n missing)  79 (0) 
Mean (Standard Deviation)  29.3 (62.6) 
 Median (Q1-Q3)  12.0 (6.0 - 24.0) 
 Min - Max  2.0 - 400.0 
 
6.4.4.2. Healthcare Professional Survey Results  
The majority of HCPs (89.7%; 70/78) were aware of the PAC, of whom 68.0% (53/78) reported having 
had access or receiving it. Half of those who had received the PAC offered it to patients with the first 
prescription (50.0%; 19/38) and 47.4% (18/38) did at or before first administration. The PAC was mainly 
provided by nurses (66.7%; 52/78). Among HCPs who received or had access to the PAC, 71.7% (38/53) 
also read it. Most HCPs explained the content of the PAC to their patients at least sometimes (65.8%; 
25/38). More nurses than physicians were aware (93.1% vs 87.8%), had accessed (77.8% vs 74.4%), read 
(90.5% vs 59.4%), distributed (80.9% vs 65.6%) and explained the content (94.1% vs 42.9%) of the PAC.  
Among readers of the PAC, the mean (SD) utilization score was 50.9% (37.3). The level of helpfulness 
of the PAC was 70.4% (20.0), clarity 75.0% (25.3), conciseness 73.7% (23.2), completeness 71.1% (25.0) 
and brevity 66.4% (25.5), resulting in an overall mean utility score of 71.3% (20.4). A graphical 
representation of the scores is provided in Figure 26. 









Figure 26. Clarity, conciseness, completeness, brevity, and understandability of the PAC in the HCP 
survey 
 
Knowledge about the risk of infections was 84.8% (67/79) (Figure 27). The recommendations of pre-
screening for TB and VH were known by 84.8% and 73.4% of HCPs, respectively. Figure 28 shows the 
differences in knowledge levels between HCPs who received the PAC vs. those who not. No 
statistically significant differences in knowledge of any safety concerns were found between HCPs 
who did and did not receive the PAC. The mean (SD) knowledge score was 72.3% (17.0), and non-
statistically significantly higher among those who remembered receiving the PAC compared to those 
who did not (74.8% vs 67.2%; p=0.274). 
 









Figure 27. Percentage of correct knowledge in HCP survey. Positive correct responses (=Yes) are displayed in dark blue and negative correct 
responses (=No) in light blue









Figure 28. Proportion differences in level of correct knowledge in HCP survey according to receipt/non-receipt of the PAC








Most HCPs (96.2%) informed patients about the side effects of abatacept. The mean behaviour score 
was higher among HCPs who recalled having received the PAC compared to those who did not 
(79.2% vs 63.5%; p=0.027).  
 
Figure 29. Scores in the patient survey: Utilisation, Knowledge, Utility, Behaviour and Global Score in 
the HCP survey 
 
The mean global score was higher among HCPs who reported having received the PAC compared 
to those who did not (68.8% vs 33.1%; p<0.001). 









Figure 30. Summary of HCP survey results 
 
  










Risk minimisation evaluations may consist of measures of effectiveness evaluated at multiple levels 
with varying epidemiological designs and methodological approaches applied to accomplish the 
prespecified objectives. While previous research in the field looked at studies individually or reviewed 
studies descriptively, this thesis analyses subject participation, results and consequences of process 
indicators in EU RM Surveys, comprehensively evaluates RMEv using process indicators and outcomes 
beyond individual studies and provides a potential methodological framework for RMEv linking 
process indicators with outcomes at the patient level via a case example with results endorsed by 
EMA. 
Process indicators are one component of RMEv which inform about the overall performance of the 
aRMMs; implementation of the aRMMs (receipt i.e., whether they reached the target population) and 
their use, as well as the level of understanding and behaviour implementation around key safety 
messages. Process indicators were assessed via EU RM Surveys in the studies reviewed in this thesis, 
which are becoming a standard tool in this research field. As such, survey studies allowed for pooling 
of results across studies and combined interpretation, however, there was great variability in the way 
study participation data and results were presented and defined across reports and publications, 
which may benefit from further standardization.  
Low participation rates in surveys may result in selection bias, and results which are not generalizable. 
Participation rates may be defined and calculated in various ways. The pooled completers/invited 
rates found in Manuscript I reflect the difficulties encountered in attaining participation in HCP surveys, 
with an average of 1000 HCPs needed to be invited to recruit a sample of about 50 HCPs. Despite 
recruitment efforts and changes in planned strategies (e.g., extension of the data collection period, 
adding new countries and/or sites, remove random selection and a mixture of contingencies), pre-
defined sample sizes were only reached in half of the included HCP surveys. Low response rates and 
lack of generalizable results were also highlighted by regulators in the assessment reports of at least 
half of the studies as a major limitation to interpret results and make appropriate decisions. In other 
studies, this was considered ‘acceptable’ owing to the rarity of the disease with a limited number of 
HCPs available for recruitment and restricted to very specialized settings or to low usage or slow 
penetration of the product. In patient/caregiver surveys, participation data were difficult to interpret 
due to the small number of reports available, and if available the small sample sizes and limited 
information on selection methods and number of patients invited or eligible in the study reports. More 
than half the studies failed to meet their pre-specified sample sizes, which may be due to low usage 
of specialty drugs, patients with grave conditions not being in a condition to complete a 
questionnaire, lack of interest by participating sites that prioritize other studies and low fees paid for 
these studies. Abstract II also found low participation in surveys, especially for patient surveys. The ISPE 








Whitepaper highlights the importance of compensation fees according to fair market value standard 
in each country as a way to secure recruitment [60] and potentially increase representativeness [101]. 
However, it is acknowledged that incentives are still low compared to other competing studies such 
as clinical trials. HCPs also consider surveys of low scientific value. These are potential reasons that 
may contribute to low participation rates.  
The evaluation of aRMMs via surveys is on top of a background of varying clinical practice and 
guidelines for prescribing and monitoring which are variably followed in different EU countries. Thus, a 
range of countries is usually included in these studies, some countries being overrepresented. Abstract 
II reported an average of 6 participating countries with a maximum of 18 in HCP surveys, and 5 with a 
maximum of 10 in patient surveys, being the UK, Spain, France and Germany the most frequently 
included countries and the highest recruiting. However, conclusions are difficult to derive about the 
country variation of results. Heterogeneity of studies by design, characteristics of participants, clinical 
situations of use, results, with the limited number of studies available may limit generalizability but 
provide an overall summary of the current situation.  
Strategies to minimise selection bias remain under discussion. Recent initiatives aim to establish a 
conceptual framework to inform engagement interventions of patients and HCPs in the context of 
regulatory pharmacovigilance [14]. In this respect, the recent update of the ENCePP Methods guide 
[102] states: ‘The increasing use of online RMM require that survey methods adapt but should not 
sacrifice representativeness by accessing only populations which visit these websites and should 
provide evidence that the results using these sampling methods are not biased. Similarly, the 
increasing use of HCP and patient panels needs to ensure that survey methods do not sacrifice 
representativeness by accessing only self-selected participants in these panels and should provide 
evidence that the results are not biased by using these convenient sampling frames.’ 
Receipt of aRMMs (sometimes referred to as distribution or awareness) is one of the process indictors 
most frequently assessed in surveys (70% of HCP surveys and 100% of patient surveys; Manuscript I). 
Manuscript I and II show that receipt was not recalled by over 40% of respondents, varying somewhat 
with the type of materials. According to regulatory assessment reports, a third of the studies with ARs 
available required reinforcement of distribution strategies for existing aRMMs in all or some study 
countries or re-distribution and re-evaluation of their effectiveness. In recent years developments have 
been directed towards the implementation of digital materials by MAHs to make aRMMs easily 
accessible on their websites and monitor access in a real-time manner, and by local agencies making 
materials available through regulatory websites, as well as to integrate materials into electronic 
prescribing systems [103], with a number of alert systems in place. Therefore, receipt may be expected 
to improve as digitalisation of materials increases.  








Overall, if aRMMs are received, they are highly likely to be read and used, varying with the type of 
measure. Results in Manuscript II suggest that aRMMs impact the level of knowledge of patients to a 
lesser extent than they do among HCPs. This is not unexpected, as HCPs are more knowledgeable in 
health-related matters and receive information from other sources (e.g., congresses, routine materials, 
company representatives, protocols in hospital departments). Reasons for the apparent lack of 
knowledge of key safety concerns in the materials among patients may include selection and 
educational level of patients, knowledge arising from several sources, reliance on caregivers, and the 
degree of contact patients have with their HCPs.  
Self-reported data on the implementation of actions and behaviours, among patients and HCPs, were 
not analysable in Manuscript I due to the heterogeneity in the formulation of survey 
questions/responses and presentation of reported results. This suggests further standardization may be 
needed in the formulation, assessment, and reporting of these behavioural measures while allowing 
flexibility for the particular needs of individual products and disease settings. In Manuscript II, the 
implementation of behaviours among HCPs was comparable to the level of knowledge while it was 
higher than knowledge among patients.  
It is argued that the analysis of knowledge and/or behaviour by receipt or use of materials is the 
strongest evidence that can be derived from surveys on whether materials truly have an effect, 
beyond a pure description of results. Knowledge was generally better among HCPs who had 
received, used or read the materials versus those who had not (Manuscript II). These results are 
encouraging as conjunctively show that aRMMs do have an effect on knowledge and behaviour. 
However, this analysis is not always included in surveys [79,83].  
Results of process indicators observed in studies may be the consequence of the interplay of several 
factors, some resulting from the selection, quality, and implementation of aRMMs, and some from the 
study planning, design and methodology. In particular, the selection of the type of material and its 
design is an important aspect to consider. Manuscript I showed that overall, among patients, patient 
brochures, leaflets and guides are more frequently received, read and used than patient cards. 
Among HCPs, most respondents reported distributing or explaining the contents of both the patient 
cards and patient brochure to patients, with patient checklists and DHPCs being the lowest on receipt. 
However, the number of studies per material is small and thus further research is warranted to better 
understand the difference in process indicators between materials. Some recent publications point 
out the need to improve the quality of information provided in materials for these to be applicable in 
clinical practice e.g. in DHPCs [104]. In particular, general practitioners seem to perceive DHPCs to be 
commercially biased, discouraging reading [105]. 
The use of pre-specified thresholds for success (i.e., the extent to which the aRMMs achieved goals or 
target performance) in surveys is another aspect of substantial controversy. In Manuscript I almost a 








third of the studies reported using a cut-off point to determine success, mostly for knowledge and 
behaviour varying in the level of success (e.g., majority, 70%, 80%). Similar findings were observed in 
previous reviews, where a minority of studies included success thresholds [45,51]. Existing guidelines in 
Europe do not require for a threshold to be pre-specified to guide results interpretation [2] however, 
this is sometimes requested by regulators. The use of thresholds may not always be actionable or 
sufficient on its own to guide interpretation of results [60]. Therefore, a case-by-case approach may 
need to be considered when deciding on the need for thresholds.  
Other biases may be present in surveys, which include recall bias inherent in questions asking about 
the past, referral to materials as they complete the survey as well as the so called ‘Hawthorne effect’ 
which may lead to participants modifying their responses/behaviour as a consequence of the 
participation in the study. However, the latter may as well result in a positive bias towards the 
occurrence of outcomes, as a consequence of the increased awareness of the materials and safety 
concerns covered by the materials and questionnaire.  
No prior research connected individual studies with regulatory consequences. Regulatory ARs in 
Manuscript I revealed that no changes to the materials or their implementation were recommended 
in 41% of studies based on results. The remaining sixty percent of studies required further action for 
distribution strategies, re-distribution, and follow-up assessment, changes to existing materials, further 
data awaited and, in a minority, removal of the materials. Inconclusive results requiring further data 
or discussion were reported in 18% of assessment reports. This suggests that in most cases results from 
EU RM Surveys provided data to inform regulatory decision making in relation to the existing aRMMs. 
However, there were instances where further evaluation or data from other studies were needed to 
reach a decision.  
Some challenges remain in the design (partly inherent to their cross-sectional nature), conduct and 
reporting of these studies, which may benefit from more detailed guidance, use of common 
definitions, standardization of reporting and adding other study designs. This may facilitate the 
evaluation, interpretation, and comparison of results across studies. 
Process indicators alone only provide a partial picture of the effectiveness of aRMMs and actions 
taken by regulators. GVP Module XVI and related publications [41] recommend that comprehensive 
approaches involving both process and outcome components be considered, and only when this is 
not clearly feasible, the effectiveness evaluation be based exclusively on process indicators [27]. The 
Report of CIOMS IX Working Group provides a practical framework for the conduct of such evaluations 
[17].  
While recent reviews described RM studies overall [24,25,29,30], they did not comprehensively look 
into the combined evaluation of process indicators and outcomes. The use of the concept ‘RMEv’ in 
this thesis allowed for the combined interpretation of studies conducted for the same product. 








Manuscript II showed that 18% of RMEv in Europe included outcomes in addition to process indicators. 
Additionally, of the 18 RMEv included in Manuscript II, direct measurement of health outcomes 
occurred in half of them, and only three assessed the effectiveness of aRMMs at the three evaluation 
levels: process indicators, behavioural outcomes, and health/safety outcomes. These would 
theoretically constitute the most complete RMEv programmes where the impact of the aRMMs can 
be fully assessed; whether they are being received and used by the target populations, with the 
assessment of the implementation of changes in clinical practice and its resulting effect on the 
occurrence of the outcome of interest. Therefore, more comprehensive approaches of this type, 
where possible, are encouraged.  
The small proportion of RMEv with process indicators and outcomes found in Manuscript II may be due 
to limitations in finding appropriate data sources to quantify the outcome of interest (e.g. healthcare 
databases) [106–109], the use of valid methodological approaches to link the effect of the aRMM with 
the outcome or the feasibility of a study if the outcome is rare. Additionally, the choice of outcome 
measure (prescribing behaviour vs safety outcomes) needs to be consistent and proportionate to the 
safety concerns targeted by the aRMMs. All these underlying factors, which are generally discussed 
during the study design phase by the MAH and the competent regulatory authority, may have 
contributed to or dictated the choice of the final study approach (e.g., whether only process 
indicators or only outcomes are assessed). Despite these being broadly discussed in publications and 
relevant discussion forums; they remain unknown or incomplete at the individual study level and were 
therefore unavailable for assessment.  
In most RMEv, outcome and process indicators were measured as part of the same study protocol. 
While surveys are becoming a standard tool to evaluate the effectiveness of aRMMs, a greater degree 
of variability and creativity is involved in the evaluation of outcomes, both in the design and the 
implementation of studies. In the other half, outcomes were assessed via indirect measures of drug 
utilisation or monitoring patterns, based on existing data. Where safety-related outcomes were 
measured, this was done via company safety databases (despite the well-known limitations of huge 
underreporting and that provide only aggregate national data), extraction from medical records or 
prospectively collected data. Outcomes may be influenced by many actions. Therefore, while the 
measurement of process indicators has limitations (e.g., cross-sectional assessment, self-reported, 
selection bias), they are needed to interpret whether the behavioural measures and outcomes were 
influenced by the aRMMs.  
Manuscript II shows that studies evaluating process indicators and those evaluating outcomes within 
one RMEv were not always conducted in the same population/countries. In fact, correlation of 
process indicators with health/safety outcomes was attempted in very few studies; of the 18 RMEv, 
only in two the assessment of process indicators and outcomes was performed in the same patient 
population. Behavioural outcomes derived from utilisation studies were preferably evaluated in 








countries or populations where feasibility of assessment is warranted by the availability of existing data 
sources. However, results may not always be generalizable to other countries where aRMMs are 
implemented. Regulatory frameworks, healthcare systems, prescription behaviour, monitoring 
requirements and drug utilisation patterns, may vary by country. This is observed in some studies where 
outcome results are substantially different across participating countries, limiting not only interpretation 
and decision-making but also extrapolation of findings to other regions. This variability is outlined by a 
recent review on studies evaluating DHPCs which highlights the need to identify nationally dependent 
factors and employ methods that better inform the effectiveness of drug risk communication at a 
regional level [49].   
It is noteworthy that, in some cases, target safety concerns are related to events that do not primarily 
depend on patients taking action but require HCPs to behave according to recommendations (e.g. 
tests to screen for prior hepatic diseases [87] or for prior infections [84]). In these instances, risk 
communication and evaluation efforts should concentrate on HCPs. Other outcome measures relied 
on the assumption that, as patients become more knowledgeable about specific safety concerns, 
they will more readily identify relevant symptoms and signs, and therefore seek medical attention 
more promptly, minimising the consequences or the severity of the event [84,95]. Therefore, study 
assessments need to be tailored to the characteristics of the target safety concern. 
The definition of an outcome indicator in this thesis includes intermediate measures related to 
behavioural changes such as off-label use or monitoring activities, as well as safety-related health 
outcomes. We aimed to differentiate between self-reported behaviour from patients or HCP from 
surveys, and prescribing behaviour based on actual clinical action data from medical records, which 
provide a higher level of evidence and may serve as indirect measures to assess the impact on health 
outcomes. Therefore, this thesis captures indirect measures of prescribing behaviour when direct 
measures of health/safety outcomes are not feasible or may not be necessary, as suggested by 
existing guidance [40].  
Studies for the same active ingredient were considered as part of the same ‘RMEv’ for the purpose of 
Manuscript II, however, some studies were requested by different competent authorities, at different 
stages of the product lifecycle or with varying objectives. Even in the instance where studies may not 
have been originally planned together, we believe it is appropriate to group them with the same 
RMEv to allow for a combined interpretation of results. The selected study period (i.e. 2011 to 2019) 
was broad to identify as many studies as possible. However, some of these studies may have been 
initiated before the more stringent guidance on the evaluation of effectiveness of aRMMs (i.e. GVP 
Module XVI) came into effect in 2014. As a result, the quality of the conduct and reporting of the 
studies may have changed with time. It is also expected that as experience in the field grows, the 
standardisation and adherence to best practices will improve. Therefore, further research to 
investigate changes in the implementation of RMEv over time is warranted. 








RMEv which only included behavioural and/or safety outcomes as well exist in the literature and are 
of great interest. Despite being identified in the review process (contributing to the number of EU RM 
studies in the selection process), they are not specifically covered by publications in this thesis. Some 
examples include diclofenac [110,111], codeine prescribing for children [112], strontium ranelate 
[113,114], flupirtine [115], mirabegron [116], pioglitazone [117,118], proton pump inhibitors [119], 
tigecycline [120], antipsychotics [121].  
Studies conducted outside the EU (e.g. [122–124]) are also outside the scope of this thesis. One 
example worth highlighting is the study to assess the effectiveness of aRMMs in place for fentanyl 
buccal tablets, which consisted of a mixed-methods approach involving a knowledge and 
understanding survey, a retrospective prescription study, and web surveillance of illicit drug use [122]. 
Study approaches also have been identified which incorporate aRMMs into clinical trials to mitigate 
an identified safety concern [125,126], more of which may be found in the future. 
Manuscripts I and II provide a screenshot of the status of EU RM studies at the time of the review. 
Therefore, EU RM studies recently published or registered in the EU PAS Register outside the review 
period would fall outside the scope of the research. Other studies may have had partial results 
available only, eventually becoming available in full. This the case of the studies evaluating the 
effectiveness of aRMMs for voriconazole and valproate. The FSRs were retrieved at the time of 
Manuscripts I and II while now also the manuscripts are available [127–131]. In the case of vismodegib, 
while only one manuscript was available at the time of Manuscript II, now a recent publication 
reporting the results of another EU RM Survey can be found in the literature [132].  
Based on the findings of Manuscript II, while great efforts are being made to evaluate processes and 
outcomes where feasible, there remains room to increase studies that correlate processes and 
outcomes at an individual patient level to provide more comprehensive evaluation of the 
implementation of aRMMs and link outcomes to the use of materials, as requested by regulatory 
agencies. The availability of new sources of information (e.g., social medial [133]), may also provide 
additional opportunities for different forms of evaluation with novel designs.  
The study reported in Manuscript III is one example of such approach, as it employed a hybrid design 
to evaluate the effectiveness of the abatacept PACs using both process indicators (via surveys) and 
clinical/safety outcomes (via retrospective chart review) in the same patients. This is the first published 
study of its type of which we are aware.  
For the study reported in Manuscript III, patients were recruited via physicians and the lower than 
anticipated recruitment of patients appeared to be due to low use of abatacept in the study centres. 
In the HCP Survey, while the planned number of HCPs was recruited, it involved a significant 
recruitment effort requiring invitations to 2385 potential HCPs. How many of the 2029 non-responders, 
despite several reminders, were not eligible is unknown but we do know that some two thirds of all 








responders were not eligible. Thus, the generalisability of the results has some uncertainty. Nonetheless, 
low response rates in surveys involving HCPs is a well-known limitation and has been previously 
acknowledged in other studies of this kind [25,82,83].   
The range of countries with different healthcare systems and multiple sites in Manuscript III provides a 
global overall picture of the performance of the abatacept PACs among RA patients and HCPs in 
Europe. 
Awareness of the PAC was moderate among patients. More reassuring is that if patients receive the 
PAC, they most often read it. Higher levels of correct knowledge about the risk of infections and pre-
screening for TB and VH, behaviours around these messages and the global score were observed 
among patients who recalled having received the PAC compared to those who did not, which 
suggests that the PAC may have an effect on levels of knowledge and behaviour.  
Potential response bias was minimised with ´best practice´ qualitative techniques to develop the 
questions and their implementation in the online survey such as sequencing of questions, skipping 
questions was not permitted, questions could not be changed once submitted. Survival bias may as 
well be present in this survey, as patients who had stopped treatment with abatacept for any reason 
before the three months’ time window for inclusion were not eligible for the survey.   
Despite low numbers of clinical and safety endpoints, a numerical increasing trend was observed in 
the primary endpoints of infections leading to hospitalisation and infections leading to emergency 
room visits as the patient survey global score decreased. However, these results are not statistically 
significant and would require a bigger sample for confirmation.   
There is potential bias in extrapolating current understanding and implementation in patient surveys 
with past events in this retrospective study. The scores were created to assess the impact of the PAC 
in the target populations, including those who reported being aware and having received the PAC 
versus never having received the PAC.  
Most HCPs reported being aware of the PAC, with fewer accessing and reading it. Nurses were 
identified as the HCP responsible for providing the PAC by more than two-thirds of HCP respondents. 
Thus, the importance of the role of the rheumatology nurse responsible for handling and explaining 
the content of the PAC to the patient is clear. Most HCPs considered the PAC to be clear, concise, 
complete, and helpful. Knowledge about the risk of infections was high among all HCPs, with no 
differences observed between HCPs who received the PAC and those who did not. HCPs who 
manage RA patients are familiar with biologic therapy – infection is a known common risk - and may 
acquire most of their information about the use and risks of abatacept from sources other than the 
PACs. Behaviour and global scores were higher among HCPs who had access to the PAC, suggesting 
a potential impact around implementation of some key messages.  








While differences in results in those who receive and do not receive the PAC is the strongest evidence 
from the surveys alone, they may not be unconfounded comparisons. Thus, results need to be 
cautiously interpreted. 
The practical impact of this study resulted in no modifications to the content of the PAC or further 
evaluations being requested by EMA regulators. Therefore, the results support the effectiveness of the 
abatacept PACs. The study results suggest that the distribution of the PAC to patients could be 
improved, despite already being included inside the abatacept product packaging and that nurses 
should be the main target of any strengthened distribution efforts, where feasible. 
The main strength of this study was the ability to correlate survey responses with clinical and safety 
outcomes in the same patients.  The study used a novel design that bridges the gap of linking process 
indicators with outcomes for the assessment of effectiveness of RMMs, strengthening the clinical 
relevance of results from surveys. Previous studies have been conducted to assess outcomes and 
process indicators [19,2], though no designs comprising within-person correlations have been reported 
in the published literature, as far as we are aware.  
This study may provide a potential framework for the evaluation of aRMMs via process indicators, 
behavioural and health/safety outcomes. This framework may be applied in circumstances where the 
aRMMs are implemented at the time of drug approval (with no possibility of a pre-implementation 
period for evaluation), patients are the target of the aRMM efforts, the outcome of interest is not rare 
and can be obtained from medical records. However, the applicability of this approach to evaluate 
the effectiveness of RMM interventions for other products needs to be assessed on a case-by-case 
basis. 
To conclude, it is apparent that great efforts are being made and substantial amount of research is 
being conducted in Europe, to advance the field of therapeutic RM and shed light into uncertainties 
surrounding the conduct of studies, with numerous research groups and initiatives representing 
regulatory, academics and industry driving it. Additionally, the EMA promotes transparency of post-
market data and regulatory decision-making in Europe, for example, facilitating publication and 
information sharing of PASS via the EU PAS Register [4]. In this regard, one example of transparency 
and stakeholder engagement in the context of RM is the recently published analysis of patient and 
HCP input on valproate teratogenicity and its RMMs, which drew proposals to be considered by PRAC 
for piloting [134]. However, room remains for improvement of methodological approaches and 
conjunctive efforts. The paper by Arlett highlights the need for more robust analytical approaches to 
generate results that are valid and informative [14]. This article also invites relevant stakeholders to 
engage in discussions and participate in the consultation initiative that the EMA will launch in 2020 
regarding methodological guidance on measuring the impact of PhV and RM [14].  
  








8. Lessons Learned and Recommendations 
 
Based on the findings of this thesis, some lessons learned, and recommendations can be drawn.  
• Standardisation of Assessment and Reporting of Process Indicators via EU RM Survey Studies:  
GVP XVI Annex 1 provides specific guidance on the methodology to be used in RM Survey Studies 
and several other documents and articles exist to guide these types of studies [2,40,60]. Previous 
reviews have described the methods and challenges used in studies evaluating the effectiveness of 
aRMMs [32,34,35,42,48,52,70]. Nevertheless, the results of this thesis illustrate the need for more detailed 
guidance, recommendations, and standardization to facilitate the design, conduct and reporting of 
these studies.  
The need for detailed guidance about the conduct and reporting of survey studies is acknowledged 
in survey research [135]. Some publications attempt to provide best practices in conducting and 
reporting survey studies; however, they do not tackle specific aspects and challenges observed in EU 
RM Survey Studies [136]. Meaningful interpretation and comparison of study results requires the use of 
common definitions and standardization of reporting. Some studies did report response rate and 
others reported it variably. 
Recommendations for standardization may include definition of response rates, pre-defined sample 
population, and a full description of the participant selection process using flowcharts and summary 
tables to display the number of subjects invited (includes those responding and not responding to 
invitations), subjects successfully contacted, subjects screened who respond to screening questions, 
eligible, those who complete the survey questionnaire (i.e. completers) and the number of subjects 
excluded with reasons. There is insufficient detail in some reports to assess how well the planned 
sampling methods performed. Therefore, reports should clearly indicate what was planned in the 
protocol and what was finally feasible. Reports should also describe efforts made to recruit the pre-
specified sample size and emphasize the context of the evaluation, e.g., orphan indication. Guidance 
documents have used ‘responded divided by the number of eligible subjects in the sample’ as a 
definition of response rate [66], i.e. completers/eligible. Operational definitions and formulas for 
calculating response rates, cooperation rates, refusal rates, and contact rates in surveys as well as a 
description of available sampling methods are available and can serve as a basis for further 
standardization with a focus on risk minimization [137]. We propose the following minimum to be 
reported: completers/eligible, completers/invited and completers/targeted. This should ideally be 
provided overall but also by country so that country-level participation can be further assessed.  
A variety of terms and definitions were used to describe process indicator dimensions. Standardization 
of the dimensions used in the RMMs may be useful to compare dimensions in different studies. 








Proposed dimensions could be categorized into the following 4 categories: receipt of materials, use 
and reading, knowledge, and behavioural implementation. The inability to extract and analyse data 
on the implementation of behaviour resulting from aRMMs in these surveys needs attention as it is, 
arguably, the most relevant measure to assess the effectiveness of aRMMs in surveys. 
Additionally, results of knowledge and behaviour should be presented and compared between those 
who receive and do not receive or used the materials as this is the strongest evidence from the surveys 
alone. 
Strengthened recommendations to guide country selection and participation are also warranted e.g., 
minimum number of countries that should be included, reasons for selection, provision of country level 
participation data, how to extrapolate results to other countries not targeted in the evaluation. 
• Approaches that Combine Process Indicators with Behavioural and Health/Safety Outcomes: 
Drug utilization studies on prescribing behaviour or studies allowing for correlation of survey data with 
other patients descriptive or outcome data, whenever possible, may provide additional information 
and help overcome some of the limitations of cross-sectional study designs. Studies addressing 
prescribing behaviour or health/safety outcomes in Europe are reported in the literature. There are 
currently few designs correlating within-patient survey results (i.e., process indicators) with clinical and 
safety outcomes. These hybrid designs could help strengthen the validity of these survey studies. In the 
context of outcome evaluation, interpretation of the effectiveness of RMMs should take into 
consideration treatment adherence as this may have an impact on the occurrence of the safety 
event. This framework may be applied in circumstances where the aRMMs are implemented at the 
time of drug approval (with no possibility of a pre-implementation period for evaluation), patients are 
the target of the aRMM efforts, the outcome of interest is not rare and can be obtained from medical 
records. However, the applicability of this approach to evaluate the effectiveness of RMM 
interventions for other products needs to be assessed on a case-by-case basis. 
  










The field of therapeutic RM has become an area of intensive research since the implementation of 
GVP XVI. As of October 2019, at least 129 EU RM studies had been designed and conducted to assess 
the effectiveness of RMMs for 102 different products in Europe. About forty percent of EU RM Surveys 
provided evidence that supports the effectiveness of RMMs based on regulatory Assessment Reports. 
The remaining sixty percent of studies required further action for distribution strategies, re-distribution, 
and follow-up assessment, changes to existing materials, further data awaited and, in a minority, 
removal of the materials. However, this review identified some challenges that remain in the design, 
conduct, and reporting of survey studies, which may benefit from more detailed guidance, use of 
common definitions, standardization of reporting. Some of the limitations of cross-sectional study 
designs (i.e., surveys) may be overcome by drug utilisation and outcomes evaluations which have 
been used conjunctively with EU RM Surveys in eighteen percent of RMEv to supplement the results of 
process indicators. There are currently few studies correlating within-patient survey results with 
heath/safety outcomes. This thesis provided a potential framework for the evaluation of effectiveness 
of aRMMs via a case study involving surveys and a retrospective chart review to correlate process 
indicators and safety outcomes in the same patients. This novel study design bridges the gap of linking 
process indicators with outcomes at the individual-patient level and strengthens the clinical relevance 
of results from surveys. The results support the effectiveness of the abatacept PACs. The practical 
impact of this study resulted in no modifications to the content of the PACs or further evaluations being 
requested by EMA regulators.  
Great efforts are being made and substantial amount of research is being conducted in Europe, to 
advance the field of therapeutic RM and shed light into uncertainties surrounding the conduct of 
studies, with numerous research groups and initiatives involving regulators, academics and industry. 
However, room remains for improvement of methodological approaches and conjunctive efforts. The 
learnings of this thesis may be used by MAHs and regulatory authorities to inform the design of future 
RMEv approaches combining process indicators and outcomes. 
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to EMA/PRAC via 
a Type II Variation 
C.I.13 to fulfil a 
PAM MEA  




















9 (FI, FR, DE, 
IT, NO, ES, 
SE, UK) 
HCP Survey 
Specialists with drug 
experience 
420 420 (100.0) Knowledge 
Submission of FSR 
to EMA/PRAC as 




11[146] Antimalarial 26/06/2015 
12-month survey 
7 months: 
 09/2013 - 03/2014 
 
24-month survey 




At product launch 4 unknown EMA 
multi-
wave  
5 3 (FR, DE, IT) HCP Survey 
GPs, specialists, 
pharmacist, with and w/o 
drug experience 
180 77 (42.8) 
Receipt, 
knowledge 
Submission of FSR 
to 
PRAC/EMA/CHMP 
as part of PSUR 
procedure to fulfil 
a PAM LEG  
Changes to 











At product launch 5 unknown EMA one-wave  2 2 (FR, NL) HCP Survey 
GPs, specialists with and 
w/o drug experience 
267 310 (100.0) 
Receipt, use, 
knowledge 
Submission of FSR 
to EMA/PRAC via 
a Type II Variation 
C.I.13, with 





















Type of Drug FSR Date 
Data Collection 
Period 



























Outcome N Targetd N Involved  N Targetd 














At product launch 6 unknown EMA one-wave  13 
10 (AT, BE, 
FR, DE, IE, IT, 




Specialists, with drug 
experience  






Submission of FSR 
to EMA/PRAC via 
a Type II Variation 
C.I.13, with 

























At extension of 
indication 
4 PASS Cat 2 EMA one-wave  13 
13 (AT, DE, 
DK, IE, IT, ES, 
SE, NO, UK, 




GPs, specialists, nurses, 
pharmacist with drug 
experience 






Submission of FSR 
to EMA/PRAC via 
a Type II Variation 
C.I.13, with 
changes to RMP, 

























1 PASS Cat 1 EMA one-wave  5 
5 (AU, CZ, 
FR, NL, ES) 
HCP Survey 
GPs, specialists with drug 
experience 
500 759 (100.0) 
Receipt, 
knowledge 
Submission of FSR 

















At product launch 12 PASS Cat 3 EMA one-wave  6 
10 (AT, BE, 
DK, FR, DE, 










Submission of FSR 
to 
EMA/PRAC/CHMP
via a Type II 
Variation C.I.13, 
with changes to 
RMP 










At product launch 12 PASS Cat 3 EMA one-wave  6 
10 (AT, BE, 
DK, FR, DE, 
IE, IT, NL, SE, 
UK) 
HCP Survey 
Specialists with drug 
experience 





Submission of FSR 
to 
EMA/PRAC/CHMP
via a Type II 
Variation C.I.13, 











At restriction of 
indication 
1 unknown EMA one-wave  12 
12 (BG, CZ, 
EE, FR, HU, 
LV, LT, PL, 
PT, RO, SK, 
ES) 
HCP Survey 
GPs, specialists with and 
w/o drug experience 




Submission of FSR 




No further action 




DHPC At product launch 1 PASS Cat 1 EMA one-wave  5 
5 (FR, DE, 
UK, BE. ES) 
HCP Survey 
GPs, specialists with drug 
experience 
1880 1805 (96.0) 
Receipt, 
knowledge 
Unknown – AR not 
available 












At new strength 1 PASS Cat 3 No one-wave  3 




GPs, specialists, nurses, 
pharmacist with and w/o 
drug experience 






Submission of FSR 
to 
EMA/PRAC/CHMP
via a Type II 
Variation C.I.13, 
with changes to 
RMP, to fulfil a 
PAM MEA  




patients/carers, 280 7 (2.5) 
Not reported due 
to low recruitment 





After new safety 
signal / label 
changes 
1 PASS Cat 3 No one-wave  8 
7 (BU, DK, 




pharmacist with and w/o 
drug experience 
200 301 (100.0) 
Knowledge, 
behaviour 
Submission of FSR 
to 
EMA/PRAC/CHMP
via a Type II 
Variation C.I.13, 
with changes to 
RMP 









At product launch 6 PASS Cat 3 EMA one-wave  5 
5 (FR, DE, 
ES, SE, UK) 
HCP Survey 
specialists, nurses with 
drug experience 






Submission of FSR 
to EMA/PRAC/ 
CHMPvia a Type II 
Variation C.I.13, 

























At product launch 3 PASS Cat 3 EMA one-wave  10 
10 (AU, BE, 
DK, FR, DE, 




GPs, specialists, nurses, 
pharmacists 





Submission of FSR 
to 
EMA/PRAC/CHMP


















Type of Drug FSR Date 
Data Collection 
Period 



























Outcome N Targetd N Involved  N Targetd 




























8 (CZ, FR, 
DE, EL, IT, 
PL, ES, UK) 
HCP Survey 
Specialists with drug 
experience 
340 246 (100.0) 
Receipt, use, 
knowledge 
Submission of FSR 
to EMA/PRAC as 
part of PSUR 
update 
Changes to 
aRMM / Improve 
distribution of 
aRMM or re-
distribute / FU 
Survey / awaiting 
further results or 
discussion 
NOTE: Only references for studies with FSRs available in the EU PAS Register are provided. The remaining are kept on file as they were provided by MAHs or by EMA via freedom of information requests. 
 
a-RMP Study Categories (GVP V[25]):  
• Category 1: imposed as an obligation in accordance with REG Art 9(4)(cb) and Art 10a(1)(a) and with DIR Art 21a(b) and Art 22a(1)(a) (category 1 of studies in GVP Module V); 
• Category 2: imposed as a specific obligation in the framework of a marketing authorisation granted under exceptional circumstances 
• Category 3: required in the risk management plan (RMP) to investigate a safety concern or to evaluate the effectiveness of risk minimisation activities  
• Other: conducted voluntarily by a marketing authorisation holder 
b-the upper extreme of the interval was used to calculate the percentage 
c-the lower extreme of the interval was used to calculate the percentage 
d-Data extracted from Study Protocol 
e-Given the variability of terms used across FSRs to name endpoints, the categories presented here relate to what is asked in the question and not the term used in the study documents. We have created 5 survey dimensions (receipt, use, reading, knowledge, behaviour) and assigned process indicators/questions to these.   
*if these data were not available from FSRs or protocols, the product Summary of Products Characteristics and the EPAR were searched and used as additional sources of information. 
 
Abbreviations: ADHD: attention deficit hyperactivity disorder; aRMM: additional risk minimisation measure; DHPC: dear healthcare professional communication; FSR: final study report; GP: general practitioner; HCP: healthcare professional; PASS: post-authorisation safety study; PSUR: Periodic safety update report; RMM: risk minimisation measure; RMP: risk management plan








Table S2. List of RMEv/products and studies included (Objective 3) 
Product / RMEv 
Type of aRMM evaluated 
Safety Concerns targeted by aRMM 
Study 
Ref. 









































































Educational materials at new safety 
















8 (AT, DE, HU, IT, 
ES, RO, UK, SE) 
HCP Survey 
800 GPs, specialists with and w/o drug 
experience 
FSR 









1 (UK) EMS Disease Analyser 
93 UK GP practices (887 patients) from 11 
January to 31 July 2012 
FSR  
x     1 (DE) EMS Disease Analyser 
42 Psychiatry and 145 Neurology practices 









DHCP in Jun-2013, educational material 
for HCPs, the Patient Information Card 
and Prescriber Checklist  Revised indication: For the treatment 
of acne only (alopecia dropped) 
CPA/EE should be used only after 
topical therapy or systemic antibiotic 
treatments have failed. CPA/EE 
should not be used in combination 
with other hormonal contraceptives 
















(Frequency of off 
label use) 
 
Retrospective Pre- and 
post-implementation 
1 (NL) PHARMO 15252 New CPA/EE users in 2011 and 2012   
Interim 
Report only 
1 (UK) THIN 5683 New CPA/EE users in 2011 and 2012   
 x x  x 







5 (AU, CZ, FR, NL, 
ES) 













5 (AU, CZ, FR, NL, 
ES) 
Drug Utilisation Survey 
of HCPs and patients 
1513 patients by 120 physicians from the 
specialties gynaecology and dermatology, as 




Patient Information Brochure, Patient 
Alert Card, HCP Frequently Asked 
Questions Brochure at drug approval in 
Jul 2013 
Gastrointestinal (GI) infusion-related 
adverse reactions (irARs) (e.g. 
diarrhoea, colitis, GI perforation)  
Hepatic irARs (e.g., hepatitis)  
Skin irARs (e.g., rash, pruritus)  
Neurologic irARs (e.g., neuropathy) 
Endocrine irARs (e.g., hypopituitarism, 
hypothyroidism, adrenal insufficiency) 
Other irARs (e.g., pneumonitis, 











(Rate of irAR for GI, 
hepatic, skin, 
neurological and 





10 (AU, BE, FR, 
DE, IE, IT, ES, SE, 
NL, UK) 
HCP and Patient 
Surveys 
88 Specialists, with drug experience,/ 27 
patients/caregivers  
FSR 
x   x x 
Retrospective Post-
implementation 





DHPC at suspension of ophthalmology 
and otolaryngology indications in Sep 
2012 
Use of trimetazidine restricted to an 
add-on therapy for patients with 
stable angina pectoris who are 
inadequately controlled by or 
intolerant to first-line anti-anginal 
therapies. Ophthalmology and 












12 (BG, CZ, EE, 
FR, HU, LV, LT, PL, 














Retrospective Pre- and 
post-implementation 
Before the restriction of 
trimetazidine to 
cardiology: from July 2011 
to June 2012 
6 months after DHPC 
sending: from April 2013 




 All prescriptions of trimetazidine made by GPs, 




1 (FR) IMS Prescribing Insights 
1 (GR) IMS Prescribing Insights 
1 (PL) IMS Prescribing Insights 
 x    











775,859 prescriptions the reference period and 
849,855 in the assessment period, by ENT 
specialists, 
ophthalmologists, cardiologist and GPs/other, 
Summary 
FSR 








Product / RMEv 
Type of aRMM evaluated 
Safety Concerns targeted by aRMM 
Study 
Ref. 









































































or ENT diagnoses 
among the total 
prescriptions of 
trimetazidine after 
the restriction of its 
indications. 
24-month reference 
period: July 2010 - June 
2012 
24-month assessment 





5,105,121 prescriptions in the reference period 
and 10,440,159 in the assessment period, by ENT 
specialists, 
ophthalmologists, cardiologist and GPs/other,   
1 (FR) IMS Prescribing Insights 
1,936 (reference period) and 371 (assessment 
period) prescriptions were included in the 
study, by ENT specialists, ophthalmologists, 
cardiologist and GPs/other, 
1 (ES) IMS Prescribing Insights 
713 (reference period) and 535 (assessment 
period) prescriptions, by ENT specialists, 





DHPC after review of product 
information to strengthen cardiac 
adverse effects, Apr-Sep 2014 
Cardiac risk - QT prolongation: 
restriction of the indication to nausea 
and vomiting; · recommended 
limitation of duration for usual use to 7 
days; · reduction of the maximum 
daily dose to 10 mg TID for adults and 
adolescents; reduction of the 
maximum daily dose to 0.25 mg/kg TID 
for neonates, infants, children (less 
than 12 years of age), and 
adolescents weighing less than 35 kg; 
- measuring devices should be 
included with liquid formulations to 
allow accurate dosing by 
bodyweight; contraindication of the 
combination with other drugs that 
increase the cardiac risks by 
themselves or increase the plasma 
level of domperidone; and · 
contraindication in patients with 
moderate or severe hepatic 











label indication; o 
Duration of use ≤7 




use of medications 
that prolong the 
QT-interval or are 
potent CYP3A4 









Retrospective Pre- and 
post-implementation 
Background period: 1 
January 2011 to 31 March 
2013 
1-year pre-
implementation period: 1 
April 2013 to 31 March 
2014 
6-month implementation 
period: 1 April 2014 to 30 
September 2014 
1-year post-
implementation period: 1 
October 2014 to 30 
September 2015 
1 (BE) Quintiles IMS 
53,575 adult prescriptions (37,098 pts) 
9,949 paediatric prescriptions (7,704 pts) 
66 for patients aged 12-14 years weighing less 
than 35 kg (54 pts) 
FSR 
1 (FR) Quintiles IMS 
324,213 adult prescriptions (194,118 pts) 
75,465 paediatric prescriptions (56,764 pts) 
1,491 prescriptions for patients aged 12-14 years 
weighing less than 35 kg (1,160 pts) 
1 (DE) Quintiles IMS 
27,173 adult prescriptions (9,192 patients) 
6 paediatric prescriptions (6 patients) 
1 prescription for patients aged 12-14 years 
weighing less than 35 kg (1 patient) 
 x    
1 (ES) Quintiles IMS 
102,494 adult prescriptions (21,713 patients); 
3,425 paediatric prescriptions (2,939 patients) 
49 prescriptions for patients aged 12-14 years 
weighing less than 35 kg (34 patients) 
1 (UK) CPRD 
532,884 adult prescriptions (109,767 patients); 
17,382 paediatric prescriptions (3,038 patients) 
141 prescriptions for patients aged 12-14 years 







5 (FR, DE, UK, BE. 
ES) 
HCP Survey 1805 GPs, specialists with drug experience FSR 
Abatacept  
(L04AA24) 
Patient alert cards for each formulation 
at drug approval in May 2007 
Infections with special reference to TB 
and patients with COPD 
Screening for tuberculosis prior to 
administration of abatacept 
Screening for viral hepatitis prior to 
administration of abatacept 
Infusion-related reactions (intravenous 
abatacept) 















5 (FR, DE, ES, SE, 
UK) 
HCP and patient 
Surveys 
79 specialists, nurses with drug experience 
patients/carers, 190 patients 
FSR 
    x 
Retrospective Post-
implementation 
Medical records data 




Prescriber Guide and Patient alert card 
in Sep 2012 at approval of new 
indication (atrial fibrillation) and later 
updated to include new indications. As 
of April 2015, a revised patient alert card 
was included inside the packaging 
Bleeding  
Liver injury 













10 (AU, BE, DK, 
FR, DE, IT, NO, ES, 
SE, UK) 




x    x 
One-wave Survey post-
implementation 
 HCP and patient 
Surveys 
370 GPs, specialists, nurses, pharmacists, 
patients, carers / 125 patients 








Product / RMEv 
Type of aRMM evaluated 
Safety Concerns targeted by aRMM 
Study 
Ref. 









































































Reader training materials 













3 (UK, ES, IT) HCP Survey Physicians: N not yet available 
Not yet 
available 
x     
Agomelatine  
(N06AX22) 
A physician guide was implemented at 
time of authorisation. Updated 
physicians’ guides were distributed in 
Europe, and DHCP were sent in 2012 and 
2013. In 2014 messages reinforced by 
redistribution of prescriber guide and 
implementation of patient booklet 











The ‘before-RMM’ period 
January 2013 to 
November 2014 
. The ‘after-RMM’ period: 
February–August 2015 to 
November 2016 
4 (DK, FR, DE and 
ES) 
Medical records data 
54 sites (21 GPs and 33 specialists) recruited 437 
patients in the before-RMM period and 404 
patients in the after-RMM period (35 patients 
contributed data to both periods)  
Manuscript 
x x  x  
One-wave Survey post-
implementation 
Patient Survey 237 patients 
Rituximab  
(L01XC02) 
HCP education leaflet, patient alert 
cards and patient education leaflets in 















implementation 5 (FR, 
DE, IT, ES, UK) 
Patient Survey 
524 patients receiving MabThera for non-
oncology indications at infusion centres Summary 
Report, 
manuscript 
x   x x 
Retrospective Post-
implementation 
Medical records data 
1012 patients receiving MabThera for non-





DHPC and educational materials for 
HCPs after review that let to 
strengthened warnings in Nov 2014 
Use of valproate in female patients 
due to the risk of malformations and 
developmental problems in children 










5 (FR, DE, ES, SE, 
UK) 
HCP survey 1153 physicians who prescribed valproate FSR 






label use;  
Health outcomes 
(pregnancy cases) 
Retrospective Pre- and 
post-implementation 
36-month period before 
the implementation: Jan 
2012 to Dec 2014 
36-month period after the 
implementation, 
depending on date of 
distribution of DHPC and 
educational materials 
1 (FR) IMS Disease Analyser 
21-month pre-implementation period: ranged 
from 1,683 patients with 14,403 valproate 
prescriptions in Spain to 14,287 patients with 
184,606 valproate prescriptions in Sweden.  
Post-implementation period: 1,839 patients with 
21,261 prescriptions in Spain to 14,444 patients 
with 257,573 prescriptions in Sweden.  
Summary 
Report 




1 (ES) IMS LPD 







time, frequency of 
indications) 









 Patient reminder card, comprised of the 
Instructions for Use and the Medication 
Record Sheet at approval of new patch 
strength in Mar 2013 
Multiple patch use which may result in 
overdose (medication error) 







Prior to study data (i.e. 
years up to the enrolment 
visit) collected at baseline 
via medical chart 
abstraction 
4 (DE, GR, PT, 
and UK) 
Primary data collection 659 FSR 
    x 
Vismodegib  
(L01XX43) 
 Pregnancy prevention program: DHPC, 
HCP reminder card, patient alert card, 
patient brochure, HCP brochure at 












HCP survey 31 
Manuscript 
 
x x  x x 
Retrospective Post-
implementation, 30 
January 2014 to 29 July 
2014  
Company Global Drug 
Safety database 
1500 Erivedge treated patients 








Product / RMEv 
Type of aRMM evaluated 
Safety Concerns targeted by aRMM 
Study 
Ref. 











































































HCP booklet and HCP key points to 
remember leaflet. Specific UK measures: 
take-care poster, feedback 
questionnaire, company pre-paid 
envelopes at drug approval in Nov 2013 Medication errors from name 
confusion could lead to dosing errors 






















x     
Retrospective Post-
implementation, 22 
February 2014 to 21 
August 2014  
Company Global Drug 
Safety database 




Prescriber guide and a patient alert card 
at approval of new indication (atrial 
fibrillation) in Aug 2011 
Safety Update in Nov 2011 
Bleeding for new indication (Stroke 










8 (UK, DE, ES, FR, 
DK, BG, CZ, SK) 
HCP and Patient 
Surveys 
411 GPs, specialists with drug experience, 
patients / 802 pts 
FSR 
x    x 
Low doses should be prescribed to 
elderly patients. Importance of 
monitoring of renal function, in 












prescription in the period 









Patient alert card at drug approval in 
Jun 2011 
Post-Transplant Lymphoproliferative 
Disease Serious infections  
Serious viral infection 
Serious herpes infections 
Serious citomegalovirus infections  
Serious polyoma infections  
CNS infections  


















4 (AU, FR, DE, SE) 
HCP and Patient 
Surveys 
 Not yet available 
Not yet 
available 
    x  
Retrospective post-
implementation 





HCP administration guide and checklist, 
and in the patient alert card at drug 











Outcomes a  
(Proportion of off-





Primary data collection Not yet available  
Not yet 
available 














HCP and Patient 
Surveys 







DHPC and educational materials for 
HCPs and patients after safety referral in 
Jan 2014 
Teratogenicity, embryotoxicity, 
spontaneous abortion, impaired male 









4 (FR, GR, IT, PT) HCP Survey 651 GPs, rheumatologists, orthopaedists FSR 







Retrospective Pre- and 
post-implementation 
  
Not yet available  
Not yet 
available 








Product / RMEv 
Type of aRMM evaluated 
Safety Concerns targeted by aRMM 
Study 
Ref. 









































































a Countries participating in the study. Country acronyms: AU (Austria); BE (Belgium); BG (Bulgaria); CZ (Czech Republic); DE (Germany); DK (Denmark); EE (Estonia); ES (Spain); FR (France); GR (Greece); HU (Hungary); IE (Ireland); IT 
(Italy); LT (Lithuania); LV (Latvia); NL (Netherlands); PL (Poland); PT (Portugal); RO (Romania); SE (Sweden); SK (Slovakia); UK (United Kingdom) 
Abbreviations: aRMM: additional risk minimisation measure; CPRD: Clinical Practice Research Datalink; CPA/EE: cyproterone acetate/ethinylestradiol; DHPC: dear healthcare professional communication; ENT: otolaryngologist; FSR: 
final study report; GI: gastrointestinal; GP: General Practitioner; HCP: healthcare professional; irARs: infusion-related adverse reactions; RMEv: risk minimisation evaluation; SPAF: Stroke Prevention in Atrial Fibrillation























% Use of the 
 aRMM  
(among those  
who received) 
% Correct Knowledge of Key Safety Risk % Correct Self-reported Behaviour around Key Safety Information 
Quetiapine  
(N05A H04) 







DHPC   46% [75] 
 - -  
Increased risk of venous and/or arterial thrombotic events [73] 100% 
Symptoms of deep vein thrombosis, pulmonary embolism, and cerebrovascular 
accident; most important risk factors for thrombosis; instructions of use in 
smokers; and approved indication for moderate-severe acne [75] 
>80% 
Approved indication for hirsutism [75] 69% 




• None of the physicians indicated they used the product as sole 
hormonal contraceptive or combined it with other oral hormonal 
contraceptives [73] 
• 88% indicated they only used the product in women of reproductive age 
[73] 
• None said they used the product in women with alopecia [73] 
• 91% informed that they used the product in women with moderate to 
severe androgen sensitive acne, if local or systemic antibiotics had not 
worked [73] 
• 28% replied they did not use the product in women with hirsutism [73] 
Patient card 16% [75] 





HCP frequently asked 
questions brochure 
47% [78] 78% [78] 97% [78] 
 
Colitis [78] 96% 
Hepatitis [78] 85% 
Toxic necrosis[78] 71% 
Neuropathy [78] 67% 
Inflammation of the eye [78] 67% 
 
Monitored irARs [78] 86% 
Appropriate actions should an irAR be identified [78] 86% 
Educate patients about the need to report symptoms [78] 88% 
Educate patients about symptoms of irARs [78] 62% 
Patient Brochure 96% [78]  - 96% [78] 
Patient card 96% [78] 93% [78] 80% [78] 
Patients
  
Patient brochure 67% [78]   83% [78] 
Colitis [78]  41% 
Hepatitis [78] 44% 
Toxic necrosis [78] 44% 
Neuropathy [78] 22% 
Inflammation of the eye [78] 41% 





Immediate notification of potential irARs [78] 96% 
Appropriate actions should an irAR be identified [78] 86% 
Patient card 59% [78]   56% [78] 
Trimetazidine 
(C01EB15) 
HCPs DHPC 35% [79] - -   Angina pectoris: 74% (weighted) [79] 
34% of all prescriptions were as an add-on therapy for patients with stable 
angina pectoris inadequately controlled by or intolerant to first-line anti-
anginal therapies [79] 
Domperidone 
(A03FA03) 
HCPs DHPC 47% [83]  - -  
Nausea and vomiting [83] 80% 
Restriction of indication to minimise cardiac risk: Recommended limitation of 
duration for usual use to 7 days  [83] 
70% 
Restriction of indication to minimise cardiac risk: Maximum Daily Dose for Adults 
and Adolescents (12 years of age and older and weighing 35 kg or more) [83] 
84% 
Restriction of indication to minimise cardiac risk: Maximum Daily Dose for 
Neonates, Infants, Children (less than 12 years of age) and Adolescents 
weighing less than 35 kg  [83] 
37% 
Restriction of indication to minimise cardiac risk: concomitant use of drugs that 
prolong the QT interval and drugs that are potent CYP3A4 inhibitors  [83] 
26% 
Restriction of indication to minimise cardiac risk: Prolongation of cardiac 
conduction intervals, particularly QTc  [83] 
87% 







HCPs Patient card 68% [84] 72%  [84] 72% [84] 
Infections  [84] 85% 
Pre-screening for tuberculosis [84] 85% 
Pre-screening for hepatitis [84] 73% 
 
Informed them about side effects  [84] 96% 
Writes down the date of treatment in the patient card [84] 54% 
Overall behaviour [84] 74% 
 
Patients Patient card 57% [84] 84% [84] 65% [84] 
Infections [84] 56% 
Pre-screening for TB [84] 78% 
Pre-screening for hepatitis [84] 47% 
 
Informed them about side effects [84] 66% 
Seek for immediate medical attention when fever [84] 69% 
Seek for immediate medical attention when chest tightness 
[84] 
81% 
Seek for immediate medical attention when wheezing [84] 66% 
Seek for immediate medical attention when severe dizziness or 
feeling light-headed [84] 
64% 
Overall behaviour [84] 68% 
 























% Use of the 
 aRMM  
(among those  
who received) 




Patient card 55% [85]  - 
88% patients has been 
provided with or given 
access to patient card [85] 
Patients with severe renal impairment (CrCl 15-29 mL/min) at increased risk of 
bleeding complications [85] 
82% 
Patients taking strong inhibitors of both CYP3A4 and P-gp at increased risk of 
bleeding complications [85] 
64% 
Patients taking oral contraception at increased risk of bleeding complications 
when treated with drug [85] 
66% 
Patients who have recently undergone brain, ophthalmic or spinal surgery at 
increased risk of bleeding complications [85] 
72% 
Patients taking NSAIDs including acetylsalicylic acid at increased risk of 
bleeding complications [85] 
86% 




Discuss the need to seek immediate medical attention for a 
bleeding event with patients [85] 
80% 
Displayed behaviour that was 




Prescriber Guide 59% [85] 98% [85] 75% [85] 
Patients Patient card 53% [85] 91% [85] 94% [85] Bleeding: 71% [85]                                               
Seek immediate medical attention for a bleeding event [85] 86% 










 -  - Hepatotoxicity: 73% [87] 
77% had a blood test ordered brefore treatment; 63% identified that the test 
was to check liver function. 82% had a blood test during treatment; 78% 
identified that the test was to check liver function [87] 
Rituximab  
(L01XC02) 
Patients Patient card 33% [88] 80% [88] -  PML: 72% [88] 






HCPs DHPC 60% [89]  -  - 
Informed about the risk of taking drug during pregnancy: 92% [89] - 






Patient Reminder Card 








PPP (DHPC, HCP reminder 
card, PAC, Patient brochure, 
HCP brochure) 
-  -  
68% (provide materials to 
patients) 
74% (patients to complete 
verification of counselling 
form) [70] 
Teratogenicity: 90% [70] 
Pregnancy testing in women of childbearing potential [70] 84% 
Compliance with contraception in women of childbearing 
potential [70] 
84% 
Contraceptive counselling [70] 79% 
Educate male patients on the use of condoms [70] 79% 
Report pregnancies to the Company [70] 74% 
Refer patient to a specialist obstetrician in the event of 
pregnancy [70] 
74% 
Limit prescriptions to 28 days of treatment. Continuation of 







HCP booklet/ Healthcare 
professional key points to 
remember leaflet / Take-care 
poster Feedback questionnaire 
Company pre-paid envelopes  





Patient card 65% [93] -  89% [93]  -  
Prescriber Guide 71% [93] 97% [93]  -  - 
Patients Patient card 56% [93] 90% [93]  - Bleeding: 53% [93] -  
Abbreviations: aRMM: additional risk minimisation measure; CPRD: Clinical Practice Research Datalink; CPA/EE: cyproterone acetate/ethinylestradiol; DHPC: dear healthcare professional communication; ENT: otolaryngologist; 
FSR: final study report; GI: gastrointestinal; GP: General Practitioner; HCP: healthcare professional; irARs: infusion-related adverse reactions; RMEv: risk minimisation evaluation; SPAF: Stroke Prevention in Atrial Fibrillation








Table S4. Summary of results of behavioural outcomes 
Product / RMEv 
Study 
Ref 
































































Quetiapine [72]  
Proportion of patients monitored of weight at 
least once  
 38.7% 0.4%          
Proportion of patients monitored of 
cholesterol at least once  
 27.7% 1%          
Proportion of patients monitored of 
hyperlipidaemia at least once  
 31.9% 0.7%          
Proportion of patients with diabetes 
monitored of signs and symptoms of 
hyperglycaemia at least once  
 50.6% 0%          
Proportion of patients at risk of diabetes 
monitored of cholesterol at least once  
 34.4% 6.9%          
Proportion of patients with lifestyle counselling 
at least once  
 30.8% 0%          
Proportion of practices monitored ≥50% of 















diagnoses among the 
total prescriptions of 
trimetazidine after the 
restriction of its 












Not reported     
Assessment 
Period 
Change in absolute 
number of prescriptions 




   
Not 
reported 
- 61% in 
otolaryngologist 





-26% in GP -57% 
in 
otolaryngologist 










diagnoses among the 
total prescriptions of 
trimetazidine after the 
restriction of its 




   
0.1%  49.1%  
  
78.1% 0.9%  
   
Assessment 
Period 
0.1% 52.8% 66.4% 0.6% 
Change in absolute 
number of prescriptions 
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Proportion of domperidone prescriptions 
before and after implementation of the risk 
minimisation measures regarding the 
composite endpoint, which consisted of the 
following components (label requirements): 
prescribing for on-label indication, duration of 
use ≤7 days, dose no higher than 
recommended, no concomitant use of 
medications that prolong the QT-interval or 
are potent CYP3A4 inhibitors, and no 
prescribing to patients with selected 
contraindicated conditions. 
 
Optimistic Scenario: moderate 
improvement in compliance 
with all label requirements was 
observed for most countries, 
with the exception of France, 
which demonstrated a large 
improvement.  
           
Intermediate scenario A 
Inconclusive: Risk ratios ranged 
from a small improvement in 
compliance (Belgium) to a 
large improvement in 
compliance (France), however, 
no conclusions could be drawn 
for Germany, Spain, or the UK 
due to the small proportions of 
prescriptions meeting all label 
requirements. 
           
Intermediate scenario B The 
findings for intermediate 
scenario-B were mostly positive 
and ranged from a modest 
improvement in compliance 
(UK) to a large improvement in 
compliance (France, Germany), 
however, no conclusions could 
be drawn for Belgium or Spain 
due to the small proportions of 
prescriptions meeting all label 
requirements. 
           
Pessimistic scenario: 
Inconclusive. 
           
Agomelatine [87] 
Proportion of patients 
with at least one liver test 
performed between 4 
weeks before and 3 days 
after the initiation of 
agomelatine treatment  
Before aRMM 24.1% 
           
After aRMM 25.2%  
Proportion of patients 
with at least one liver test 
performed between 2 
and 28 weeks after 
treatment initiation and 
while on treatment 
Before aRMM 56.3%             
After aRMM 61.5% 
Composite of the above  
Before aRMM 15.1%            
After aRMM 16.3%  
Proportion of patients 
with At least one liver test 
before or at dose 
escalation, defined as 
within 1 week before or 1 
week after dose 
escalation  
Before aRMM 31.0%            
After aRMM 44.8% 
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Study 
Ref 
































































Proportion of patients 
with At least one liver test 
after dose escalation, 
defined as 2–28 weeks 
after dose escalation 
and during treatment  
Before aRMM 50.0%            
After aRMM 67.2% 
Composite of the above  
Before aRMM 20.7%            
After aRMM 39.7% 
Rituximab [70,88] 
Proportion of patients prescribed Mabthera 
for off-label non-oncology indications 










Proportion of valproate 
prescriptions with at least 
one medication used 
prior the valproate 
initiation and related to 
the valproate indication 
(epilepsy, bipolar 
disorder, migraine 
headaches) within 12 
months before the 































Proportion of valproate prescribing in women 
aged 14-45 years over 6-month periods 
01/01/2010-30/06/2015 
17% decrease in valproate 
prevalence in the first half of 
2015 compared to the first half 
of 2010 (0.28 vs. 0.23%) 
           
Proportion of prescribing for epilepsy 
indication 
-22%            
Proportion of prescribing for bipolar disorder 
indication 
-20%            
Proportion of prescribing for migraine 
indication 
-14%            
Rivastigmine [92] 
Proportion of 
inappropriate use of all 
doses as recorded by 
patients and/or their 
assistants 
Prior to study 28% 61% 15% 
  
41%  
     
7%  
During study 18% 27% 16% 22% 6% 
Dabigatran [94] 
Proportion of prescriptions to patients >75 
years of high daily dose (150 mg bid) in 
relation to total number of prescriptions (110 
and 150 mg bid) in this age group (incident 
users). 
30% but then rapidly declined 
and later stabilised around 15% 
a year after the safety update 






Proportion of patients with prescription 
indications for CPA/EE  
The most frequent indication 
was acne with 66% of the 
prescriptions. The main reasons 
for prescription of CPA/EE were 
contraception (67%) and acne 
(66%).            
Proportion of use of CPA/EE in accordance 
with the updated label 
Prescriptions in 35% of patients 
reflect an approximation to 
accordance with the updated 
label of CPA/EE: 20% patients 
with a diagnosis of moderate to 








Product / RMEv 
Study 
Ref 
































































severe acne who had “previous 
topical and/or systemic 
antibiotic treatment” and those 
with hirsutism (15%). 
Proportion of concomitant use of CPA/EE 
and other combined hormonal 
contraceptives, 
The prescription of CPA/EE 
together with another hormonal 
contraceptive was 3% 
[74] Interim data available only   
           
Abbreviations: aRMM: additional risk minimisation measure; CPA/EE: cyproterone acetate/ethinylestradiol;








Table S5. List of EU RM Studies (Objectives 1, 2 and 3) 







EU PAS [155] 
Evaluation of the effectiveness of risk minimisation measures: a survey among health care 
professionals and patient/caregivers to assess their knowledge and attitudes on prescribing 
and home administration conditions of velaglucerase alpha (vpriv®) in 6 European 
countries 
velaglucerase alpha Vpriv ongoing 1   
EU PAS [156] 
Post Authorization Safety Study: Knowledge about safety precautions among physicians in 
Denmark prescribing CPA/EE products 
CPA/EE  Study 4 1 1 Obj 1, Obj 2 
EU PAS [157] 
Study to Evaluate Physician Knowledge of Safety and Safe Use Information for Diane-35 
and Its Generics in Europe: An Observational Post-Authorisation Safety Study 
CPA/EE Diane-35 Study 15 1  Obj 1, Obj 2 
ISPE Abstract [158] 
529. Evaluation of Risk Minimisation Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 
35 mg 
CPA/EE Diane-35 Du_Study 15 1   
Google  https://ichgcp.net/es/clinical-trials-registry/NCT02410031 CPA/EE Diane-35 Du_Study 15 1   
EU PAS [74] Drug Utilization Study on Diane®-35 (and generics) in European healthcare databases CPA/EE Diane-35 Study 75  1 Obj 3 
Google [159] https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.4319 CPA/EE Diane-35 Du_Study 75    
ISPE Abstract [160] 
1095 | Reduction in use of Cyproterone/ Ethinylestradiol (Diane35 and generics) after risk 
minimisation measures in the Netherlands, UK and Italy 
CPA/EE Diane-35 Du_Study 75  1  
EU PAS [77] Drug Utilization Study on the Prescribing Indications for CPA/EE in 5 European Countries CPA/EE Diane-35 Study 86  1 Obj 3 
EU PAS [84] 
Evaluation of the effectiveness of the abatacept (ORENCIA®) intravenous and 
subcutaneous formulation Patient Alert Cards in patients with rheumatoid arthritis in a 
sample of European Economic Area countries 
abatacept Orencia Study 22 1 1 
Obj 1, Obj 2, Obj 
3 
ISPE Abstract [160] 
1138 | Health care professional survey to assess the effectiveness of abatacept (Orencia®) 
patient alert cards in rheumatoid arthritis patients 
abatacept Orencia Du_Study 22 1   
ISPE Abstract [160] 
440 | A novel approach to correlate soft and hard outcomes: Effectiveness of abatacept 
(Orencia®) patient alert cards in rheumatoid arthritis patients 
abatacept Orencia Du_Study 22 1 1  
EU PAS [161] 
Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for 
Aflibercept in Europe: An Observational Post Authorisation Study 
aflibercept Eylea Study 25 1  Obj 2 
EU PAS [162] 
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept 
Administered by Intravitreal Injection in Europe: A Follow-up Physician Survey  
aflibercept Eylea ongoing 1   
EU PAS [163] 
Fabrazyme (agalsidase beta) home infusion educational materials effectiveness 
evaluation: a survey for healthcare providers and patients 
agalsidase alfa Fabrazyme ongoing 1   
EU PAS [164] 
Agomelatine Drug Utilisation Study in Selected European Countries: A Multinational, 
Observational Study to Assess Effectiveness of Risk-Minimisation Measures 
agomelatine Valdoxan Study 37 1 1 Obj 2, Obj 3 
Pubmed [87] 
Agomelatine Drug Utilisation Study in Selected European Countries: A Multinational, 
Observational Study to Assess Effectiveness of Risk-Minimisation Measures 
agomelatine Valdoxan Du_Study 37 1 1  
ISPE Abstract [160] 500 | Agomelatine post authorization safety studies program: Comprehensive results agomelatine Valdoxan Du_Study 37 1 1  
EU PAS [165] 
Myozyme (alglucosidase alfa) Safety Information Packet effectiveness evaluation: a health 
care professional survey 
alglucosidase alfa Myozyme Study 31 1  Obj 2 
ISPE Abstract [160] 
1132 | Pre/post effectiveness evaluation of the myozyme (alglucosidase alfa) safety 
information packet 
alglucosidase alfa Myozyme Du_Study 31 1   
EU PAS [166] 
A drug utilization study (DUS) of alirocumab in Europe to assess the effectiveness of the 
dosing recommendation to avoid very low LDL-C levels 
alirocumab Praluent ongoing  1  
ISPE Abstract [167] 
806. Assessment of the Effect of Minimization Measures of the Risk of Stroke with 
Antipsychotic Use in Elderly Persons: A Nested Case-Control Study 
antipsychotic  Study 79  1  
EU PAS [85] "Evaluation of the effectiveness of Eliquis® (apixaban) risk minimization tools in European  apixaban Eliquis Study 23 1 1 
Obj 1, Obj 2, Obj 
3 
EU PAS [148] 
ABILIFY for the Adolescent Bipolar I Mania Indication of Tool Effectiveness Evaluation 
Strategy 
aripiprazole Abilify Study 14 1  Obj, 1, Obj 2 
















Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of 
Aripiprazole in the European Union: Results from a Post-Authorization Safety Study. 
aripiprazole Abilify Du_Study 14 1   
EU PAS [169] 
Survey to evaluate the effectiveness of risk minimization measures for Atezolizumab use in 
the European Union  
atezolizumab Tecentriq ongoing 1   
EU PAS [142] 
Physician Survey to Assess Effectiveness of Strattera Risk Minimisation Activities in Prescribers 
Treating Adult Patients with ADHD 
atomoxetina Strattera Study 7 1  Obj 1, Obj 2 
EU PAS [143] Physician Survey to Re-assess Effectiveness of Strattera Risk Minimisation Activities atomoxetina Strattera Study 8 1  Obj 1, Obj 2 
EU PAS [170] 
Quantitative Testing of Healthcare Provider Knowledge about YESCARTA® (axicabtagene 
ciloleucel) Risk Minimisation Measures 
axicabtagene ciloleucel Yescarta ongoing 1   
EU PAS [171] 
Rheumatologist Survey to Assess the Effectiveness of the Risk Minimisation Measures (RMM) 
for Olumiant® (baricitinib) a JAK1/2 inhibitor 
baricitinib Olumiant ongoing 1   
EU PAS [95] 
Evaluation of the effectiveness of the belatacept (Nulojix®) Patient Alert Card in patients 
following renal transplantation in European Economic Area countries. 
belatacept Nulojix ongoing 1 1 Obj 3 
EU PAS [172] A Cross-sectional Survey of Patients and Caregivers (20150228) blinatumomab Blincyto Study 89 1  Obj 2 
EU PAS [173] 
Survey of Physicians, Pharmacists, and Nurses Involved in the Prescribing, Preparation and 
Administration of Blincyto in Europe to Evaluate the Effectiveness of Additional Risk 
Minimization Measures (20150163) 
blinatumomab Blincyto Study 90 1  Obj 2 
Google [174] 
Evaluation of Risk Minimisation Measures for Blood Components – Based on Reporting Rates 
of Transfusion-Transmitted Reactions (1997–2013) 
blood components  Study 82  1  
EU PAS [175] 
An international, observational retrospective data collection study assessing efficacy of 
applied risk minimisation measures in burn patients treated with NexoBrid  
bromelains NexoBrid Study 45  1  
EU PAS [176] 
Healthcare Professional and Patient Surveys to Evaluate the Effectiveness of the Risk 
Minimisation Educational Materials for Certolizumab Pegol (CZP; CIMZIA®)  
certolizumab Cimzia Study 88 1  Obj 2 
EU PAS [177] Cilostazol Drug Utilisation Study cilostazol Ekistol Study 46  1  
ISPE Abstract [167] 712. Impact of Risk Minimization Measures on the Use of Cilostazol in Europe cilostazol Ekistol Du_ Study 46  1  




Prescription behavior for gastroprotective drugs in new users as a result of communications 
regarding clopidogrel–proton pump inhibitor interaction. 
clopidogrel  Study 83  1  
EU PAS [180] 
A Prospective, Observational Drug Utilization Study of Cobicistat in Adults with HIV-1 
Infection 
cobicistat Tybost cancelled  1  
EU PAS [181] 
Drug utilisation study of risk minimisation measures for codeine using IMS electronic health 
records in Germany and France 
codeine  ongoing  1  
EU PAS [182] 
A Cross-sectional Study to Evaluate the Effectiveness of the Colobreathe Risk Minimisation 
Educational Programme Among Healthcare Professionals and Patients 
colistimethate Sodium colobreathe ongoing 1   
ISPE Abstract [160] 
956 | Assessment of colobreathe risk minimisation measures in the European Union: a cross-
sectional study 
colistimethate Sodium colobreathe ongoing 1   
EU PAS [183] 
Effectiveness of Xiapex® educational material for healthcare professionals in the treatment 
of Dupuytren’s contracture - a non-interventional post-authorization safety study 
collagenase Xiapex ongoing 1   
EU PAS [184] 
Effectiveness of Xiapex® educational material for healthcare professionals in the treatment 
of Peyronie’s disease - a non-interventional post-authorization safety study 
collagenase Xiapex ongoing 1   
EU PAS [185] 
Study of regulatory communication and risk awareness following the Article 31 referral of 
Combined Hormonal Contraceptives in relation to thromboembolism  
contraceptives  Study 47  1  
EU PAS [186] Study of utilisation of combined hormonal contraceptives in Europe  contraceptives  ongoing  1  
EU PAS [149] 
A cross-sectional study to evaluate the effectiveness of XALKORI Patient Information 
Brochure among non-small cell lung cancer (NSCLC) patients receiving XALKORI treatment 
in Europe 
crizotinib Xalkori Study 16 1  Obj 1, Obj 2 
EU PAS [150] 
A cross-sectional study to evaluate the effectiveness of XALKORI Therapeutic Management 
Guide among physician prescribing XALKORI in Europe 
crizotinib Xalkori Study 17 1  Obj 1, Obj 2 















EU PAS [93] 
Post-authorisation study to evaluate the effectiveness of the risk minimisation activities in 
the treatment of SPAF 
dabigatran Pradaxa Study 3 1  
Obj 1, Obj 2, Obj 
3 
Pubmed [94] 
Evaluating the effectiveness of risk minimisation measures: the application of a conceptual 
framework to Danish real-world dabigatran data. 
dabigatran Pradaxa Study 48  1 Obj 3 
ISPE Abstract  
523. A Framework for the Evaluation of the Effectiveness of Risk Minimisation Measures 
Applied to Retrospective Danish Real-World Dabigatran Etexilate Data 
dabigatran Pradaxa Du_Study 48  1  
Google [94] d dabigatran Pradaxa Du_Study 48  1  
EU PAS [187] 
RRA-19284 Survey of the Effectiveness of the DARZALEX® Educational Materials Regarding 
the Minimization of Risk of Interference for Blood Typing with Daratumumab 
daratumumab Darzalex ongoing 1   
ISPE Abstract [158] 
981 | A survey among health care professionals to assess their knowledge and 
understanding on Darzalex® (daratumumab) 






1   
EU PAS [145] 
Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their 
Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of 
the Jaw (20110102) 
denosumab Xgeva Study 10 1  Obj 1, Obj 2 
EU PAS [188] Injectors’ Survey to Assess Effectiveness of BELKYRA Risk Minimisation Activities  
deoxycholic acid 
/dexamethasone 
Belkyra ongoing 1   
ISPE Abstract [167] 
800. Evaluation of Effectiveness of Risk Minimisation Measures Applied to the Use of 
Desmopressin by Elderly Patients in Denmark 
desmopressin  Study 78  1  
EU PAS [189] Evaluation of the Physician Education Component of the Ozurdex Risk Management Plan  dexamethasone Ozurdex Study 39 1  Obj 2 
EU PAS [190] 
A Multicentre, Non-interventional, Prospective, Observational Drug Utilisation Study of 
Ayendi Nasal Spray Prescribed as Treatment in Emergency Departments in the United 
Kingdom (UK) 
diamorphine Ayendi Study 49  1  
EU PAS [191] 
Impact of EU label changes for systemic diclofenac products: post-referral prescribing 
trends 
diclofenac  Study 50  1  
ISPE Abstract [160] 
954 | Are the risk minimization measures for diclofenac effective? A pre/post comparison 
based on German claims data 
diclofenac  Du_Study 50  1  
ISPE Abstract [160] 
1098 | Impact of European label changes for systematic diclofenac products: Post-referral 
prescribing trends for initiation of systemic diclofenac products and time series regression 
diclofenac  Du_Study 50  1  
EU PAS [82] A Drug Utilisation Study of Domperidone in Europe Using Databases  domperidone  Study 51  1 Obj 3 
EU PAS [83] 
A Post-Authorisation Safety Study (PASS) to Assess the Effectiveness of the Risk Minimisation 
Measures of Domperidone – Physician Survey 
domperidone  Study 19 1  
Obj 1, Obj 2, Obj 
3 
ISPE Abstract [158] 
525. Assessment of Effectiveness of Dronedarone Risk Minimization Measures Through a 
Drug Utilization Study in Two European Countries 
dronedarone Multaq Study 77  1  
EU PAS [192] 
Edoxaban prescription patterns in Europe: a retrospective drug utilisation chart review 
study 
edoxaban Lixiana Study 52  1  
EU PAS [193] 




Stribild Study 53  1  
EU PAS [194] 
Hemlibra Survey to Prescribers and Patients/Carers to Evaluate Awareness, Knowledge and 
Compliance to Additional Risk Minimization Measures 
emicizumab Hemlibra ongoing 1   
EU PAS [195] 
GS EU 276 4027: A Cross Sectional Post Authorization Safety Study to Assess Healthcare 
Provider’s Level of Awareness of Risk Minimisation Materials for Truvada® for Pre Exposure 
Prophylaxis in the European Union  
emtricitabine 
tenofovir disoproxil 
Truvada Study 35 1  Obj 2 
EU PAS [196] 
Survey on the knowledge and use of the Jext prescriber’s checklist among physicians – a 
post-authorisation safety study 
epinephrine Jext ongoing 1   
EU PAS [197] 
Assessment of Health Care Professionals’ Knowledge and Behaviour Regarding Prescribing 
Conditions of Cholib® (fenofibrate and simvastatin fixed combination): A European PASS 
conducted in Austria, Portugal, Slovenia, Croatia, Greece and Bulgaria  
fenofibrate / 
simvastatina 
Cholib ongoing 1   















EU PAS [147] 
Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care 
Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions of Instanyl® 
in France and the Netherlands 
fentanil instanyl Study 12 1  Obj 1, Obj 2 
ISPE Abstract [167] 
711. Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey Among Health 
Care Professionals to Assess Their Knowledge and Attitudes on Prescribing Conditions of 
Instanyl® in France and the Netherlands 
fentanil instanyl Du_Study 12 1   
EU PAS [198] 
A prospective observational study to assess effectiveness of the training and risk 
minimisation measures recommended for the usage of the diagnostic agent NeuraCeqTM 
in the post-authorisation clinical situation: A post-authorisation safety study (PASS) 
florbetaben NeuraCeq ongoing  1  
EU PAS [86] Evaluation of Effectiveness of Amyvid Reader Training (I6E-AV-AVBE) florbetapir Amyvid ongoing 1 1 Obj 3 
EU PAS [199] Drug utilisation study (DUS) on flupirtine-containing medicinal products flupirtine  Study 85  1  
EU PAS [199] Drug utilisation study (DUS) on flupirtine-containing medicinal products flupirtine  Du_Study 85  1  
EU PAS [200] 
Drug utilisation study (DUS) on flupirtine-containing products  
Retrospective drug utilisation study using patient-level databases to characterise 
prescribing practices of flupirtine-containing drugs during routine clinical use and assess the 
main reasons for prescription by representative groups of prescribers 
flupirtine  Study 91  1  
EU PAS [201] 
Post-Authorisation Safety Study (PASS) for Flupirtine – Effect of Risk Minimisation Measures in 
Germany 
flupirtine  Study 92  1  
EU PAS [202] 
Post-Authorisation Safety Study (PASS) on Flupirtine-containing Medicinal Products - A 
retrospective, multicentre, non-interventional study to evaluate the effectiveness of the risk 
minimisation activities for flupirtine-containing medicinal products 
flupirtine  Study 84  1  
EU PAS [203] 
Retrospective Chart Review to Evaluate the Effectiveness of the Risk Minimization Measures 
for the Use of Flupirtine 100 mg Immediate-Release Capsules in daily Practice 
flupirtine  Study 54  1  
EU PAS [204] 
A Post-Authorisation Safety Study to Evaluate the Effectiveness of VIZAMYL™ Reader 
Training in Europe 
flutemetamol Vizamyl ongoing  1  
EU PAS [205] 
WEUSKOP5233: Arixtra Physician Adherence to the Prescribing Information in isolated 
superficial vein thrombosis (SVT) Patients 
fondaparinux Arixtra ongoing  1  
EU PAS [206] 
Effectiveness of the Additional Risk Minimization Measures in Conveying Safety Information 
to HCPs Dispensing, Administering or Prescribing Fosphenytoin  
forphenytoin  ongoing 1   
EU PAS [207] Drug Utilization Study on the Risk Minimisation Tools for Sialanar glycopyrronium bromide Sialanar ongoing  1  
Pubmed [208] 
Effectiveness of the golimumab educational program in ensuring healthcare professionals' 
awareness of risks described in the European risk management plan. 
golimumab Simponi Study 40 1  Obj 2 
Google [208] https://journals.sagepub.com/doi/full/10.1177/2042098619847420 golimumab Simponi Du_Study 40 1   
ISPE Abstract [158] 
528. Evaluation of Physician Awareness of Risks Described in the SIMPONI (Golimumab, 
GLM) EU-RMP Educational Program 
golimumab Simponi Du_Study 40 1   
EU PAS [209] Impact of EU label changes for hydroxyzine products: post-referral prescribing trends hydroxyzine  ongoing  1  
EU PAS [210] 
GS-EU-313-4226 A Cross-Sectional Post-Authorization Safety Study to Assess Healthcare 
Provider Awareness of Risks Associated with Zydelig® in the European Union  
idelalisib Zydelig Study 33 1  Obj 2 
EU PAS [151] 
Healthcare Professional and Patient Surveys to Assess the Effectiveness of Risk Minimisation 
Measures for Concentrated Insulin Lispro (Humalog 200 units/ml KwikPen; Liprolog 200 
units/ml KwikPen) 
Insulin Lispro  Study 20 1  Obj 1, Obj 2 
Google [211] https://diabetes.diabetesjournals.org/content/68/Supplement_1/2324-PUB Insulin Lispro  Du_Study 20 1   
EU PAS [212] 
Survey to evaluate the knowledge and understanding of the key safety messages in the 
healthcare professional guide and the patient guide for suliqua  
Insulina 
glargina/lixisenatida 
Suliqua ongoing 1   
EU PAS [78] YERVOY Risk Minimisation Tool Evaluation Survey ipilimumab Yervoy Study 13 1 1 Obj 1, Obj 2 
Google  https://ichgcp.net/es/clinical-trials-registry/NCT02224768 ipilimumab Yervoy Du_Study 13 1   
















Evaluation of compliance with isotretinoin PPP recommendations and exploration of 
reasons for non-compliance: Survey among French-speaking health care professionals and 
patients in Belgium. 
isotretinoin  Study 55  1  
EU PAS [214] Isotretinoin and the effectiveness of the pregnancy prevention programmes in Europe isotretinoin  Study 56  1  
EU PAS [215] 
Severe hypersensitivity reactions associated with iv iron containing medicinal products in 
countries of the European Economic Area – before and after implementation of risk 
minimisation measures 
IV Iron  Study 57  1  
Pubmed [216] 
Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the 
European Economic Area (EEA) Before and After Implementation of Risk Minimization 
Measures. 
IV Iron  Du_Study 57  1  
EU PAS [217] 
Ivabradine Drug Utilisation Study in Select European Countries: A Multinational, 
Retrospective, Observational Study to Assess Effectiveness of Risk-Minimisation Measures  
Ivabradine Procoralan Study 58  1  
ISPE Abstract [160] 
450 | Ivabradine drug utilization study in five European countries: A pass to assess 
effectiveness of risk minimization measures 
Ivabradine Procoralan Du_Study 58  1  
EU PAS [218] 
Protocol for the Effectiveness Check of the Awareness and Knowledge of Educational 
Materials for the Eligard Risk Minimization Program  
leuprorelin Eligard ongoing 1   
EU PAS [219] Global Lomitapide (Juxtapid and Lojuxta) Pregnancy Exposure Registry lomitapide  ongoing  1  
EU PAS [220] LOWER: Lomitapide (Juxtapid and Lojuxta) Observational Worldwide Evaluation Registry lomitapide Juxtapid y Lojuxta ongoing  1  
EU PAS [97] 
Evaluation of the effectiveness of Penthrox® (methoxyflurane) educational tools adopted 
as additional risk minimisation measures: Healthcare professional and Patient Survey. 
methoxyflurane Penthrox ongoing 1  Obj 3 
EU PAS [96] 
Post Authorisation Safety Study (PASS) to evaluate the Risks of Hepatotoxicity and 
Nephrotoxicity from administration of Methoxyflurane (Penthrox®) for Pain Relief in Hospital 
Accident & Emergency Departments in the United Kingdom. 
methoxyflurane Penthrox ongoing  1 Obj 3 
EU PAS [153] 
Survey to Measure the effectiveness of the Mycamine Prescriber Checklist in the European 
Union 
micafungim Mycamine Study 24 1  Obj 1, Obj 2 
EU PAS [221] 
Drug utilization study of mirabegron (Betmiga®) using real-world healthcare databases 
from the Netherlands, Spain, United Kingdom and Finland 
mirabegron Betmiga Study 59  1  
ISPE Abstract [160] 
951 | Risk minimization effectiveness for Mirabegron in the Netherlands, Spain, UK and 
Finland 
mirabegron Betmiga Du_Study 59  1  
EU PAS [222] 
Program to evaluate the Tasigna (nilotinib) educational materials: survey to patients and 
physicians in five EU countries 
nilotinib Tasigna Study 34 1   
EU PAS [223] 
Use of Intravitreal JETREA® in Clinical Practice: A European Prospective Drug Utilisation 
Study  
ocriplasmin Jetrea Study 41 1  Obj 2 
EU PAS [224] 
An Observational Study to Assess the Effectiveness of the Neulasta® Patient Alert Card and 
to Measure Medication Errors Related to the Use of the Neulasta® On-Body Injector 
(20170701) 
pegfilgrastim Neulasta ongoing 1   
EU PAS [225] 
A PHARMO Study on the Utilization of Pioglitazone in Clinical Practice in The Netherlands 
with Regard to Diabetic Treatment Regimen and Co-morbidities 
pioglitazone  Study 69  1  
EU PAS [226] 
A study on the utilization of pioglitazone in clinical practice in the UK after the label change 
in July 2011 
pioglitazone  Study 70  1  
EU PAS [227] 
A Study on the Utilization of Pioglitazone in Clinical Practice With Regard to Diabetic 
Treatment Regimen and Comorbidities 
pioglitazone  Study 71  1  
EU PAS [228] Assessment of Utilisation of Pioglitazone in Denmark Post Label Change (July 2011) pioglitazone  Study 72  1  
ISPE Abstract  211. Post-Authorisation Safety Study of Pioglitazone Use in Denmark Post Label Change pioglitazone  Du_Study 72  1  
EU PAS [229] 
Monitoring the effectiveness of risk minimisation in patients treated with pioglitazone-
containing products 
pioglitazone  Study 73  1  
EU PAS [146] Effectiveness evaluation survey for Eurartesim piperaquine / artenimol Eurartesim Study 11 1  Obj 1, Obj 2 
EU PAS [230] 
Assessment of the effectiveness of risk minimisation measures set up for new safety 
information for Efient® (Prasugrel): a multinational survey among physicians to evaluate 
prasugrel Efient Study 29 1  Obj 2 















their knowledge and consideration of the new safety warning for Prasugrel in four 
European countries 
EU PAS [231] 
Assessment of physician behaviour regarding metabolic monitoring of patients treated with 
SEROQUEL® (quetiapine fumarate) Tablets and SEROQUEL® (quetiapine fumarate) 
Extended-Release Tablets in selected countries in the European Union (EU) 
quetiapine Seroquel Study 2 1  
Obj 1, Obj 2, Obj 
3 
Pubmed [232] 
Effectiveness of a risk-minimization activity involving physician education on metabolic 
monitoring of patients receiving quetiapine: results from two post-authorization safety 
studies. 
quetiapine Seroquel Du_Study 2 1   
EU PAS [233] 
An observational study to assess the impact of educational material on the metabolic 
monitoring of patients treated with quetiapine fumarate in Croatia 
quetiapine Seroquel ongoing  1  
EU PAS [72] 
Objective assessment of metabolic monitoring in patients treated with Seroquel® or 
Seroquel® XR/quetiapine fumarate: use of IMS Disease Analyzer to assess physician 
behaviour in the UK and Germany 
quetiapine Seroquel Study 60  1 Obj 3 
EU PAS [141] PRJ2250: Survey of prescriber understanding of risks associated with TROBALT retigabine Trobalt Study 6 1  Obj 1, Obj 2 
EU PAS [140] 
WEUKBRE5744: European Survey of Patient and Prescriber Understanding of Risks Associated 
with TROBALT™ 
retigabine Trobalt Study 5 1  Obj 1, Obj 2 
Pubmed [234] Survey of Physicians' Understanding of Specific Risks Associated with Retigabine. retigabine Trobalt Du_Study 5 / Study 6 1   
EU PAS [235] 
Impact of EU label changes and revised pregnancy prevention programme for oral 
retinoid containing medicinal products: utilization and prescribing trends 
retinoids  ongoing  1  
EU PAS [88] 
Mabthera Drug Utilisation Study and Patient Alert Card Evaluation in Non-Oncology 
Patients in Europe: An infusion Centre Based Approach 
rituximab Mabthera Study 26 1 1 Obj 2, Obj 3 
Publication  [70] 
Additional Risk Minimisation Measures for Medicinal Products in the European Union: A 
Review of the Implementation and Effectiveness of Measures in the United Kingdom by 
One Marketing Authorisation Holder 
rituximab MabThera Du_Study 26    
EU PAS [236] 
Xarelto (Rivaroxaban) Risk Minimisation Plan Evaluation: Patient and Physician Knowledge 
of Key Safety Messages  
rivaroxaban Xarelto Study 42 1  Obj 2 
ISPE Abstract [158] 9. Evaluating Patient Knowledge of Risks and Safe Use of Xarelto (Rivaroxaban) rivaroxaban Xarelto Du_Study 42 1   
ISPE Abstract [158] 493. Evaluating Physician Knowledge of Risks and Safe Use of Xarelto (Rivaroxaban) rivaroxaban Xarelto Du_Study 42 1   
EU PAS [92] 
A drug utilisation study in patients treated with EXELON®/PROMETAX® (rivastigmine) 
transdermal patch 
rivastigmine Exelon / Prometa Study 43 1 1 Obj 2 
EU PAS [237] 
A cross-sectional study of patients with immune thrombocytopenic purpura and caregivers 
to estimate the proportion who administer romiplostim correctly after receipt of home 
administration training materials (20120269)  
romiplostim Nplate Study 61  1  
ISPE Abstract [167] 
1004. Assessment of Romiplostim Self- Administration After Receipt of Home Administration 
Training (HAT) Materials: A Cross-Sectional Study of Patients with Immune 
Thrombocytopenic Purpura (ITP) and Caregivers 
romiplostim Nplate Du_Study 61    
Pubmed [238] 
Assessment of Self-Administration of Romiplostim in Patients with Immune 
Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a 
Cross-Sectional Study. 
romiplostim Nplate Du_Study 61    
EU PAS [239] Impact of risk minimisation in patients treated with rosiglitazone-containing products rosiglitazone  Study 62  1  
EU PAS [240] 
Post-authorisation safety study (PASS) to evaluate risk minimisation measures for medication 
errors with Uptravi during the titration phase in patients with pulmonary arterial hypertension 
(PAH) in clinical practice 
selexipag Uptravi ongoing 1   
EU PAS [241] 
Survey of pharmacists to evaluate the effectiveness of the Viagra Connect national 
additional Risk Minimisation Measure (aRMM) in the United Kingdom (UK)  
sildenafil Viagra Study 44 1  Obj 2 
EU PAS [242] XYREM EU-RMP: Effectiveness Assessment Protocol of Educational Materials sodium oxybate Xyrem Study 36 1   
EU PAS [152] 
Observational, Cross-Sectional Post-Authorisation Safety Study to Assess Healthcare 
Provider Awareness of Risks Related to Sofosbuvir and Ledipasvir/Sofosbuvir 
sofosbuvir and 
ledipasvir/sofosbuvir 
Harvoni Study 21 1  Obj 1, Obj 2 















EU PAS [243] 
European Program of Post-Authorization Safety Studies for Protelos®/Osseor® through EU-
ADR Alliance 
strontium ranelate Protelos Study 63  1  
ISPE Abstract [244] 
408 | Impact of risk minimisation measures on the use of strontium ranelate: A multinational 
cohort study in 5 EU countries by the EU-ADR Alliance 
strontium ranelate Protelos Du_Study 63  1  
ISPE Abstract [167] 
799. Impact of Risk Minimisation Measures on the Use of Strontium Ranelate: A Multi-
National Cohort Study in 5 EU Countries by the EU-ADR Alliance 
strontium ranelate Protelos Du_Study 63  1  
ISPE Abstract [167] 
8. The Impact Of Risk Minimisation Measures On The Incidence And Prevalence Of Use Of 
Strontium Ranelate At The Population Level: Preliminary Results Of A Multi-National Cohort 
Study Including 5 European Countries 
strontium ranelate Protelos Du_Study 63  1  
EU PAS [245] 
Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care 
Professionals to Assess their Knowledge on Dosing and Administration of Obizur® 
(Susoctocog alfa) in 6 European Countries  
susoctocog alfa Obizur ongoing 1   
EU PAS [246] 
A Post-Authorization Safety Study of the Use of Intravenous Telavancin (VIBATIV®) in the 
Clinical Setting 
telavancin Vivatib ongoing  1  
EU PAS [247] 
An Observational, Drug Utilization Study of Viread® in Children and Adolescents with HIV-1 
Infection 
tenofovir Viread Study 64  1  
EU PAS [248] 
Viread Observational, Cross -Sectional Drug Utilisation Study in Children and Adolescents 
with Chronic Hepatitis B 
tenofovir Viread Study 65  1  
EU PAS [99] Drug Utilization Study of Thiocolchicoside (TCC) containing medicinal products for systemic thiocolchicoside  ongoing  1 Obj 3 
EU PAS [249] 
Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey among 
Health Care Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions 
of Thiocolchicoside containing Medicinal Products for Systemic Use in France, Greece, Italy 
and Portugal 
thiocolchicoside  Study 27 1  Obj 2, Obj 3 
ISPE Abstract [160] 
960 | Evaluation of the effectiveness of risk minimisation measures targeting physicians on 
prescribing practices of thiocolchicoside containing medicinal products for systemic use 





thiocolchicoside  Du_Study 27 1   
Publication [70] 
Additional Risk Minimisation Measures for Medicinal Products in the European Union: A 
Review of the Implementation and Effectiveness of Measures in the United Kingdom by 
One Marketing Authorisation Holder 
trastuzumab Kadcyla Study 81 1 1 Obj 2, Obj 3 
EU PAS [80] 
Drug utilisation study, in five European countries, using cross sectional analysis, to assess the 
extent of prescriptions of trimetazidine for its withdrawn ophthalmological and ENT 
indications among general practitioners, ophthalmologists and ENT specialists 
trimetazidine  Study 66  1 Obj 3 
EU PAS [79] 
Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey among 
Health Care Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions 
of Trimetazidine in Bulgaria, Czech Republic, Estonia, France, Hungary, Latvia, Lithuania, 
Poland, Portugal, Romania, Slovakia, and Spain 
trimetazidine  Study 18 1  
Obj 1, Obj 2, Obj 
3 
Pubmed [250] 
Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross 
sectional joint PASS survey among physicians in selected European countries. 
trimetazidine  Du_Study 18 1   
EU PAS [81] 
Evaluation of the Effectiveness of Risk Minimization Measures: Trimetazidine Drug Utilization 
Study in European Countries using databases – analysis for France, Hungary, Romania and 
Spain 
trimetazidine  Study 67  1 Obj 3 
Pubmed [251] 
A drug utilization study to evaluate effectiveness of risk minimization measures for 
trimetazidine in France, Hungary, Romania and Spain. 
trimetazidine  Du_Study 67  1  
EU PAS [252] 
Non-interventional post-authorization safety study to describe use by indication and clinical 
outcomes among patients with complicated intra-abdominal infection or complicated skin 
and soft tissue infection treated with tigecycline (tygacil®) in the European union 
tygeciclina Tygacil Study 68  1  
EU PAS [90] 
A Joint Drug Utilisation Study (DUS) of valproate and related substances, in Europe, using 
databases 
valproate  Study 87  1 Obj 3 
EU PAS [89] 
Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey and Drug 
Utilisation Study among Health Care Professionals to Assess their Knowledge and Attitudes 
valproate  Study 28 1  Obj 2, Obj 3 















on Prescribing Conditions of valproate in France, Germany, Spain, Sweden and United 
Kingdom 
ISPE Abstract [158] 533. Usage Of Valproate In Women In The UK valproate  Study 76  1 Obj 3 
ISPE Abstract [244] 
834 | Utilising the CPRD pregnancy register to examine the pattern of antiepileptic drug 
use during pregnancy in the United Kingdom 
valproate  Du_Study 76  1  
EU PAS [253] 
An assessment of physician knowledge and understanding of the risks of vandetanib 
(Caprelsa®) within the European Union.  
vandetanib Caprelsa Study 38 1  Obj 2 
Publication [70] 
Additional Risk Minimisation Measures for Medicinal Products in the European Union: A 
Review of the Implementation and Effectiveness of Measures in the United Kingdom by 
One Marketing Authorisation Holder 
vismodebig Erivedge Study 80 1 1 Obj 2, Obj 3 
Pubmed [254] 
Relevance of a "Dear Doctor letter" to alert healthcare providers to new recommendations 
for vitamin D administration. 
vitamin D  Study 30* 1   
EU PAS [138] 
Evaluation of the effectiveness of additional risk minimisation measures (aRMMs) that aim to 
reduce the risks of phototoxicity, squamous cell carcinoma (SCC) of the skin and hepatic 
toxicity in patients receiving voriconazole in the European Union (EU) 
voriconazole Vfend Study 1 1  Obj 1, Obj 2 
ISPE Abstract [167] 
705. Evaluating the Effectiveness of Additional Risk Minimisation Measures (aRMM) for 
Voriconazole in 10 European Countries 
voriconazole Vfend Du_Study 1 1   
Google [127] https://link.springer.com/article/10.1007/s40290-019-00273-4 voriconazole Vfend Du_Study 1 1   
EU PAS [255] 
E2090-E044-501: A Retrospective database Study of the Prescribing of Zonismaide in UK 
General Practice: A Drug Utilisation Study as Part of Post-Marketing Safety Surveillance 
zonismaide Zonegran ongoing  1  
EU PAS [256] 
Evaluating the effectiveness of the revised alli® pack information in helping pharmacy staff 
within the EU supply alli® appropriately 
orlistat Alli Study 32 1  Obj 2 




Edurant / Eviplera Study 9 1  Obj 1, Obj 2 
EU PAS [257] 
Evaluation of referring HCPs’ and parents’/carers’ understanding of specific risks associated 
with Strimvelis™ treatment 
autologous cd34+ 
enriched cell fraction 
that contains cd34+ cells 
transduced with retroviral 
vector that encodes for 
the human ada cdna 
sequence 
Strimvelis ongoing  1  
*Excluded from Objective 2 as considered outside the scope of the review 
Studies with Status ‘Du_’ are duplicates of EU RM studies
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